Imaging Diagnostic Systems (IMDS) 10-K 2007 FY Annual report

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-K

[Mark One]

x           ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended: June 30, 2007

or

¨           TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________to_____________

Commission file number: 0-26028

IMAGING DIAGNOSTIC SYSTEMS, INC.

(Exact name of registrant as specified in its charter)

Florida	22-2671269
(State of incorporation)	(IRS employer Ident. No.)

6531 NW 18th Court, Plantation, FL.	33313
(address of principal office)	(Zip Code)

Registrant's telephone number, including area code: (954) 581-9800

Securities registered under Section 12(b) of the Exchange Act:

None

Securities registered under Section 12(g) of the Exchange Act:

Common Stock, no par value

(Title of class)

Indicate by check mark whether the registrant:(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  x No  o

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.  x

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non- accelerated filer.  See definition of “accelerated filer and large accelerated filer” in Rule 12b-2 of the Exchange Act.

¨  Large accelerated filer x  Accelerated filer ¨  Non Accelerated filer

Indicate by check mark whether the registrant is a shell company (as defined in rule 12b-2 of the act).    Yes  o     No  x

Based on the average closing bid and asked prices of the common stock on the latest practicable date, September 12, 2007, the aggregate market value of the voting stock held by non-affiliates of the registrant was $21,472,210.

The number of shares outstanding of each of the issuer’s classes of common stock, as of September 12, 2007 was 318,205,363.  As of September 12, 2007, the issuer had no shares of preferred stock outstanding.

Documents Incorporated By Reference

[None]

IMAGING DIAGNOSTIC SYSTEMS, INC.

FORM 10-K

ANNUAL REPORT

TABLE OF CONTENTS

PART I		Page No
ITEM 1.	Our Business	3
ITEM 2.	Description of Our Property	14
ITEM 3.	Legal Proceedings	14
ITEM 4.	Submission of Matters to a Vote of Securities Holders	15
PART II
ITEM 5.	Market for Registrant’s Common Equity and Related Stockholder Matters	16
ITEM 6.	Selected Financial Data	20
ITEM 7.	Management’s Discussion and Analysis of Financial Conditions and
	Results of Operations	21
ITEM 7A.	Quantitative and Qualitative Disclosures About Market Risk	32
ITEM 8.	Financial Statements	33
ITEM 9.	Changes In and Disagreements with Accountants on Accounting and
	Financial Disclosure	88
ITEM 9A	Controls and Procedures	88
ITEM 9B	Other Information	92
PART III
ITEM 10.	Directors and Executive Officers of the Registrant	92
ITEM 11.	Executive Compensation	97
ITEM 12.	Security Ownership of Certain Beneficial Owners and Management	106
ITEM 13.	Certain Relationships and Related Transactions	107
ITEM 14.	Principal Accounting Fees and Services	107
PART IV
ITEM 15.	Exhibits, Financial Statement Schedules, and Reports on Form 8-K	108
SIGNATURES		110

2

THIS REPORT CONTAINS FORWARD-LOOKING STATEMENTS WITHIN THE MEANINGS OF SECTION 27A OF THE SECURITIES ACT OF 1933 AND SECTION 21E OF THE SECURITIES EXCHANGE ACT OF 1934.  ACTUAL RESULTS AND EVENTS COULD DIFFER MATERIALLY FROM THOSE PROJECTED AS A RESULT OF THE “KNOWN UNCERTAINTIES” AS SET FORTH IN ITEM 7 “MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS-CAUTIONARY STATEMENTS.”

PART I

Item 1.  Our Business

Overview

Imaging Diagnostic Systems, Inc. (“IDSI”) is a development stage medical technology company.  Since its inception in December 1993, we have been engaged in the development and testing of a Computed Tomography Laser Breast Imaging System for detecting breast cancer (CT Laser Mammography or, "CTLM®").  We are currently in the process of commercializing the CTLM® in certain international markets where approvals to market have been secured although CTLM® is not yet approved for sale in the U.S.  CTLM® is a Class III medical device and we are continuing efforts to secure the Food and Drug Administration’s PreMarket Approval based upon clinical studies.  CTLM® has been declared a Non-Significant risk (NSR) device when used for our intended use.

The CTLM® system is a CT-like scanner, but its energy source is a laser beam and not ionizing x-radiation such as is used in conventional x-ray mammography or CT scanners.  The advantages of imaging without ionizing radiation may be significant in our markets.  CTLM® is an emerging new imaging modality offering the potential of molecular functional imaging, which can visualize the process of angiogenesis which may be used to distinguish between benign and malignant tissue.  X-ray mammography is a well-established method of imaging the breast but has limitations especially in dense breast cases.  Ultrasound is often used as an adjunct to mammography to help differentiate tumors from cysts or to localize a biopsy site.  The CTLM® is being marketed as an adjunct to mammography not a replacement for it, to provide the radiologist with additional information to manage the clinical case. We believe that the adjunctive use of CT Laser Mammography may help diagnose breast cancer earlier, reduce diagnostic uncertainty especially in mammographically dense breast cases, and may help decrease the number of biopsies performed on benign lesions.  The CTLM® technology is unique and patented.  We intend to develop our technology into a family of related products.  We believe these technologies and clinical benefits constitute substantial markets for our products well into the future.

As of the date of this report we have had no substantial revenues from our operations and have incurred net losses applicable to common shareholders since inception through June 30, 2007 of approximately $98,341,059 after discounts and dividends on preferred stock.  We anticipate that losses from operations will continue for at least the next 12 months, primarily due to an anticipated increase in marketing and manufacturing expenses associated with the international commercialization of the CTLM®, expenses associated with our FDA Pre-Market Approval (“PMA”) process, and the costs associated with advanced product development activities.  There can be no assurances that we will obtain the PMA, that the CTLM®will achieve market acceptance or that sufficient revenues will be generated from sales of the CTLM®to allow us to operate profitably.

Breast Cancer

The American Cancer Society (ACS) estimated that approximately 178,480 new cases of invasive breast cancer and 62,030 cases of carcinoma in situ (CIS) non-invasive (localized) breast cancer will be diagnosed in the United States during 2007.  Breast cancer ranks as the second leading cause of cancer-related death among women, causing an estimated 40,460 deaths in 2007.

There is widespread agreement that screening for breast cancer, when combined with appropriate follow-up, will reduce mortality from the disease.  According to the National Cancer Institute (NCI), the five-year survival rate decreases from 96% to 78% after the cancer has spread to the lymph nodes, and to 18% after it has spread to other organs such as the lung, liver or brain.  A major problem with current detection methods is that studies have shown that mammography does not detect 15%-20% of breast cancers detected by physical exam alone.

Breast cancer screening is generally recommended as a routine part of preventive healthcare for women over the age of 20 (approximately 90 million in the United States).  For these women, the American Cancer Society (ACS) has published guidelines for breast cancer screening including: (i) monthly breast self-examinations for all women over the age of 20; (ii) a clinical breast exam (CBE) every three years for women in their 20s and 30s; (iii) a baseline mammogram for women by the age of 40; and (iv) an annual mammogram for women age 40 or older.

3

Each year, approximately eight million women in the United States require diagnostic testing for breast cancer due to a physical symptom, such as a palpable lesion, pain or nipple discharge, discovered through self or physical examination (approximately seven million) or a non-palpable lesion detected by screening x-ray mammography (approximately one million).  Once a physician has identified a suspicious lesion in a woman’s breast, the physician may recommend further diagnostic procedures, including a diagnostic x-ray mammography, an ultrasound study, a magnetic resonance imaging procedure, or a minimally invasive procedure such as fine needle aspiration or large core needle biopsy.  In each case, the potential benefits of additional diagnostic testing must be balanced against the costs, risks and discomfort to the patient associated with undergoing the additional procedures.

Due in part to the limitations in the ability of the currently available modalities to identify malignant lesions, a large number of patients with suspicious lesions proceed to surgical biopsy, an invasive and expensive procedure.  Approximately 1.3 million surgical biopsies are performed each year in the United States, of which approximately 70-80% result in the surgical removal of benign breast tissue.  The average cost of a surgical biopsy ranges from approximately $1,000 to $5,000 per procedure.  Thus, biopsies of benign breast tissue may cost the U.S. health care system approximately $2.45 billion annually.  In addition, biopsies result in pain, scarring, and anxiety to patients.  Patients who are referred to biopsy usually are required to schedule the procedure in advance and generally must wait up to 48 hours for their biopsy results.

Screening and Diagnostic Modalities

Mammography

Mammography is an x-ray imaging modality commonly used for both routine breast cancer screening and as a diagnostic tool.  A mammogram produces either films or electronic images of the internal structure of the breast and surrounding tissues.  In a screening mammogram, radiologists seek to detect suspicious lesions, while a diagnostic mammogram seeks to characterize suspicious lesions.

In the U.S., a certified technologist performs the x-ray procedure under the Congressional Mammography Quality Standards Act (MQSA).  MQSA was enacted to improve x-ray breast cancer detection studies by regulating machine specifications, quality control procedures, technologist training and certification, and other variables.  Still, mammography is viewed as an ‘imperfect’ breast cancer detection tool and is often supplemented with follow-up studies including more x-rays at later dates, closer physical examination of the patient, adjunctive ultrasound exams, and, when available, breast MRI or scintimammography, and biopsy.

Because x-ray mammography exposes the patient to radiation, the American Cancer Society recommends that mammograms be limited to once per year.  X-ray mammography is documented to be less effective for women with dense breasts.  X-ray mammography machines use mechanical means to squeeze or compress the breast and flatten the volume so that x-rays may penetrate more uniform tissue.  These techniques are technically necessary but are often painful and uncomfortable to patients.  Most mammography exams include 2 views of each breast which equates to 4 compressions per session.

According to the CDC, 62.8% of women over age 40 received a mammogram in 2004.  Estimates are that in 2004 there were more than 49 million screening mammograms alone in the U.S. and 117 million world wide (TriMark, Jan. 2005 estimates).

The Medicare billing of a diagnostic mammogram is approximately $120 to $160 per procedure and requires the use of x-ray equipment ranging in cost from $75,000 to $225,000 and perhaps ultrasound equipment ranging from $60,000 to $200,000.

Digital Mammography

Digital mammography, also referred to as “full-field digital” mammography, is the latest form of breast x-ray examination.  These systems eliminate the use of x-ray film and record images directly on electronic panels. The digital images can then be manipulated and examined on an electronic viewing station.  However, the limitations of conventional mammography still exist in digital mammography. Digital mammography units sell for $300,000 to $430,000 and Medicare billing for the procedures ranges from $170 to $200.

Magnetic Resonance Imaging

Magnetic resonance imaging (“MRI”) produces images using a magnetic field and radiofrequency (RF) gradients under computer control to produce proton density images.  MRI has proven effective in imaging breasts with prosthetic implants, detecting recurrent cancer, evaluating the response to chemotherapy and serving as an additional imaging option when mammography or ultrasound fails to provide sufficient imaging information.

4

MRI offers the advantage over x-ray that not only visualizes fine-details in breast tissue but also detects blood flow and angiogenesis associated with malignancies.  The disadvantages are that MRI systems are not widely available in the global market and the costs of using conventional MRI scanners for breast exams are sometimes prohibitive.  Dedicated breast MRI systems sell for approximately $1,200,000 and Medicare billing is approximately $1,500.

Ultrasound

Ultrasound imaging is routinely used in breast imaging practices.  Ultrasound systems can image breast tissue by ‘sonar’ techniques.  Sound transducers are placed directly on breast tissue coupled with an acoustic gel substance.  Trained sonographers locate suspicious areas by moving the transducer over the area of interest.  In some countries physicians perform the study and interpret the results.

Ultrasound images are localized to areas of suspicion usually detected by a previous mammogram.  If mammographic results suggest the presence of a lesion, ultrasound may help differentiate a solid from a cystic mass and locate a biopsy site.  The Medicare billing rate is approximately $240 per procedure and requires the use of capital equipment ranging in cost from approximately $60,000 to $200,000.

CTLM®

The CTLM® laser breast imaging system is being marketed as an adjunct to mammography and will not compete directly with X-ray mammography.  CTLM® is, however, an emerging new modality offering the potential of molecular functional imaging, which can visualize the process of angiogenesis which may be used to distinguish between benign and malignant tissue.

We believe that the adjunctive use of CT laser breast imaging will improve early diagnosis, reduce diagnostic uncertainty, decrease the number of biopsies performed on benign lesions, and improve breast cancer case management, especially in dense breasts.

A CTLM® breast exam is non-invasive and can be performed by a medical technician.  A patient lies face down on a scanning table with one breast hanging naturally into a specially designed scanning chamber.  The scanner images the breast in contiguous slices from chest wall to nipple in minutes.  One breast is scanned at a time.  The CTLM® is a sophisticated electro-mechanical scanner under microprocessor and computer control.  Results are available immediately in digital format for comparison to mammography results, consultation, transmission to multi-modality reading stations, or archiving.

Images and study results present as multiple-slice data sets which can be viewed slice-by-slice or as a 3D volume with image manipulation tools.  Images are usually viewed in gray and green color shades, since color displays are common with other molecular imaging modalities such as nuclear medicine, PET, fMRI, and in radiation therapy imaging.

Fluorescence Imaging

Fluorescence and molecular imaging techniques are of growing importance to the drug development industry and for disease detection. Certain molecules exhibit the phenomenon of emitting light after being illuminated by light of an appropriate wavelength, e.g., from a laser.  The light that is emitted is referred to as “fluorescent” light.  The compounds that produce fluorescence are commonly referred to as fluorescent dyes.  At least one company to our knowledge is developing a fluorescent compound for possible use in breast cancer detection.

The CTLM® system laser diodes can stimulate fluorescent light emissions when used in conjunction with such compounds. When an appropriate fluorescent compound has been introduced into the blood, areas with an abundance of blood vessels, i.e., the angiogenesis associated with a tumor, may retain a higher concentration of the fluorescent compound.  As the CTLM® scanner illuminates these areas; fluorescent light is emitted and detected.  Reconstructed CTLM® images then locate and quantify the fluorescent area within the area of interest.

Several CTLM®’s were retrofitted with laser diodes tuned to specific wavelengths of light which matched the compounds. Optical filters limited the spectral responses to selected wavelengths.  Experiments were conducted by placing fluorescent compounds inside a breast equivalent phantom and scanning it with CTLM®.  To our knowledge we were the first with the ability to excite a fluorescent compound, detect its location within the simulated breast, and create an image.  On September 14, 1999, a patent was issued to IDSI titled “Laser Imaging Apparatus Using Biomedical Markers that Bind to Cancer Cells” as Patent No 5,952,664.

In March 2002, we signed an agreement with Schering AG to evaluate the advantages of new fluorescence compounds for the potential use of detecting breast cancer.  We installed three CTLM® systems for Schering AG’s clinical trials: one at Charite’s Robert-Rössle Clinic in Berlin, one at the University of Muenster, and the third at

5

Charite Hospital in Berlin, Germany as part of their Phase 1 clinical studies of fluorescent imaging compounds.  In November 2005, we announced that Schering AG had completed the evaluation of fluorescent imaging compound SF64 with three modified CT Laser Mammography systems.  The loaned systems, which had been modified to Schering AG's specifications were subsequently returned to IDSI and have been re-manufactured.  IDSI is continuing to research and develop fluorescence imaging techniques.

Laser Imager for Lab Animals

Our Laser Imager for Lab Animals “LILA™” program has developed an optical helical micro-CT scanner in a third-generation configuration.  The system was designed to image numerous compounds, especially green fluorescent protein, derived from the DNA of jellyfish.  The LILA scanner is targeted at pharmaceutical developers and researchers who monitor cancer growth and who use multimodality small animal imaging in their clinical research.

IDSI’s strategic thrust for the LILA project changed in 2006.  As we previously announced, IDSI is focusing on women’s health business markets with a family of CTLM® systems and related devices and services.  The animal imager does not fit our business model although the fundamental technology is related to the human breast imager.  Consequently, we sought to align the project with a company already in the animal imaging market that might complete the LILA and commercialize it.

On August 30, 2006 we announced an exclusive license agreement under which Bioscan, Inc. would integrate LILA technology into their animal imaging portfolio.  Under the agreement, we would transfer technology to Bioscan by December 2006 upon receipt of a $250,000 technology transfer fee.  We have received full payment of the technology transfer fee and plans are in place for Bioscan to begin the project during the fourth quarter of calendar 2007.  The agreement also provides for royalties on any future sales of LILA products.  On May 9, 2007 we announced that a new patent for our optical CT scanner for small laboratory animals was issued on May 1, 2007 as U.S. Patent 7,212,848.  This second patent adds the concept of a second laser which will provide a geographic reference for the fluorescence image.  Our first patent covered the basic CT fluorescent imaging of small laboratory animals.

Government Regulation

United States Regulation

The CTLM® is a medical device and it is subject to the relevant provisions of the United States Food, Drug and Cosmetic Act (FD&C Act”) and its implementing regulations.  Pursuant to the FD&C Act, the FDA regulates, among other things, the manufacturing, labeling, distribution, and promotion of the CTLM® in the United States.  The Act requires that a medical device must (unless exempted by regulation) be cleared or approved by the FDA before being commercially distributed in the United States.  The FD&C Act also requires that manufacturers of medical devices, among other things, comply with specific labeling requirements and manufacture devices in accordance with Current Good Manufacturing Practices, which require that companies manufacture their products and maintain related documentation in a conformed manner with respect to manufacturing, testing, and quality control activities.  The FDA inspects medical device manufacturers and distributors, and has broad authority to order recalls of medical devices, to seize non-complying medical devices, to enjoin and/or impose civil penalties, and to criminally prosecute violators.

The FDA classifies medical devices intended for human use into three classes: Class I; Class II; and Class III.  The CTLM is a Class III device.  Class III devices are devices for which the FDA has insufficient information to conclude that either general controls or special controls would be sufficient to assure safety and effectiveness, and which are life-supporting, life-sustaining, of substantial importance in preventing impairment of human health (e.g., a diagnostic device to detect a life-threatening illness), or present a potentially unreasonable risk of illness or injury.  Manufacturers of Class III devices must apply to the FDA for pre-marketing approval (“PMA”) before marketing can begin.  PMA applications must demonstrate, among other matters, that the medical device is safe and effective.  A PMA application is typically a complex submission, usually including the results of clinical studies and statistical analyses.

Once a PMA application has been filed, the FDA has 180 days to review it; however, the review time may be extended by the FDA asking for additional information or clarification of information already provided in the submission.  The FDA will inspect the manufacturing facility to ensure compliance with the FDA’s quality system regulations commonly referred to as QSRs prior to approval of a PMA.  The PMA process is lengthy and expensive and there can be no assurance that a PMA application will be approved within 180 days.

6

We have engaged the services of U.S. regulatory consultants who specialize in FDA matters to assist us in the final preparation and submission of our PMA application.  See Item 1.  “Business-Regulatory and Clinical Status, United States/FDA”.  If we are unable to obtain prompt FDA approval, it will have a material adverse effect on our business and financial condition and would result in postponement of the commercialization of the CTLM®.  See “Regulatory and Clinical Status”.

Any products manufactured or distributed by us pursuant to a PMA are or will be subject to pervasive and continuing regulation by the FDA.  Labeling, advertising and promotional activities are subject to scrutiny by the FDA and, in certain instances, by the Federal Trade Commission.  In addition, the marketing and use of our products may be regulated by various state agencies.  The export of medical devices is also subject to regulation in certain instances.  Both the FDA and the individual states may inspect the manufacturers of our products on a routine basis for compliance with current QSR regulations and other requirements.

In addition to the foregoing, we are subject to numerous federal, state, and local laws relating to such matters as safe working conditions, manufacturing practices, environmental protection, and fire hazard control.  There can be no assurance that we will not be required to incur significant costs to comply with such laws and regulations and that such compliance will not have a material adverse effect upon our ability to conduct business.  See Item 7.  “Management’s Discussion and Analysis of Financial Condition and Results of Operations-Cautionary Statements – Extensive Government Regulation, No Assurance of Regulatory Approvals”.

Foreign Regulation

Sales of CTLM® systems outside of the United States are subject to foreign regulatory requirements that vary widely from country to country.  The time required to obtain approval for sale in foreign countries may be longer or shorter than that required for FDA clearance or approval, and the requirements may differ.  The laws of certain European and Asian countries have permitted us to begin marketing the CTLM® in Europe and Asia before marketing would be permitted in the United States.  In order to sell our products within the European Economic Area (“EEA”), we were required to achieve compliance with requirements of the Medical Devices Directive (“MDD”) and affix a “CE” marking on our products to attest such compliance.  In Europe, we have obtained the certifications necessary to enable the CE mark to be affixed to our products.  In obtaining these certifications, we utilized the services of a notified body (“NB”).  A NB is a private sector regulatory body responsible for the review and approval of the documentation submitted by us to gain CE approval. In November 2000, we were recommended for CE marking, subject to review by UL’s Notified Body.  In January 2001, we received regulatory approval from UL to apply the CE marking to our CTLM® system.  CE marking provides us the opportunity to market the CTLM® within the European Union, one of the largest markets in the world and permits medical device product sales in many other markets worldwide.

In October 2000, we contracted Underwriters Laboratories Inc. (“UL”) to perform safety testing and assist us in achieving the regulatory certifications necessary to begin selling the CTLM® system outside the United States.  We also chose our Notified Body to certify our compliance with EN29000/46001/ISO9000 quality assurance standards.  In January 2001 we received notice from UL of completion for worldwide safety classification of our CTLM® system.  We replaced our European authorized representative with Emergo Europe effective August 1, 2005 in the normal course of business.

In May 2001, we received ISO 9002 certification demonstrating our commitment for quality and our ability to provide consistency, reliability, value and exceptional customer service.  ISO 9002 certification is significant in facilitating the global marketing of our CTLM® system by conforming to an effective quality management system recognized around the world.

On September 25, 2001, we received a Certificate of Exportability from the FDA for the CTLM®.  The FDA requires unapproved Class III products that are subject to PMA requirements to have FDA Certificate of Exportability in order to be exported outside of the United States.   We received a renewal of our Certificate of Exportability dated May 30, 2007, which is valid for two years.

In October 2003, we announced that we received a Certificate of Approval that our Quality Management System has been inspected and upgraded to the following quality assurance standards: ISO 9001:2000, ISO, 13485:2003, and Annex II have been granted.  As of the date of this report, almost 100 countries, including the United States, the United Kingdom, Germany, Australia, Canada, Japan and France have adopted ISO Standards as the primary means for evaluating the quality of manufacturing products.  We have been re-inspected by UL and our Certificates of Approval have been renewed through May 29, 2009.

7

Regulatory and Clinical Status

In our initial PMA application we followed the guidelines of the “Standardized Shell for Modular Submission” for the FDA approval process.  We filed four modules from September 2000 to May 2001, which were accepted, and then filed our PMA application in April 2003.  In June 2003 we received notification from FDA that an initial review of our PMA had been conducted and was sufficiently complete to permit a substantive review and was, therefore, suitable for filing.  An in-depth evaluation of the safety and effectiveness of the device was conducted as part of the PMA application process.

On November 14, 2003 we announced that we received notification from the Medical Device Bureau of Health Canada that our application for a “New Medical Device” license was approved.  The license was issued in accordance with the Medical Device Regulations, Section 36.  Furthermore, we possess the CMDCAS ISO 13485-2003 certification, which is an additional regulatory requirement that is evidence of compliance to the quality system of the medical device.

In August 2003, we received a letter from the FDA citing some deficiencies in the PMA application.  The FDA identified measures to make the PMA approvable, and we worked with our FDA counsel and consultants to prepare an appropriate amendment.

In February 2004, we received a warning letter from the FDA specifically regarding the biomonitoring section of an inspection of our facility conducted August 13-18^th, 2003.  We submitted our response on February 9, 2004.  On March 29, 2004, we announced in an 8-K filing that our responses to the FDA’s warning letter addressed each of the issues and no further response to the FDA was required at that time.

In March 2004, we received an extension of time to respond with an amendment to the FDA’s August, 2003 letter regarding our pre-market approval application.

In September 2004, we announced that our CT Laser Mammography System, CTLM®, had received Chinese State Food and Drug Administration (SFDA) marketing approval.  The People’s Republic of China SFDA issued the registration “Certificate for Medical Device”.  The medical device registration number is 20043241646.

In October 2004, we issued a press release announcing our decision to withdraw our current PMA application and resubmit the entire package in a simpler and more clinically and technically robust filing.  We said we would submit a new PMA application with a rephrased intended use statement better supported by our data, the inclusion of new clinical cases to improve the biometrics, and with a new clinical protocol to fully support the adjunctive use of CTLM® in clinical mammography settings.

In November 2004, we received a letter from the FDA stating that it had determined that the CTLM® proposed clinical investigation was a non-significant risk (NSR) device study because it did not meet the definition of a significant risk (SR) device under section 812.3(m) of the investigational device exemptions (IDE) regulation 21 CFR 812.  We view this new classification as helpful in securing new research and development collaborative agreements.

In January 2005 we issued a press release stating that the clinical study we intended to submit to the FDA did not, in our opinion, adequately reflect the capabilities of CTLM® as an adjunctive mammography tool.  The clinical cases were collected on CTLM® systems dating back to 2001.  Since that time IDSI had developed significant improvements in the scanning subsystems, image reconstruction and image display software.  We had also improved quality assurance routines to ensure better operator and physician training, and improved image quality control.  We therefore announced our intention to collect data using our latest systems because we believed the results would yield a stronger study to support our PMA application.  Consequently, we decided to install updated CTLM® systems in the U.S.,which has extended the time to actual PMA submission from what we were earlier anticipating, but we believe this approach will better support the application.

We reported in our December 14, 2005 S-1 filing that we experienced further delays because of difficulties in designing a revised clinical protocol and in enlisting hospitals and imaging centers to participate in acquiring new clinical cases.  In spite of the delays we have experienced in obtaining the necessary approvals from the hospitals and their respective Institutional Review Boards (“IRB”), we have made good progress in advancing PMA activities. Several sites have been installed and we have begun collecting clinical data.  We intend to install 8-10 sites depending on patient volume.  Following data collection we plan to submit the PMA application in its entirety.

8

In our S-1 Registration Statement filed on March 23, 2006, we reported that changes would be incorporated to bring the CTLM® system to its most current design level.  Those changes were made and do, we believe, improve the device’s image quality and reliability.  Upgraded CTLM® systems have been installed at eight U.S. clinical sites and data collection is proceeding in accordance with our clinical protocol.  We are continuing to research and develop CTLM® technologies to advance the state-of-art of this new imaging modality.

Clinical Collaboration Sites Update

CTLM® Systems have been installed and patients are being scanned under clinical collaboration agreements as follows:

1.	Humboldt University of Berlin, Charite Hospital, Berlin, Germany
2.	The Comprehensive Cancer Centre, Gliwice, Poland (Two Systems)
3.	Catholic University Hospital, Rome, Italy
4.	Charles University Hospital, Prague, Czech Republic
5.	Friendship Hospital, Beijing, Peoples Republic of China

In November 2005, we announced that Schering AG had completed the evaluation of their new fluorescent imaging compound SF64 with three modified CT Laser Mammography systems.  Other research studies have been and are being completed in various countries.

We are in discussions with other hospitals and clinics wishing to participate in our clinical collaboration program.  We have been commercializing the CTLM® in many global markets and we previously announced our plans to set up this network to foster research and to promote the technology in local markets.  We will continue to support similar programs in other global regions.  These investments may accelerate CTLM® market acceptance while providing valuable clinical experiences.

Domestic Sales and Marketing

The CTLM will be positioned as an adjunct to x-ray mammography and may be especially useful in studies of dense breasts.  Consequently, CTLM will be marketed to centers performing x-ray mammography.  There are approximately 9,000 Mammography Quality Standards Act (MQSA) centers certified in the United States.  Sales in the U.S. cannot occur unless and until we receive pre-market approval from the FDA.  IDSI will begin marketing to the centers following FDA approval.

Since CT laser breast imaging is a new imaging modality the rate at which the CTLM® achieves market acceptance and penetration will depend on many variables.  These include, but are not limited to, the establishment and demonstration in the medical community of the clinical safety, efficacy, and cost-effectiveness of the CTLM®, and the advantage of the CTLM® when used as an adjunct to existing technology and cancer detection methods.  We believe that the clinical data being collected and assessed under our PMA and at research sites will have a significant impact on the ultimate market size for our device.  Failure of our products to gain market acceptance would have a material adverse effect on our business, financial condition, and results of operations.  There can be no assurance that physicians or the medical community in general will accept and/or utilize the CTLM®.

In order to effectively market any products we may develop, we will have to develop a marketing and distribution channel with technical expertise and distribution capability.  There can be no assurance that we will be able to establish sales and distribution capabilities or that we will be successful in gaining market acceptance for any products we may develop.

9

International Sales

We are pursuing international sales in those countries where regulations permit us to begin marketing the CTLM® subject to certain homologations.  Some countries, including Japan, require FDA approval before the CTLM® can be marketed.  As part of our global commercialization program for the CTLM®, we have installed systems at a number of International locations as clinical partner reference sites.  See “Clinical Collaboration Sites Update”.

Until we receive pre-market approval from the FDA to market the CTLM® in the United States, a significant portion of our revenues may be subject to the risks associated with international sales, including economical and political instability, shipping delays, fluctuation of foreign currency exchange rates, foreign regulatory requirements and various trade restrictions, all of which could have a significant impact on our ability to deliver products on a timely basis.  Future imposition of, or significant increases in the level of customs duties, export quotas or other trade restrictions could have a material adverse effect on our business, financial condition and results of operations.  The regulation of medical devices continues to develop and there can be no assurance that new laws or regulations will not have an adverse effect on us.

International Distributors

IDSI intends to commercialize CTLM® in non-U.S. markets through distributors, representative organizations and agents.  We select exclusive distributors who have demonstrated the ability to sell and service similar devices.  In some regions we may add direct sales management, clinical applications or service support personnel if business conditions require such resources.  IDSI has a major commercial presence in the Peoples Republic of China (PRC).  In February 2006, we hired a company to represent our interests in the Asia Pacific region.  Subsequently, we opened a Representative Office in Beijing where presently we have a contract sales management employee, a field service technician and an office manager.

We intend to continually add new or replacement distributors to cover international regions.  Where performance fails to meet agreed upon targets, distributors may be terminated.  We expect such changes to occur in the normal course of introducing a new product to global markets.

Third-Party Reimbursement; Health Care Reform

In the United States, suppliers of health care products and services are greatly affected by Medicare, Medicaid, and other government insurance programs, as well as by private insurance reimbursement programs.  Third-party payers (Medicare, Medicaid, private health insurance companies and other organizations) may affect the pricing or relative attractiveness of our products by regulating the level of reimbursement provided by such payers to the physicians and clinics utilizing the CTLM® or by refusing reimbursement.  There can be no assurance that third-party payers will provide reimbursement for use of our products.  In international markets, reimbursement by private third-party medical insurance providers, including governmental insurers and independent providers, varies from country to country.  In certain countries, our ability to achieve significant market penetration may depend upon the availability of third-party governmental reimbursement.

Product Liability

Our business exposes us to potential product liability risks, which are inherent in the testing, manufacturing and marketing of cancer detection products.  While the CTLM® is being developed as an adjunct to other diagnostic techniques, there can be no assurance that we will not be subjected to future claims and potential liability.  At present we carry $3,000,000 in product liability insurance to cover both clinical sites and sales.

Competition

The medical device industry generally, and the diagnostic imaging segments in particular, are characterized by rapidly evolving technology and intense competition.  The IDSI approach of employing continuous wave laser optical technology in a CT-like device to produce 3D images is unique and patented, and the concept of imaging angiogenesis in the breast to differentiate between benign and malignant tissue is well accepted.

Although the CTLM® system is a CT-like scanner, its energy source for imaging is a laser beam and not ionizing radiation such as is found in conventional x-ray mammography or CT scanners.  The advantage of imaging without ionizing radiation may be significant in our markets.  X-ray mammography is a well-established method of imaging the structures within the breast.  Ultrasound is often used as an adjunct to help differentiate tumors and cysts.  The CTLM® is being marketed as an adjunct to mammography and will not compete directly with X-ray

10

mammography.  CTLM® is, however, a method of molecular functional imaging, which can visualize the process of angiogenesis which may be used to distinguish between benign and malignant tissue.  Unlike X-ray or ultrasound, optical molecular imaging is a revolutionary functional imaging modality.  In this respect, CTLM® may compete with magnetic resonance imaging (MRI) in breast imaging because both CTLM and MRI have the capacity to visualize function at the molecular level.

To our knowledge, several companies are targeting the breast optical imaging market.  Advanced Research Technologies, Inc. (ART) (TSX:ARA) is developing a non-3D imager which does not utilize our patented continuous wave technology and in which the breast must be immersed in a gel to be scanned.  ART may have distribution agreements with GE Medical should a product become available.  ART has not received a PMA.

In December 2005, Philips Medical Systems announced their intent to develop optical imaging equipment with an intention to “be on the market early after 2010.”  IDSI also believes that Siemens Medical Systems is developing optical imaging equipment.

CTLM® Laser Mammography Systems are in clinical settings including Italy, Germany, Poland, the Czech Republic, the Peoples Republic of China, Malaysia and the United Arab Emirates.  Over 9,000 breast exams have been completed on CTLM® systems.  In vivo human studies of fluorescent compounds have been conducted at three clinical locations in Germany.

Patents

The rapid technological advancements that characterize the medical device industry have led us to rely on a combination of patents, trade secrets, copyrights, trademarks, and confidentiality procedures and processes to protect our CTLM® and other technologies that we have developed.

The original patent for the CTLM® was granted in December 1997 under U.S. Patent Number 5,692,511 (the “Patent”).  The Patent has a total of 4 independent claims and 24 subordinate claims.  The independent claims serve to provide an overall outline of the disclosure of the invention.  The subordinate claims provide additional information to identify pertinent details of the invention as they relate to the respective specific independent claim.  We own the rights to the Patent for its 17-year life pursuant to an exclusive patent licensing agreement with the late Richard Grable, who invented the CTLM® and served as our Chief Executive Officer and whose estate has owned the Patent since his death in August 2001.  See “Patent Licensing Agreement” and “Certain Transactions.”  As of the date of this report, we own 20 patents and have 7 additional United States patents pending with regard to optical tomography, many of which are based on the original CTLM® technology.  We also have 15 International patents and have 7 International patents pending.

In September 1999, we were granted a patent for “A Laser Imaging Apparatus Using Biomedical Markers That Bind To Cancer Cells”.  This patent was issued under U.S. Patent No. 5,952,664.  The biomedical marker we are currently testing is a fluorescent marker.  We plan to continue studying other biomedical markers in conjunction with major pharmaceutical companies as a potential advanced diagnostic feature to be used with our CTLM® system.  The CTLM® in combination with the fluorescent feature has the potential to be used with photodynamic therapy (PDT) to aid in the treatment of breast cancer.

In November 1999, we were granted an Australian patent for “Diagnostic Tomographic Laser Apparatus” as Australian patent number 712849.  This patent, the Australian counterpart of U.S. Patent No. 5,692,511, was issued in the name of Richard J. Grable and is exclusively licensed to Imaging Diagnostic Systems, Inc.   See “Patent Licensing Agreement”.

In February 2000, we were granted a patent for: “Device for Determining the Perimeter of the Surface of an Object Being Scanned and for Limiting Reflection from the Object Surface”.  The patent was issued under U.S. Patent No. 6,029,077.  This particular patent covers the technique for determining the perimeter of the breast, which simplifies the algorithms necessary to produce the image.

In March 2000, we were granted a patent for: “Apparatus And Method for Determining the Perimeter of the Surface of an Object Being Scanned”.  The patent was issued under U.S. Patent No. 6,044,288. This patent covers an optical technique to determine the perimeter of a scanned breast. The U.S. Patent No. 6,029,077 described in the previous paragraph covers a different technique to perform the same measurement.  Together, these two patents protect the practical techniques that can be used to acquire this information.

11

In August 2000, we were granted a patent for: “Detector Array for Use in a Laser Imaging Apparatus”.  The patent was issued under U.S. Patent No. 6,100,520.  This patent describes the several different variations that can be used while scanning the breast without any contact between the breast and the optical components.  Unlike the conventional method, this unique feature allows the CTLM® to scan the breast without the use of breast compression.

In October 2000, we were granted a patent for: “Method of Reconstructing an Image Being Scanned”.  The patent was issued under U.S. Patent No. 6,130,958.  This patent describes the algorithms used to reconstruct images from data acquired from CTLM® scans.

In December 2000, we were granted a patent for: “Detector Array With Variable Gain Amplifiers For Use In A Laser Imaging Apparatus”.  The patent was issued under U.S. Patent No. 6,150,649.  This patent describes the proprietary electronics used in the CTLM® detector array.

In February 2001, Mr. Richard Grable was granted a patent for “Diagnostic Tomographic Laser Imaging Apparatus”.  This patent was issued for his proprietary scanning bed, a unique feature of the CTLM®, and was issued as U.S. Patent No. 6,195,580.  The patent allows for a fixed horizontal platform including a top surface with an opening through which the female breast is vertically pendent using a laser beam for the detection of breast abnormalities.    See “Patent Licensing Agreement”.

In April 2001, we were granted a patent for: “Detector Array for Use in a Laser Imaging Apparatus”.  The patent was issued under Patent No. 6,211,512.  The patent allows for several different optics variations while scanning the breast without contact between the breast and the optical components.  This feature allows the CTLM® to scan the breast without the use of breast compression.

In January 2002, we announced that we were granted a patent for “Detector Array With Variable Gain Amplifiers for Use in a Laser Imaging Apparatus,” as U.S. Patent No. 6,331,700.  This patent protects some of the non-obvious, but essential, design aspects of an optical CT scanner.  This patent addresses the solution to the problem of accommodating a huge dynamic range of light intensities emitted from the breast.

In February 2002, we were issued a patent for “Time-Resolved Breast Imaging Device,” as U.S. Patent No. 6,339,216.  This patent protects the key electronics of a time-resolved optical CT scanner.  It addresses the solution to the problem of simultaneously accommodating a large dynamic range of light intensities emitted from the breast while achieving the necessary temporal resolution.

In May 2003, we were granted a patent for “Medical Optical Imaging Scanner Using Multiple Wavelength Simultaneous Data Acquisition for Breast Imaging,” as U.S. Patent No. 6,571,116.

In October 2003, we were granted a Canadian patent for “Diagnostic Tomographic Laser Imaging Apparatus” as Canadian patent number 2223606.  This patent, the Canadian counterpart of U.S. Patent No. 5,692,511, was issued in the name of Richard J. Grable and is exclusively licensed to Imaging Diagnostic Systems, Inc.   See “Patent Licensing Agreement”.

In December 2003, we were granted a European patent for “Diagnostic Tomographic Laser Imaging Apparatus” as European patent number 0837649.  This patent, the European counterpart of U.S. Patent No. 5,692,511, was issued in the name of Richard J. Grable and is exclusively licensed to Imaging Diagnostic Systems, Inc.   See “Patent Licensing Agreement”.

In January 2004, we were granted a patent for “Phantom For Optical And Magnetic Resonance Imaging Quality Control,” as U.S. Patent No. 6,675,035.  This invention relates to phantoms for use in optical and magnetic resonance imaging that emulates the optical characteristics of breast tissue that resembles the breast in shape and size, as an integral component of a quality assurance protocol to verify the performance of the medical imaging apparatus being evaluated.

In January 2004, we were granted a patent for “Method For Improving The Accuracy Of Data Obtained In A Laser Imaging Apparatus,” as U.S. Patent No. 6,681,130.  This method improves the accuracy of data obtained using a diagnostic medical imaging apparatus that employs a near-infrared laser and array of detectors with variable gain amplifiers that can accommodate the wide dynamic range of signals available from the detectors.

In February 2004, we were granted a patent for “Laser Imaging Apparatus Using Biomedical Markers That Bind To Cancer Cells” as U.S. Patent No. 6,693,287.  This patent protects the proprietary method of collecting data while

12

using “biomedical” markers that bind to cancer cells during a CT laser scan to provide a positive identification of the cancer area, to selectively activate the Photo Dynamic Therapy (PDT) drug to destroy the cancer.

In April 2004, we were granted a Canadian Patent for “Laser Imaging Apparatus Using Biomedical Markers That Bind To Cancer Cells” as Canadian Patent No. 2,373,299.  This patent broadly covers the optical imaging of fluorescent compounds.

In May 2004, we were granted a patent for “Medical Optical Imaging Scanner Using Multiple Wavelength Simultaneous Data Acquisitions For Breast Imaging” as U.S. Patent No. 6,738,658.  This patent protects the concept of differential reconstruction: reconstructing the difference in data before and after an injection of a contrast agent, such as a fluorescent compound.

In June 2004, we were granted a Chinese Patent for “Diagnostic Tomographic Laser Imaging Apparatus” as Chinese Patent No. ZL95197940X.  The patent, the Chinese counterpart of U.S. Patent 5,692,511, was issued in the name of Richard J. Grable for a period of 20 years from the date of filing until July 10, 2015, and is exclusively licensed to Imaging Diagnostic Systems, Inc.  See “Patent Licensing Agreement”.

In July 2004, we were granted a European patent for “Method For Reconstructing The Image Of An Object Scanned With A Laser Imaging Apparatus” as European patent number 1005286.  This patent is the European counterpart of U.S. Patent No. 6,130,958 and protects the algorithms used to reconstruct CTLM images.

In July 2004, we were granted an Australian patent for “Laser Imaging Apparatus Using Biomedical Markers That Bind To Cancer Cells” as Australian patent number 775069.  This patent is the Australian counterpart of U.S. Patent No. 5,952,664 and protects the fluorescent imaging application of the CTLM.

In August 2004, we were granted a European Patent for “Apparatus For Determining The Perimeter Of The Surface Of An Object Being Scanned” as European Patent No. 1003419.  This is the European equivalent of U.S. Patent No. 6,044,288, which protects a key element in the optical technique used to determine the perimeter of an object being scanned.

In December 2004, we were granted a Hong Kong patent for “Apparatus For Determining The Perimeter Of The Surface Of An Object Being Scanned” as Hong Kong patent number HK1029506.  This patent is the Hong Kong counterpart of U.S. Patent No. 6,044,288, which protects a key element in the optical technique used to determine the perimeter of an object being scanned.

In December 2004, we were granted a Hong Kong patent for “Method For Reconstructing The Image Of An Object Scanned With A Laser Imaging Apparatus” as Hong Kong patent number HK1029508.  This patent is the Hong Kong counterpart of U.S. Patent No. 6,130,958 and protects the algorithms used to reconstruct CTLM images.

In June 2005, we were granted a European patent for “Laser Imaging Apparatus Using Biomedical Markers That Bind To Cancer Cells” as European patent number 1181511.  This patent is the European counterpart of U.S. Patent No. 5,952,664 and protects the fluorescent imaging application of the CTLM.

In September 2006, our patent counsel was notified by the patent examiner that all of the claims of our first patent application of the LILA technology have been allowed.  In January 2007, we announced the issuance of U.S. Patent 7,155,274, entitled “Optical Computed Tomography Scanner for Small Laboratory Animals.”

In May 2007 we announced that a new patent for our optical CT scanner for small laboratory animals was issued as U.S. Patent 7,212,848.  This second patent adds the concept of a second laser which will provide a geographic reference for the fluorescence image.  Our first patent covered the basic CT fluorescent imaging of small laboratory animals.

We intend to file for patents on products, including the CTLM®, for which we believe the cost of obtaining a patent is economically reasonable in relation to the expected protection obtained.  There can be no assurances that any patent that we apply for will be issued, or that any patents issued will protect our technology.  If the patents we license or obtain are infringed upon, or if we are required to defend any patent infringement cases brought against us that will require substantial capital, the expenditure of which we might not be able to afford.

13

Patent Licensing Agreement

IDSI was formed in December 1993 for the sole purpose of developing and commercializing Mr. Richard Grable's invention, a CT laser breast-imaging device (the “Mammoscan™”).

In June 1998, IDSI signed an exclusive patent license agreement with Mr. Grable, which covers some of the technology for the CTLM®.  The term of the license is for the life of the Patent (17 years) and any renewals, subject to termination under specific conditions.  As consideration for this license, Mr. Grable received 7,000,000 shares of common stock and a royalty based upon a percentage, ranging from 6% to 10%, of the dollar amount earned from each sale before taxes minus the cost of the goods sold and commissions or discounts paid.  The royalty provisions do not apply to sales made prior to receipt of the PMA for the CTLM®.  In addition, following issuance of the PMA, Mr. Grable would be eligible for minimum royalties of $250,000 per year based on the sales of the products and goods in which the CTLM® patent is used.  Mr. Grable’s interests in the patent license agreement passed to his estate in August 2001.  Mrs. Richard Grable, our former Chairman and CEO, is the principal beneficiary of Mr. Grable’s estate.

The following table sets forth the Patent licensing royalty structure:

ANNUAL ADJUSTED SALES	PERCENTAGE
$0 to $1,999,999	10%
$2,000,000 to $3,999,999	9%
$4,000,000 to $6,999,999	8%
$7,000,000 to $9,999,99	7%
Greater than $10,000,000	6%

Employees

As of September 2007, we have 28 full-time employees, including our three executive officers.  Thirty-two percent of our employees (9) are employed in the areas of scientific, clinical and product research and development.  In September 2006, we had 40 full-time employees, of which 35% or 14 employees were employed in the areas of scientific, clinical and product research and development.  The decrease is due to reduction in staff as a result of our overall cost control measures.  Our ability to develop our products and provide our services is dependent upon our recruiting, hiring and retaining qualified technical personnel.  To date, we have been able to recruit and retain sufficient qualified personnel.  None of our employees are represented by a labor union.  We have not experienced any work stoppages and consider our relations with our employees to be good.

Due to the specialized scientific nature of our business, we are highly dependent upon our ability to attract and retain qualified scientific, technical and managerial personnel.  Therefore, we have entered into employment agreements with certain executive officers and key employees.  The loss of the services of existing personnel as well as the failure to recruit key scientific, technical and managerial personnel in a timely manner would be detrimental to our research and development programs and to our business.  Our anticipated growth and expansion into areas and activities requiring additional expertise, such as marketing, will require the addition of new management personnel.  Competition for qualified personnel is intense and there can be no assurance that we will be able to continue to attract and retain qualified personnel necessary for the development of our business.

Item 2.  Description of Our Property

Our headquarters facility is located at 6531 N.W. 18^th Court, Plantation, Florida.  The facilities are owned by us and comprise a 24,000-sq. ft. building with ample space to expand, located on a 5-acre landscaped tract.  On September 13, 2007, we entered into an agreement with an unaffiliated third-party for the sale and lease-back of our property.  See Item 9B "Other Information - Sale Lease-Back”.  We believe that our facility is adequate for our current and reasonably foreseeable future needs.  We intend to assemble the CTLM® at our facility from hardware components that will be made by vendors to our specifications.

Item 3.  Legal Proceedings

We are not aware of any material legal proceedings, pending or contemplated, to which we are, or would be a party to, or of which any of our property is, or would be, the subject.

14

Item 4.  Submission of Matters to a Vote of Security Holders

On November 8, 2006, we held our annual meeting of stockholders at our corporate offices at 6531 NW 18^th Court, Plantation, Florida for the following purposes:

1. To elect six directors;

2. To consider and act upon a proposal to amend the Company’s Articles of Incorporation to increase the number of authorized shares of the Company’s common stock, no par value, from 300,000,000 to 450,000,000.

3. To ratify the appointment by the Board of Directors of Sherb and Co., LLP as independent auditors of the Company for the fiscal year ending June 30, 2007.

For proposal no. 1, the stockholders elected six incumbent directors with the following votes:

Timothy B, Hansen	FOR       230,891,751	WITHHELD       7,535,887
Allan L. Schwartz	FOR       230,989,034	WITHHELD       7,438,604
Sherman Lazrus	FOR       230,828,963	WITHHELD       7,598,675
Patrick J. Gorman	FOR       230,888,718	WITHHELD       7,538,920
Edward Rolquin	FOR       230,798,132	WITHHELD       7,629,506
Jay S. Bendis	FOR       230,966,137	WITHHELD       7,461,501

For proposal no. 2, the stockholders voted in favor of the proposal.  The affirmative vote of a majority of the outstanding shares of the Common Stock present in person or represented by proxy at the Annual Meeting and entitled to vote were required to approve the proposal to amend the Company’s Articles of Incorporation to increase the number of authorized shares from 300,000,000 to 450,000,000.  The vote was as follows:

FOR   219,825,663 AGAINST    17,382,939 ABSTAIN     1,219,037

For proposal no. 3, the stockholders voted to ratify the Board of Directors’ appointment of Sherb & Co., LLP as independent auditors of the Company for the fiscal year ending June 30, 2007, with the following votes:

FOR   233,901,149 AGAINST     2,259,973 ABSTAIN   2,266,516

15

PART II

Item 5.  Market for Registrant's Common Equity and Related Stockholder Matters

Our Common Stock is traded on the NASDAQ’s OTC Bulletin Board market under the symbol IMDS.  There has been trading in our common stock since September 20, 1994.  The following table sets forth, for each of the fiscal periods indicated, the high and low bid prices for the common stock, as reported on the OTC Bulletin Board.  These per share quotations reflect inter-dealer prices in the over-the-counter market without real mark-up, markdown, or commissions and may not necessarily represent actual transactions.

QUARTER ENDING	High Bid	Low Bid
FISCAL YEAR 2006
First Quarter	$0.31	$0.17
Second Quarter	$0.20	$0.121
Third Quarter	$0.19	$0.125
Fourth Quarter	$0.19	$0.129
FISCAL YEAR 2007
First Quarter	$0.15	$0.09
Second Quarter	$0.107	$0.065
Third Quarter	$0.155	$0.068
Fourth Quarter	$0.073	$0.038
FISCAL YEAR 2008
First Quarter (through September 12, 2007)	$0.078	$0.035

On September 12, 2007, the closing trade price of the common stock as reported on the OTC Bulletin Board was $.0725.  As of such date, there were approximately 2,753 registered holders of record of our common stock.

Sale of Unregistered Securities

Private Placement of Preferred Stock

We have had to rely on the private placement of preferred and common stock to obtain working capital.  In deciding to issue preferred stock pursuant to the private placements, we took into account the number of common shares authorized and outstanding, the market price of the common stock at the time of each preferred sale and the number of common shares the preferred stock would have been convertible into at the time of the sale.  At the time of each private placement of preferred stock there were enough shares, based on the price of our common stock at the time of the sale of the preferred to satisfy the preferred conversion requirements.  Although our board of directors tried to negotiate a floor on the conversion price of each series of preferred stock prior to sale, it was unable to do so. In order to obtain working capital we will continue to seek capital through debt or equity financing which may include the issuance of convertible preferred stock whose rights and preferences are superior to those of the common stock holders.  We have endeavored to negotiate the best transaction possible taking into account the impact on our shareholders, dilution, loss of voting power and the possibility of a change-in-control; however, in order to satisfy our working capital needs, we have been and may continue to be forced to issue convertible securities and debentures with no limitations on conversion.  In addition, the dividends on the preferred stock affect the net losses applicable to shareholders.  There are also applicable adjustments as a result of the calculation of the deemed preferred stock dividends because we have entered into contracts providing for discounts on the preferred stock when it is converted.

In the event that we issue preferred stock without a limit on the number of shares that can be issued upon conversion and the price of our common stock decreases, the percentage of shares outstanding that will be held by preferred holders upon conversion will increase accordingly.  The lower the market price the greater the number of shares to be issued to the preferred holders, upon conversion, thus increasing the potential profits to the holders when the price per share increases and the holders sell the common shares.  In addition, the sale of a substantial amount of preferred stock to relatively few holders could cause a possible change-in-control.  In the event of a voluntary or

16

involuntary liquidation while the preferred stock is outstanding, the holders will be entitled to a specified preference in distribution of our property available for distribution.  As of the date of this report there are no outstanding shares of preferred stock.

Series K Preferred

See “Financing/Equity Line of Credit”.

Private Placement of Common Stock

Issuance of Stock for Services

We, from time to time, have issued and may continue to issue stock for services rendered by consultants, all of whom have been unaffiliated.

Since we have generated no significant revenues to date, our ability to obtain and retain consultants may be dependent on our ability to issue stock for services.  Since July 1, 1996, we have issued an aggregate of 2,306,500 shares of common stock according to registration statements on Form S-8.  The aggregate fair market value of the shares when issued was $2,437,151.  The issuance of large amounts of our common stock, sometimes at prices well below market price, for services rendered or to be rendered and the subsequent sale of these shares may further depress the price of our common stock and dilute the holdings of our shareholders.  In addition, because of the possible dilution to existing shareholders, the issuance of substantial additional shares may cause a change-in-control.

Issuance of Stock for Settlements In Lieu of Cash

On March 28, 2002, we issued 350,000 restricted shares of common stock to Anthony Giambrone in settlement of a lawsuit for alleged breach of a consulting agreement.  The shares were issued in an exempt transaction pursuant to section 4(2) of the Securities Act of 1933, as amended.  The suit was dismissed by stipulation on April 23, 2002.  In addition we agreed that, if the market price of our common stock on March 28, 2003, was less than $.75 per share, then we would issue to him additional shares of common stock equal to the quotient of (a) 262,500 minus the product of (i) 350,000 and (ii) the market price, divided by (b) the market price.  On March 28, 2003, the market price of our stock was $.17, so we issued to him 1,194,118 additional shares bearing a restricted legend.  Under the settlement agreement, we were obligated to register the shares issued to Mr. Giambrone, subject to certain conditions.  The shares were subsequently registered on July 23, 2003.

On or about September 18, 2003, we entered into a settlement agreement to settle a lawsuit filed by Ladenburg Thalmann & Co. Inc. for alleged breach of an investment-banking contract.  Under this settlement we agreed to issue 401,785 shares of our common stock to Ladenburg in exchange for Ladenburg’s dismissal with prejudice of its claims against us.  As of the date of the Settlement Agreement the value of the stock was approximately $450,000.  We and Ladenburg jointly moved for Court approval of the settlement as fair to Ladenburg so that the delivery of the shares to and the resale of the shares in the United States by Ladenburg may be exempt from registration under Section 3(a)(10) of the Securities Act of 1933.  In an order dated October 24, 2003, the Judge ordered and adjudged that the settlement was approved as fair to the party to whom the shares will be issued within the meaning of Section 3(a)(10) and the case was closed.  The shares were issued on November 12, 2003.

FINANCING/EQUITY LINE OF CREDIT

We will require substantial additional funds for working capital, including operating expenses, clinical testing, regulatory processes and manufacturing and marketing programs and our continuing product development programs.  Our capital requirements will depend on numerous factors, including the progress of our product development programs, results of pre-clinical and clinical testing, the time and cost involved in obtaining regulatory approvals, the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights, competing technological and market developments and changes in our existing research, licensing and other relationships and the terms of any new collaborative, licensing and other arrangements that we may establish.  Moreover, our fixed commitments, including salaries and fees for current employees and consultants, and other contractual agreements are likely to increase as additional agreements are entered into and additional personnel are retained.

17

Since July 17, 2000, Charlton Avenue LLC (“Charlton”) has provided substantially all of our necessary funding through the private placement sale of convertible preferred stock with a 9% dividend and common stock through various private equity credit agreements.  We initially sold Charlton 400 shares of our Series K convertible preferred stock for $4 million and subsequently issued an additional 95 Series K shares to Charlton for $950,000 on November 7, 2000.  We paid Spinneret Financial Systems Ltd. (“Spinneret”), an independent financial consulting firm unaffiliated with the Company and, according to Spinneret and Charlton, unaffiliated with Charlton, $200,000 as a consulting fee for the first tranche of Series K shares and five Series K shares as a consulting fee for the second tranche.  The total of $4,950,000 was designed to serve as bridge financing pending draws on the Charlton private equity line provided through the various private equity credit agreements described in the following paragraphs.

From November 2000 to April 2001, Charlton converted 445 shares of Series K convertible preferred stock into 5,600,071 common shares and we redeemed 50 Series K shares for $550,000 using proceeds from the Charlton private equity line.  Spinneret converted 5 Series K shares for $63,996.  All Series K convertible preferred stock has been converted or redeemed and there are no convertible preferred shares outstanding.

Prior Equity Agreements

From August 2000 to February 2004, we obtained funding through three Private Equity Agreements with Charlton.  Each equity agreement provided that the timing and amounts of the purchase by the investor were at our sole discretion.  The purchase price of the shares of common stock was set at 91% of the market price.  The market price, as defined in each agreement, was the average of the three lowest closing bid prices of the common stock over the ten day trading period beginning on the put date and ending on the trading day prior to the relevant closing date of the particular tranche.  The only fee associated with the private equity financing was a 5% consulting fee payable to Spinneret.  In September 2001 Spinneret proposed to lower the consulting fee to 4% provided that we pay their consulting fees in advance.  We reached an agreement to pay Spinneret in advance as requested and paid them $250,000 out of proceeds from a put.

From the date of our first put notice, January 25, 2001 to our last put notice, February 11, 2004, under our Third Private Equity Credit Agreement, we drew a total of $20,506,000 and issued 49,311,898 shares to Charlton.  As each of the obligations under these prior agreements was satisfied, the agreements were terminated.  The Third Private Equity Agreement was terminated on March 4, 2004 upon the effectiveness of our first Registration Statement for the Fourth Private Equity Credit Agreement.

On January 9, 2004, we and Charlton entered into a new “Fourth Private Equity Credit Agreement” which replaced our prior private equity agreements.  The terms of the Fourth Private Equity Credit Agreement were more favorable to us than the terms of the prior Third Private Equity Credit Agreement.  The new, more favorable terms were: (i) The put option price was 93% of the three lowest closing bid prices in the ten day trading period beginning on the put date and ending on the trading day prior to the relevant closing date of the particular tranche, while the prior Third Private Equity Credit Agreement provided for 91%, (ii) the commitment period was two years from the effective date of a registration statement covering the Fourth Private Equity Credit Agreement shares, while the prior Third Private Equity Credit Agreement was for three years, (iii) the maximum commitment was $15,000,000, (iv) the minimum amount we were required to draw through the end of the commitment period was $1,000,000, while the prior Third Private Equity Credit Agreement minimum amount was $2,500,000, (v) the minimum stock price requirement was controlled by us as we had the option of setting a floor price for each put transaction (the previous minimum stock price in the Third Private Equity Credit Agreement was fixed at $.10), (vi) there were no fees associated with the Fourth Private Equity Credit Agreement; the prior private equity agreements required the payment of a 5% consulting fee to Spinneret, which was subsequently lowered to 4% by mutual agreement in September 2001, and (vii) the elimination of the requirement of a minimum average daily trading volume in dollars.  The previous requirement in the Third Private Equity Credit Agreement was $20,000.

We made sales under the Fourth Private Equity Credit Agreement from time to time in order to raise working capital on an “as needed” basis.  Under the Fourth Private Equity Credit Agreement we drew down $14,198,541 and issued 66,658,342 shares of common stock.  We terminated use of the Fourth Private Equity Credit Agreement and instead began to rely on the Fifth Private Equity Credit Agreement (described below) upon the April 26, 2006 effectiveness of our S-1 Registration Statement filed March 23, 2006.

18

The Fifth Private Equity Credit Agreement

On March 21, 2006, we and Charlton entered into a new “Fifth Private Equity Credit Agreement,” which replaced our prior Fourth Private Equity Credit Agreement upon the April 25, 2006, effectiveness of our S-1 Registration Statement filed on March 23, 2006 to register shares underlying the Fifth Private Equity Credit Agreement.  The terms of the Fifth Private Equity Credit Agreement are similar to the terms of the prior Fourth Private Equity Credit Agreement.  The new credit line’s material terms are (i) the put option price is 93% of the three lowest closing bid prices in the ten day trading period beginning on the put date and ending on the trading day prior to the relevant closing date of the particular tranche (the “Valuation Period”), (ii) the commitment period is two years from the effective date of a registration statement covering the Fifth Private Equity Credit Agreement shares, (iii) the maximum commitment is $15,000,000, (iv) the minimum amount we must draw through the end of the commitment period is $1,000,000, (v) the minimum stock price, also known as the floor price is computed as follows:  In the event that, during a Valuation Period, the Bid Price on any Trading Day falls more than 18% below the closing trade price on the trading day immediately prior to the date of the Company’s Put Notice (a “Low Bid Price”), for each such Trading Day the parties shall have no right and shall be under no obligation to purchase and sell one tenth of the Investment Amount specified in the Put Notice, and the Investment Amount shall accordingly be deemed reduced by such amount.  In the event that during a Valuation Period there exists a Low Bid Price for any three Trading Days—not necessarily consecutive—then the balance of each party’s right and obligation to purchase and sell the Investment Amount under such Put Notice shall terminate on such third Trading Day (“Termination Day”), and the Investment Amount shall be adjusted to include only one-tenth of the initial Investment Amount for each Trading Day during the Valuation Period prior to the Termination Day that the Bid Price equals or exceeds the Low Bid Price and (vi) there are no fees associated with the Fifth Private Equity Credit Agreement.  The conditions to our ability to draw under this private equity line, as described above, may materially limit the draws available to us.

We intend to use the proceeds from the $4.4 million sale/lease-back of our property to finance our current operations.  See Item 9B "Other Information - Sale/Lease-Back".  The Fifth Private Equity Credit Agreement will continue to be available, and we may use it from time to time in order to raise working capital on an “as needed” basis.  Based on our current assessment of our financing needs, we do not expect to draw the full $15,000,000 available under the Fifth Private Equity Credit Agreement.  As of the date of this report, under the Fifth Private Equity Credit Agreement we have drawn down $5,917,717 and issued 81,646,450 shares of common stock.

As of the date of this report, since January 2001, we have drawn an aggregate of $40,622,258 in gross proceeds from our equity credit lines with Charlton and have issued 197,616,690 shares as a result of those draws.

There can be no assurance that adequate financing will be available when needed, or if available, will be available on acceptable terms. Insufficient funds may prevent us from implementing our business plan or may require us to delay, scale back, or eliminate certain of our research and product development programs or to license to third parties rights to commercialize products or technologies that we would otherwise seek to develop ourselves.  To the extent that we utilize our Private Equity Credit Agreements, or additional funds are raised by issuing equity securities, especially convertible preferred stock and convertible debentures, dilution to existing shareholders will result and future investors may be granted rights superior to those of existing shareholders.  Moreover, substantial dilution may result in a change in our control.

19

ITEM 6. SELECTED FINANCIAL DATA
The following selected financial data should be read in conjunction with "Item 7. Management's Discussion and Analysis
of Financial Condition and Results of Operations" and "Item 8. Financial Statements"
	Year Ended			Year Ended			Year Ended			Year Ended			Year Ended
	June 30, 2007			June 30, 2006			June 30, 2005			June 30, 2004			June 30, 2003
										(Restated)			(Restated)
Sales	$	65,136		$	675,844		$	374,952		$	733,211		$	184,085
Cost of Sales		17,870			316,189			166,685			284,682			79,189
Gross Profit		47,266			359,655			208,267			448,529			104,896
Operating Expenses		7,123,347			6,984,057			7,338,806			8,160,982			7,487,696
Operating Loss		(7,076,081	)		(6,624,402	)		(7,130,539	)		(7,712,453	)		(7,382,800	)
Gain (Loss) on sale of fixed assets		-			(2,439	)		-			(5,669	)		11,254
Interest income		11,455			8,416			5,680			9,305			689
Other income		250,001			21,500			409,962			-			-
Interest expense		(387,697	)		(565,797	)		(598,021	)		(694,142	)		(987,917	)
Net Loss		(7,202,322	)		(7,162,722	)		(7,312,918	)		(8,402,959	)		(8,358,774	)
Dividends on cumulative Pfd. stock:
From discount at issuance		-			-			-			-			-
Earned		-			-			-			-			-
Net loss applicable to
common shareholders	$	(7,202,322	)	$	(7,162,722	)	$	(7,312,918	)	$	(8,402,959	)	$	(8,358,774	)
Net Loss per common share	$	(0.03	)	$	(0.03	)	$	(0.04	)	$	(0.05	)	$	(0.06	)
Weighted avg. no. of common shares,
Basic & Diluted		271,667,256			218,846,738			185,636,553			167,982,750			145,150,783
Cash and Cash Equivalents	$	477,812		$	1,467,687		$	765,523		$	554,354		$	1,361,507
Total Assets		4,365,427			6,250,909			5,608,004			5,683,328			5,943,415
Deficit accumulated during
the development stage		(98,341,059	)		(91,138,737	)		(83,976,015	)		(76,663,097	)		(68,260,138	)
Stockholders' Equity		3,441,322			5,651,916			4,772,538			4,170,395			4,706,003

20

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis should be read in conjunction with the “Selected Financial Data” and the Condensed Financial Statements included elsewhere in this report and the information described under the caption “Risk Factors” below.

CRITICAL ACCOUNTING POLICIES

The discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with accounting principles generally accepted in the U.S.  The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates, including those related to inventories, and intangible assets.  We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that may not be readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

We believe the following critical accounting policies affect our more significant judgments and estimates used in the preparation of our consolidated financial statements.

Inventory

Our inventories consist of raw materials, work-in-process and finished goods, and are stated at the lower of cost (first-in, first-out) or market.  As a designer and manufacturer of high technology medical imaging equipment, we may be exposed to a number of economic and industry factors that could result in portions of our inventory becoming either obsolete or in excess of anticipated usage.  These factors include, but are not limited to, technological changes in our markets, our ability to meet changing customer requirements, competitive pressures in products and prices and reliability, replacement and availability of key components from our suppliers.  We evaluate on a quarterly basis, using the guidance of ARB 43, Chapter 4, Statement 5, our ability to realize the value of our inventory based on a combination of factors including the following: how long a system has been used for demonstration or clinical collaboration purpose; the utility of the goods as compared to their cost; physical obsolescence; historical usage rates; forecasted sales or usage; product end of life dates; estimated current and future market values; and new product introductions.  Assumptions used in determining our estimates of future product demand may prove to be incorrect, in which case excess and obsolete inventory would have to be adjusted in the future.  If we determined that inventory was overvalued, we would be required to make an inventory valuation adjustment at the time of such determination.  Although every effort is made to ensure the accuracy of our forecasts of future product demand, significant unanticipated changes in demand could have a significant negative impact on the value of our inventory and our reported operating results. Additionally, purchasing requirements and alternative usage avenues are explored within these processes to mitigate inventory exposure.

Stock-Based Compensation

The computation of the expense associated with stock-based compensation requires the use of a valuation model.  SFAS 123(R) is a new and very complex accounting standard, the application of which requires significant judgment and the use of estimates, particularly surrounding Black-Scholes assumptions such as stock price volatility, expected option lives, and expected option forfeiture rates, to value equity-based compensation.  The Company currently uses a Black-Scholes option pricing model to calculate the fair value of its stock options.  The Company primarily uses historical data to determine the assumptions to be used in the Black-Scholes model and has no reason to believe that future data is likely to differ materially from historical data.  However, changes in the assumptions to reflect future stock price volatility and future stock award exercise experience could result in a

change in the assumptions used to value awards in the future and may result in a material change to the fair value calculation of stock-based awards.  SFAS 123(R) requires the recognition of the fair value of stock compensation in net income.  Although every effort is made to ensure the accuracy of our estimates and assumptions, significant unanticipated changes in those estimates, interpretations and assumptions may result in recording stock option expense that may materially impact our financial statements for each respective reporting period.

21

Results of Operations

In the continuing process of commercializing our operations and as part of our transition plan to exit from SFAS 7 reporting as a development stage enterprise, we continue to use the format established for the fiscal year ending June 30, 2005 of our management discussion and analysis of financial condition and results of operations (MD&A) to better disclose and discuss the three most significant categories of expenses, i.e., general and administrative, research and development, and sales and marketing.

Beginning with the fiscal year ending June 30, 2005 we also expanded our discussion of health insurance and worker’s compensation insurance so that they fell into compensation and related benefits for one of the three expense categories, where previously they were included under insurance costs.  For the fiscal year ending June 30, 2006, we expanded our compensation and related benefits disclosure to include the non-cash compensation related to the expensing of stock options in the three expense categories.

Twelve Months Ended June 30, 2007 and June 30, 2006

SALES AND COST OF SALES

Revenues during the year ended June 30, 2007, were $65,136 representing a decrease of $610,708 or 90% from $675,844 during the year ended June 30, 2006.  The Cost of Sales during the year ended June 30, 2007, was $17,870 representing a decrease of $298,319 or 94% from $316,189 during the year ended June 30, 2006.  The decrease in revenues and Cost of Sales is a result of no CTLM® sales being recorded compared to selling five CTLM® Systems during the year ended June 30, 2006.

GENERAL AND ADMINISTRATIVE

Our general and administrative expenses include compensation and related benefits for employees in administration, finance, human resources and information technology.  Also included are travel/subsistence related to general and administrative activities; property and casualty insurance; directors’ and officers’ liability insurance; professional fees associated with our corporate and securities attorneys and independent auditors; patent maintenance; corporate governance expenses; stockholder expenses; consulting; utilities; maintenance; telephones; office supplies and sales and property taxes.

General and administrative expenses during the year ended June 30, 2007, were $3,012,575 representing a decrease of $353,851 or 11% from $3,366,426 during the year ended June 30, 2006.  Of the $3,012,575 and $3,366,426, compensation and related benefits comprised $2,090,560 (69%) and $2,228,994 (66%), respectively, representing a decrease of $138,434 or 6%.  Of the $2,090,560 and $2,228,994 compensation and related benefits, $360,695 (17%) and $481,556 (22%), respectively, were due to non-cash compensation associated with expensing stock options. The general and administrative decrease of $353,851 is due primarily to decreases of $138,434 in compensation and related benefits ; $124,256 in consulting expenses as we did not incur any general and administrative consulting expenses during the period; $64,502 in proxy service expenses as a result of reduced printing charges due to the elimination of the color pages to the annual report and lower mailing costs due to online delivery of materials and shareholder voting during the period; and $18,027 in board meeting expenses as a result of fewer board of directors meetings and workshop days. These reductions were a result of our cost control measures.

We do not expect a material increase in our general and administrative expenses until we realize a significant increase in revenue from the sale of our product.

RESEARCH AND DEVELOPMENT

We incur research and development expenses to develop significant enhancements to our sole product, the CTLM®.  These expenses consist primarily of compensation and related benefits; clinical, legal and consulting fees associated with our PMA application; costs of materials and components we use to make product enhancements; new product research; professional fees associated with the research and applications for new patents; and the costs associated with the travel/subsistence, shipping, training, installing and servicing clinical collaboration sites.

22

Research and development expenses during the year ended June 30, 2007, were $2,089,497 representing an increase of $42,809 or 2% from $2,046,688 during the year ended June 30, 2006.  Of the $2,089,497 and $2,046,688, compensation and related benefits comprised $1,475,076 (71%) and $1,470,539 (72%), respectively, representing an increase of $4,538 or 0%.  Of the $1,475,076 and $1,470,539 compensation and related benefits, $40,672 (3%) and $125,423 (9%), respectively, were due to non-cash compensation associated with expensing stock options.

The research and development increase of $42,809 is due primarily to increases of $142,092 in clinical expenses due to costs associated with our PMA clinical trials; and $4,538 in research and development compensation and related benefits.  The total increase is partially offset by decreases of $71,105 in consulting expenses because of decreased use of consultants in the field of scientific and clinical disciplines; and $31,960 in travel expenses due to decreased travel to our international clinical collaboration sites.

Clinical expenses during the year ended June 30, 2007, were $257,795 representing an increase of $142,092 or 124% from $115,703 as a result of higher clinical activity in the current year.

We expect a significant increase in our research and development expenses during the fiscal year ending June 30, 2008 due to increased costs associated with conducting clinical trials in the United States required for our PMA application.  We also expect our consulting expenses and professional fees to increase due to the costs associated with our PMA application.  See Item 1. Our Business - “Clinical Collaboration Sites Update”.

SALES AND MARKETING

Our sales and marketing expenses consist primarily of compensation and related benefits for employees in the areas of sales, marketing, sales support and sales administration.  Also included are the expenses associated with advertising and promotion; representative office expense; trade shows; conferences; promotional and training costs related to marketing the CTLM®; commissions; travel/subsistence; consulting; certification expenses; and product liability insurance.

Sales and marketing expenses during the year ended June 30, 2007, were $1,351,521 representing an increase of $140,604 or 12% from $1,210,917 during the year ended June 30, 2006.  Of the $1,351,521 and $1,210,917, compensation and related benefits comprised $412,283 (31%) and $429,568 (35%), respectively, representing a decrease of $17,285 or 4%.  Of the $412,283 and $429,568 compensation and related benefits, $29,946 (7%) and $25,578 (6%), respectively, were due to non-cash compensation associated with expensing stock options.

The sales and marketing increase of $140,604 was due primarily to increases of $222,550 in representative office expense as a result of opening our representative office in Beijing, China; $24,681 in travel expenses associated with sales and marketing related activities; $20,146 in advertising and promotion; and $9,162 in translation expenses.  The total increase is partially offset by decreases of $72,281 in regulatory expense due to the recording of the Chinese regulatory fee in the prior fiscal year; $26,974 in consulting expenses due to a reduced reliance on outside sales consultants; $17,285 in compensation and related benefits; and $17,915 in commission expense as a result of having no sales subject to commissions during the current fiscal year compared to five sales in the prior fiscal year.

We expect commissions, trade show expenses, advertising and promotion and travel and subsistence costs to increase as we continue to implement our global commercialization program.  We are in the process of expanding our sales and marketing department and have opened a representative office in Beijing, China to support sales and service for our distribution network in that country.

AGGREGATED OPERATING EXPENSES

Total operating expenses (general and administrative, research and development, sales and marketing, inventory valuation adjustments and depreciation and amortization) during the year ended June 30, 2007, were $7,123,347 representing an increase of $139,290 or 2% from $6,984,057 when compared to the operating expenses during the year ended June 30, 2006.

Compensation and related benefits during the year ended June 30, 2007, were $3,977,920 representing a decrease of $151,180 or 4% from $4,129,100 during the year ended June 30, 2006.  Of the $3,977,920 and $4,129,100 compensation and related benefits, $431,313 (11%) and $632,558 (15%), respectively, were due to non-cash compensation associated with expensing stock options.  The net decrease of $151,180 was due to a $201,245 decrease in the recording of non-cash compensation related to the expensing of stock options combined with an increase of cash compensation of $50,065.

23

Inventory valuation adjustments during the year ended June 30, 2007, were $493,596 representing an increase of $309,377 or 168% from $184,219 during the year ended June 30, 2006.  The increase is due primarily to the recording of a one-time Inventory Reserve of $300,000 at the end of the fiscal year.  See “Critical Accounting Policy – Inventory”.

Depreciation and amortization during the year ended June 30, 2007, were $176,158 representing an increase of $351 or 0% from $175,807during the year ended June 30, 2006.

Interest expense during the fiscal year ended June 30, 2007, was $387,697 representing a decrease of $178,100 or 31% from $565,797 during the year ended June 30, 2006.  The decrease is due primarily to the reduced dollar amount of the draws and the recording of the 7% discount on our equity credit line as interest with Charlton Avenue, LLC (“Charlton”).  See Item 5.  Market for Registrant’s Common Equity and Related Stockholder Matters – “Financing/Equity Line of Credit”

Other income during the year ended June 30, 2007, was $250,001 representing an increase of $228,501 or 1,068% from $21,500 during the year ended June 30, 2006.  The $250,001 represents payments for the technology transfer fee pursuant to the Bioscan Agreement (See Item 1 Our Business -“Laser Imager for Lab Animals”).  The $21,500 was a result of the extinguishment of debt from a loan and related accrued interest payable as of June 30, 2006.  See Notes to the Financial Statements, Note 10 “Short-Term Debt”.

Twelve Months Ended June 30, 2006 and June 30, 2005

SALES AND COST OF SALES

Revenues during the year ended June 30, 2006, were $675,844 representing an increase of $300,892 or 80% from $374,952 during the year ended June 30, 2005.  The Cost of Sales during the year ended June 30, 2006, was $316,189 representing an increase of $149,504 or 90% from $166,685 during the year ended June 30, 2005.  The increase in revenues is a result of selling five CTLM® Systems compared to three CTLM® System during the year ended June 30, 2005.

We previously reported the sale of five CTLM® systems and revenue of $671,750 in our first quarter ending September 30, 2005.  During the fourth quarter we reversed one sale made to a distributor in the Middle East because payments were not made in accordance with the contract schedule.  We therefore reversed the $120,000 sale and recorded the initial $10,000 down payment to customer deposits.  We believe the distributor will begin to make payments in fiscal year 2007.

GENERAL AND ADMINISTRATIVE

Our general and administrative expenses include compensation and related benefits for employees in administration, finance, human resources and information technology.  Also included are travel/subsistence related to general and administrative activities; property and casualty insurance; directors’ and officers’ liability insurance; professional fees associated with our corporate and securities attorneys and independent auditors; patent maintenance; corporate governance expenses; stockholder expenses; consulting; utilities; maintenance; telephones; office supplies and sales and property taxes.

General and administrative expenses during the year ended June 30, 2006, were $3,366,426 representing an increase of $351,626 or 12% from $3,014,800 during the year ended June 30, 2005.  Compensation and related benefits comprised $2,228,994 (66%) and $1,846,825 (61%), respectively, representing an increase of $382,169 or 21% primarily due to recording non-cash compensation related to expensing stock options of $481,556 although cash compensation decreased $99,387.

The general and administrative increase of $351,626 is due primarily to increases in compensation and related benefits of $382,169, an increase in proxy service expenses of $80,264 due to costs for our annual report and an increase of $28,447 in accounting fees primarily due to the SOX-Internal Control audit.   The net total increase takes into account decreases from lower board meeting expenses of $34,415 due to fewer director workshop days; $19,062 in manufacturing expense; $14,867 in quality assurance expense; $14,243 in general corporate travel; $11,807 in maintenance and repairs; $20,046 in telephone expenses; $12,389 in relocation expenses; $9,458 in corporate legal fees, and $5,968 in legal expenses.

We do not expect a material increase in our general and administrative expenses until we realize a significant increase in revenue from the sale of our product.

24

RESEARCH AND DEVELOPMENT

We incur research and development expenses to develop significant enhancements to our sole product, the CTLM®.  These expenses consist primarily of compensation and related benefits; clinical, legal and consulting fees associated with our PMA application; costs of materials and components we use to make product enhancements; new product research; professional fees associated with the research and applications for new patents; and the costs associated with the travel/subsistence, shipping, training, installing and servicing clinical collaboration sites.

Research and development expenses during the year ended June 30, 2006, were $2,046,688 representing a decrease of $506,879 or 20% from $2,553,567 during the year ended June 30, 2005.  Compensation and related benefits comprised $1,470,539 (72%) and $1,525,531 (60%), respectively, representing a decrease of $54,992 or 4%.  The decrease of $54,992 was due to the recording of non-cash compensation related to the expensing of stock options of $125,423 combined with lower cash compensation of $180,415.

The decrease of $506,879 was due primarily to the decreases of $54,992 in research and development compensation and related benefits; $329,619 in clinical expenses; $79,493 in research and development expenses due to the completion of several on-going projects; $48,659 in legal patent expenses; and $2,271 in travel expenses combined with an $8,821 increase in consulting expenses.

Clinical expenses during the year ended June 30, 2006, were $115,703 representing a decrease of $329,619 or 74% from $445,322 as a result of higher activity in the prior year.

We expect a significant increase in our research and development expenses during the fiscal year ending June 30, 2007 due to increased costs associated with conducting clinical trials in the United States required for our PMA application.  We also expect our consulting expenses and professional fees to increase due to the costs associated with our PMA application.  See Item 1. Our Business - “Clinical Collaboration Sites Update”.

SALES AND MARKETING

Our sales and marketing expenses consist primarily of compensation and related benefits for employees in the areas of sales, marketing, sales support and sales administration.  Also included are the expenses associated with advertising and promotion; trade shows; conferences; promotional and training costs related to marketing the CTLM®; commissions; travel/subsistence; consulting; certification expenses; and product liability insurance.

Sales and marketing expenses during the year ended June 30, 2006, were $1,210,917 representing an increase of $127,211 or 12% from $1,083,706 during the year ended June 30, 2005.  Compensation and related benefits comprised $429,568 (35%) and $347,657 (32%), respectively, representing an increase of $81,911 or 24%.  The increase of $81,911 was due to the recording of non-cash compensation related to the expensing of stock options of $25,578 combined with an increase of cash compensation of $56,333.

The sales and marketing increase of $127,211 was due primarily to increases of $81,911 in compensation and related benefits; $26,809 in regulatory expenses; $7,500 in relocation expenses; $6,615 in consulting expense; and $40,000 in bad debt expense (See Note 2c, Allowance for Doubtful Accounts), combined with decreases of $19,879 in advertising and promotion and $27,877 in trade show expense.

We expect commissions, trade show expenses, advertising and promotion and travel and subsistence costs to increase as we continue to implement our global commercialization program.  We are in the process of expanding our sales and marketing department and have opened a representative office in Beijing, China to support sales and service for our distribution network.

AGGREGATED OPERATING EXPENSES

The following discussion explains the sum of significant expenses that are included in our three most significant categories of expenses, i.e., general and administrative, research and development, and sales and marketing.  Also included are inventory valuation adjustments and depreciation and amortization.

Total operating expenses (general and administrative, research and development, sales and marketing, inventory valuation adjustments and depreciation and amortization) during the year ended June 30, 2006, were $6,984,057 representing a decrease of $354,749 or 5% from $7,338,806 when compared to the operating expenses during the year ended June 30, 2005.

25

Compensation and related benefits during the year ended June 30, 2006, were $4,129,100 representing an increase of $409,087 or 11% from $3,720,013 during the year ended June 30, 2005.  The increase of $409,087 was due to the recording of non-cash compensation related to the expensing of stock options of $632,558 combined with a decrease of cash compensation of $223,471.

Inventory valuation adjustments during the year ended June 30, 2006, were $184,219 representing a decrease of $314,975 or 63% from $499,194 during the year ended June 30, 2005.  The decrease is due to a reduction in write-downs of components that are obsolete and are no longer used in the manufacturing of the CTLM®.  See “Critical Accounting Policy – Inventory”.

Depreciation and amortization during the year ended June 30, 2006, were $175,807 representing a decrease of $11,732 or 6% from $187,539 during the year ended June 30, 2005.

Interest expense during the fiscal year ended June 30, 2006, was $565,797 representing a decrease of $32,224 or 5% from $598,021 during the year ended June 30, 2005.  The decrease is due primarily to the dollar amount of the draws and the recording of the 7% discount on our equity credit line as interest with Charlton Avenue, LLC (“Charlton”).  See Item 5.  Market for Registrant’s Common Equity and Related Stockholder Matters – “Financing/Equity Line of Credit”

We recorded other income of $21,500 as a result of the extinguishment of debt from a loan and related accrued interest payable as of June 30, 2006.  See Notes to the Financial Statements, Note 10 “Short-Term Debt”.

Balance Sheet Data

We have financed our operations since inception by the issuance of equity securities with aggregate net proceeds of approximately $64,910,367 and through loan transactions in the aggregate net amount of $2,845,029.  Furthermore, we issued equity securities for the conversion of all outstanding convertible debentures in the aggregate net amount of $3,240,000.

Our combined cash and cash equivalents totaled $477,812 at June 30, 2007.  We do not expect to generate a positive internal cash flow for at least the next 12 months due to our efforts to obtain the PMA, the expected costs of commercializing our initial product, the CTLM®, and the time required for homologations from certain countries.

Our inventory, which consists of raw materials, work in process (including completed units under testing), finished goods less Inventory Reserve, totaled $1,363,156 at June 30, 2007 and $1,891,904 at June 30, 2006.  Raw materials used for research and development or other purposes are expensed and not included in inventory.  This decrease is primarily due to the recording of Inventory Reserve and an inventory valuation adjustment of $493,596 recorded during the year.  We have re-classed $121,094 from Inventory to Clinical Equipment to reflect systems on consignment for international demonstration, clinical collaboration, training and research.  We expect to recover our investment because the CTLM® represents a new technology for imaging the breast using a laser beam instead of ionizing x-ray to produce three dimensional images.  We expect over time that the CTLM® will gain worldwide acceptance in the medical community because its basis in science is Computed Tomography.  See Note 6 “Inventories”.

Our property and equipment, net, totaled $2,030,795 at June 30, 2007 and $2,035,183 at June 30, 2006.

Our Intangible assets (formerly “Other assets”) totaled $273,412 at June 30, 2007 compared to $307,588 at June 30, 2006.  This decrease is due to the amortization of a patent licensing agreement.

Liquidity and Capital Resources

We are currently a development stage company and our continued existence is dependent upon our ability to resolve our liquidity problems, principally by obtaining additional debt and/or equity financing.  We have yet to generate a positive internal cash flow, and until significant sales of our product occur, we are mostly dependent upon debt and equity funding from outside investors.  In the event that we are unable to obtain debt or equity financing or are unable to obtain such financing on terms and conditions acceptable to us, we may have to cease or severely curtail our operations.  This would materially impact our ability to continue as a going concern.

We have financed our operating and research and development activities through several private placement transactions.  Net cash used for operating and product development expenses, which include our purchase of additional materials to continue the manufacture of CTLM® Systems in anticipation of receiving orders from our distributors in certain countries where permitted by

26

law was $5,416,092 during fiscal 2007, compared to net cash used by operating activities and product development of the CTLM® and related software development of $6,122,032 in fiscal 2006.  At June 30, 2007, we had working capital of $1,137,115 compared to working capital of $3,309,145 at June 30, 2006.  On June 27, 2007, we borrowed the sum of $250,000 from Charlton Avenue LLC, and we repaid the loan plus a $20,000 premium on August 2, 2007.

If and when we receive a PMA from the FDA, which cannot be assured, we believe that, based on our current business plan approximately $5 million will be required above and beyond normal operating expenses over the next year to complete all necessary stages in order for us to market the CTLM® in the United States and foreign countries.  The $5 million will be used to purchase inventory, sub-contracted components, tooling and manufacturing templates and pay non-recurring engineering costs associated with preparation for full capacity manufacturing and assembly and marketing, advertising and promotion, training, ongoing regulatory expenses, and other costs associated with product launch.  We intend to use the proceeds of $4.4 million from the sale/lease-back of our property to finance our current operations.  See “Item 9B. Other Information”.  The Fifth Private Equity Credit Agreement will continue to be available which we may use from time to time in order to raise working capital on an “as needed” basis.  If the need should arise for capital in excess of proceeds from the sale/lease-back transaction, we will use the Fifth Private Equity Credit Agreement.  If the Fifth Private Equity Credit Agreement is unavailable due to the price of our common stock, our inability to comply with the registration provision, Charlton’s breach of its agreement, or any other reason, we may be forced to seek additional funding through public or private financing, collaboration, licensing and other arrangements with corporate partners.  See “Item 5. Market for Registrant’s Common Equity and Related Stockholder Matters/Financing/Equity Line of Credit”.

During fiscal 2007, we raised a total of $4,192,717 less expenses through private placement transactions pursuant to our Fifth Private Equity Credit Agreement.  We do not expect to generate a positive internal cash flow for at least the next 12 months due to our need to obtain the PMA, the expected costs of commercializing our initial product, the CTLM®, and the expense of our continuing product development program.  We will require additional funds for operating expenses, FDA regulatory processes, manufacturing and marketing programs and to continue our product development program.  Accordingly, we intend to use the proceeds from the sale/lease-back of our property to finance our current operations and if necessary, the Fifth Private Equity Credit Agreement to raise the funds required through the end of fiscal year 2008 and thereafter in order to continue operations.  In the event that we are unable to utilize the Fifth Private Equity Credit Agreement, we would have to raise the additional funds required by either equity or debt financing, including entering into a transaction(s) to privately place equity, either common or preferred stock, or debt securities, or combinations of both; or by placing equity into the public market through an underwritten secondary offering.  If additional funds are raised by issuing equity securities, dilution to existing stockholders will result, and future investors may be granted rights superior to those of existing stockholders.

We now have issued and outstanding 318,205,363 shares of common stock out of 450,000,000 authorized shares.  In addition, we have reserved approximately 20,600,000 shares to cover outstanding options.  We had anticipated that revenues would have been a significant source of cash by the date of this report, but commercialization has been slower than expected largely due to the delay in obtaining PMA from the FDA, which we believe has depressed our stock price.  The continued dilution caused by the issuance of common shares through the utilization of our Fifth Private Equity Credit Agreement was the compelling reason why we made the decision to sell and lease back our building.

Capital expenditures for the fiscal 2007 were $16,500 as compared to $20,079 for the prior year. These expenditures were related to the purchases of computer and other equipment, office, warehouse and manufacturing fixtures and computer software.  We anticipate that our capital expenditures for fiscal 2008 will be approximately $25,000.

During the year ending June 30, 2007, there were no changes in our existing debt agreements and we had no outstanding bank loans as of June 30, 2007.  Our annual fixed commitments, including salaries and fees for current employees and consultants, rent, payments under license agreements and other contractual commitments are approximately $7.2 million, as of the date of this report, and are likely to increase as additional agreements are entered into and additional personnel are retained.  We will require substantial additional funds for our product development programs, operating expenses, regulatory processes, and manufacturing and marketing programs, which are presently estimated at an aggregate of approximately $600,000 per month.  The foregoing projections are subject to many conditions most of which are beyond our control.  Our future capital requirements will depend on many factors, including the following: the progress of our product development projects, the time and cost involved in obtaining regulatory approvals; the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; competing technological and market developments; changes and developments in our existing collaborative, licensing and other relationships and the terms of any new collaborative, licensing and other arrangements that we may establish; and the development of commercialization activities and arrangements.

27

We do not expect to generate a positive internal cash flow for at least 12 months as substantial costs and expenses continue due principally to the international commercialization of the CTLM®, activities related to our FDA PMA process, and advanced product development activities.  We intend to use the proceeds from the sale/lease-back of our property to finance our current operations and, if necessary, the Fifth Private Equity Credit Agreement as our principal source of additional capital.  No assurances, however, can be given that this financing or any necessary future financing will be available or, if available, that it will be obtained on terms satisfactory to us.  Our ability to effectuate our business plan and continue operations is dependent on our ability to raise capital, structure a profitable business, and generate revenues.  If our working capital were insufficient to fund our operations, we would have to explore additional sources of financing.  We plan to continue our policy of investing excess funds, if any, in a High Performance Money Market account at Wachovia Bank N.A.

CAUTIONARY STATEMENTS REGARDING FORWARD-LOOKING STATEMENTS

This report on Form 10-K and certain information incorporated by reference contains “forward-looking statements” within the meaning of the federal securities laws and use terminology such as “may,” “will,” “expects,” “plans,” “anticipates,” “estimates,” “projects”, “potential,” or “continue,” or the negative or other comparable terminology regarding beliefs, plans, expectations, or intentions regarding the future.  These forward-looking statements involve substantial risks and uncertainties, and actual results could differ materially from those discussed and anticipated in such statements.  These forward-looking statements include, among others, statements relating to our business strategy, which is based upon our interpretation and analysis of trends in the healthcare treatment industry, especially those related to the diagnosis and treatment of breast cancer, and upon management’s ability to successfully develop and commercialize its principal product, the CTLM®.  This strategy assumes that the CTLM® will provide benefits, from both a medical and an economic perspective, to alternative techniques for diagnosing and managing breast cancer.  Factors that could cause actual results to materially differ include, without limitation, the timely and successful completion of our U.S. Food and Drug Administration (“FDA”) pre-market approval (“PMA”) clinical trials; the timely and successful submission of our PMA application to the FDA; manufacturing risks relating to the CTLM®, including our reliance on a single or limited source or sources of supply for some key components of our products as well as the need to comply with especially high standards for those components and in the manufacture of optical imaging products in general; uncertainties inherent in the development of new products and the enhancement of our existing CTLM® product, including technical and regulatory risks, cost overruns and delays; our ability to accurately predict the demand for our CTLM® product as well as future products and to develop strategies to address our markets successfully; the early stage of market development for medical optical imaging products and our ability to gain market acceptance of our CTLM® product by the medical community; our ability to expand our international distributor network for both the near and longer-term to effectively implement our globalization strategy; our dependence on senior management and key personnel and our ability to attract and retain additional qualified personnel; risks relating to financing utilizing our Private Equity Credit Agreement or other working capital financing arrangements; technical innovations that could render the CTLM® or other products marketed or under development by us obsolete; competition; risks and uncertainties relating to intellectual property, including claims of infringement and patent litigation; risks relating to future acquisitions and strategic investments and alliances; and reimbursement policies for the use of our CTLM® product and any products we may introduce in the future.  There are also many known and unknown risks, uncertainties and other factors, including, but not limited to, technological changes and competition from new diagnostic equipment and techniques, changes in general economic conditions, healthcare reform initiatives, legal claims, regulatory changes and risk factors detailed from time to time in our Securities and Exchange Commission filings that may cause these assumptions to prove incorrect and may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.  These risks and uncertainties include, but are not limited to, those described above or elsewhere in this annual report.  All forward-looking statements and risk factors included in this document are made as of the date of this report based on information available to us as of the date of this report, and we assume no obligation to update any forward-looking statements or risk factors.  You are cautioned not to place undue reliance on these forward-looking statements.

28

CERTAIN FACTORS THAT MAY AFFECT FUTURE RESULTS

Risks associated with our business

We must comply with extensive government regulation and have no assurance of regulatory approvals or clearances, which could cause us to cut back or cease operations.

A delay or inability to obtain any necessary United States, state or foreign regulatory clearances or approvals for our products would prevent us from selling the CTLM® system in the U.S. and other countries.

In the United States, the CTLM® is regulated as a medical device and is subject to the FDA's pre-market clearance or approval requirements.  To obtain FDA approval of an application for pre-market approval of a diagnostic tool such as the CTLM®, the pre-market approval application must demonstrate based on statistically significant results from extensive clinical studies, that the subject device is safe and has clinical utility, meaning that as a diagnostic tool it provides information that measurably contributes to a diagnosis or management of a disease or condition.  We rely on outside FDA consultants to assist us in obtaining the PMA from the FDA.

In addition, sales of medical devices outside the United States may be subject to international regulatory requirements that vary from country to country.  The time required to gain approval for international sales may be longer or shorter than required for FDA approval and the requirements may differ.

Regulatory approvals, if granted, may include significant limitations on the indicated uses for which the CTLM® may be marketed.  In addition, to obtain these approvals, the FDA and certain foreign regulatory authorities may impose numerous other requirements which medical device manufacturers must comply with.  Product approvals could be withdrawn for failure to comply with regulatory standards or the occurrence of unforeseen problems following initial marketing.

The third-party manufacturers upon which we will depend to manufacture our products are required to adhere to applicable FDA regulations regarding quality systems regulations commonly referred to as QSRs, which include testing, control and documentation requirements.  Failure to comply with applicable regulatory requirements, including marketing and promoting products for unapproved use, could result in warning letters, fines, injunctions, civil penalties, recall or seizure of products, total or partial suspension of production, refusal of the government to grant pre-market clearance or approval for devices, withdrawal of approvals and criminal prosecution.  Changes in existing regulations or adoption of new government regulations or polices could prevent or delay regulatory approval of our products.  Material changes to medical devices also are subject to FDA review and clearance or approval.

There can be no assurance that we will be able to obtain or maintain the following:

· FDA approval of a pre-market approval application for the CTLM®,

· foreign marketing clearances for the CTLM® or regulatory approvals or clearances for other products that we may develop, on a timely basis, or at all,

· timely receipt of approvals or clearances,

· continued approval or clearance of previously obtained approvals and clearances, and

· compliance with existing or future regulatory requirements.

If we do not obtain or maintain any of the above-mentioned standards, there may be material adverse effects on our business, financial condition and results of operations.

We may not be able to develop other products that are currently in the early stages of development due to our need for additional capital.

Due to our need for additional capital, products other than the CTLM® device are at early stages of development.  There can be no assurance that any of our proposed products, including the CTLM®, will:

· be found to be safe and effective,

· meet applicable regulatory standards or receive necessary regulatory clearance,

29

· be safe and effective, developed into commercial products, manufactured on a large scale or be economical to market, or

· achieve or sustain market acceptance.

Therefore, there is substantial risk that our product development and commercialization efforts will prove to be unsuccessful.

We depend on market acceptance to sell our products, which have not been proven, and a lack of acceptance of the CTLM® could cause our business to fail.

There can be no assurance that physicians or the medical community in general will accept and utilize the CTLM® or any other products that we develop.  The extent and rate the CTLM® achieves market acceptance and penetration will depend on many variables, including, but not limited to the establishment and demonstration in the medical community of the clinical safety, efficacy and cost-effectiveness of the CTLM® and the advantages of the CTLM® over existing technology and cancer detection methods.

There can be no assurance that the medical community and third-party payers will accept our unique technology.  Similar risks will confront any other products we develop in the future.  Failure of our products to gain market acceptance would hinder our sales efforts resulting in a loss of revenues and potential profit and, ultimately, could cause our business to fail.  It would further prevent us from developing new products.

We depend upon suppliers with whom we have no contracts, which suppliers could cause production disruption if they terminated or changed their relationships with us.

We believe that there are a number of suppliers for most of the components and subassemblies required for the CTLM®; however, components for our laser system are provided by one supplier.  Although these components are provided by a limited number of other suppliers, we believe our laser supplier and their products are the most reliable.  We have no agreement with our laser supplier and purchase the laser components on an as-needed basis.   For certain services and components, we currently rely on single suppliers.  If we encounter delays or difficulties with our third-party suppliers in producing, packaging, or distributing components of the CTLM® device, market introduction and subsequent sales would be adversely affected.

We have limited experience in sales, marketing and distribution, which could negatively impact our ability to enter into collaborative arrangements or other third party relationships which are important to the successful development and commercialization of our products and potential profitability.

We have limited internal marketing and sales resources and personnel.  There can be no assurance that we will be able to establish sales and distribution capabilities or that we will be successful in gaining market acceptance for any products we may develop.  There can be no assurance that we will be able to recruit and retain skilled sales, marketing, service or support personnel, that agreements with distributors will be available on terms commercially reasonable to us, or at all, or that our marketing and sales efforts will be successful.

There can be no assurance that we will be able to further develop our distribution network on acceptable terms, if at all, or that any of our proposed marketing schedules or plans can or will be met.

We depend on qualified personnel to run and develop our specialized business who we may be unable to retain or hire.

Due to the specialized scientific nature of our business, we are highly dependent upon our ability to attract and retain qualified scientific, technical and managerial personnel.  We have entered into employment agreements with some of our executive officers.  The loss of the services of existing personnel, as well as the failure to recruit key scientific, technical and managerial personnel in a timely manner would be detrimental to our research and development programs and could have an adverse impact upon our business affairs and finances.  Our anticipated growth and expansion into areas and activities requiring additional expertise, such as marketing, will require the addition of new management personnel.  Competition for qualified personnel is intense and there can be no assurance that we will be able to continue to attract and retain qualified personnel necessary for the development of our business.

30

We have a limited manufacturing history that could cause delays in the production and shipment of our product.

We will have to expand our CTLM® manufacturing and assembly capabilities and contract for the manufacture of the CTLM® components in volumes that will be necessary for us to achieve significant commercial sales in the event we begin substantial foreign sales and/or obtain regulatory approval to market our products in the United States.  We have limited experience in the manufacture of medical products for clinical trials or commercial purposes.  Should we continue to manufacture our products at our facility, our manufacturing facilities would continue to be subject to the full range of the FDA's current quality system regulations.  In addition, there can be no assurance that our manufacturing efforts will be successful or cost-effective.

We depend on third parties who may not be in compliance with the FDA's quality system regulations which may delay the approval or decrease the sales of the CTLM®.

We have used and do use third parties to manufacture and deliver the components of the CTLM® and intend to continue to use third parties to manufacture and deliver these components and other products we may develop.  There can be no assurance that the third-party manufacturers we depend on for the manufacturing of CTLM® components will be in compliance with the quality system regulations (QSR) at the time of the pre-approval inspection or will maintain compliance afterwards.  This failure could significantly delay FDA approval of the pre-market approval application for the CTLM® device.

We will rely on international sales and may be subject to risks associated with international commerce.

We have commenced international sales efforts for the CTLM® in Europe, Asia, South America and the Middle East.  Until we receive pre-market approval from the FDA to market the CTLM® in the United States, our revenues, if any, will be derived from sales to international distributors.  A significant portion of our revenues may be subject to the risks associated with international sales, including:

· economical and political instability,

· shipping delays,

· fluctuation of foreign currency exchange rates,

· foreign regulatory requirements, and

· various trade restrictions, all of which could have a significant impact on our ability to deliver products on a timely basis.

Significant increases in the level of customs duties, export quotas or other trade restrictions could have a material adverse effect on our business, financial condition and results of operations.  The regulation of medical devices in foreign countries continues to develop, and there can be no assurance that new laws or regulations will not have an adverse effect on us.  While we attempt to minimize the risk of doing business with distributors in countries which are having difficult financial times by requesting payment via an irrevocable letter of credit (“L/C”) drawn on a United States bank prior to shipment of the CTLM®, it is not always possible to obtain an L/C from our distributor.  In these cases we must seek alternative payment arrangements which include third-party financing, leasing or extending payment terms to our distributors.

Our business has the risk of product liability claims, and preferred insurance coverage may be expensive or unavailable, which may expose us to material liabilities.

Our business exposes us to potential product liability risks, which are inherent in the testing, manufacturing, and marketing of cancer detection products.  Significant litigation, not involving us, has occurred in the past based on the allegations of false negative diagnoses of cancer.  There can be no assurance that we will not be subjected to claims and potential liability.  Although the FDA does not require product liability insurance with regard to clinical investigations, we obtained and presently carry product liability insurance in the amount of $3,000,000.  While we plan to maintain insurance against product liability and defense costs, there can be no assurance that claims against us arising with respect to our products will be successfully defended or that the insurance to be carried by us will be sufficient to cover liabilities arising from any claims.  A successful claim against us in excess of our insurance coverage could have a material adverse effect on us.  Furthermore, there can be no assurance that we will be able to continue to obtain or maintain product liability insurance on acceptable terms.

31

Risks associated with our industry

Lack of third-party reimbursement may have a negative impact on the sales of our products, which would negatively impact our revenues.

In the United States, suppliers of health care products and services are greatly affected by Medicare, Medicaid and other government insurance programs, as well as by private insurance reimbursement programs.  Third-party payers (Medicare, Medicaid, private health insurance companies, and other organizations) may affect the pricing or relative attractiveness of our products by regulating the level of reimbursement provided by these payers to the physicians, clinics and imaging centers utilizing the CTLM® or any other products that we may develop, by refusing reimbursement.  The level of reimbursement, if any, may impact the market acceptance and pricing of our products, including the CTLM®.  Failure to obtain favorable rates of third-party reimbursement could discourage the purchase and use of the CTLM® as a diagnostic device.

In international markets, reimbursement by private third-party medical insurance providers, including governmental insurers and independent providers varies from country to country.  In addition, such third-party medical insurance providers may require additional information or clinical data prior to providing reimbursement for a product.  In some countries, our ability to achieve significant market penetration may depend upon the availability of third-party governmental reimbursement.  Revenues and profitability of medical device companies may be affected by the continuing efforts of governmental and third party payers to contain or reduce the cost of health care through various means.

There are uncertainties regarding healthcare reform including possible legislation, whereby our customers may not receive medical reimbursement for the use of our product on their patients, which may cause our customers to use other services and products.

Several states and the United States government are investigating a variety of alternatives to reform the health care delivery system.  These reform efforts include proposals to limit and further reduce and control health care spending on health care items and services, limit coverage for new technology and limit or control the price health care providers and drug and device manufacturers may charge for their services and products, respectively.  If adopted and implemented, these reforms could cause our healthcare providers to limit or not use the CTLM® systems.

Competition in the medical imaging industry may result in competing products, superior marketing and lower revenues and profits for us.

The market in which we intend to participate is highly competitive.  Many of the companies in the cancer diagnostic and screening markets have substantially greater technological, financial, research and development, manufacturing, human and marketing resources and experience than we do.  These companies may succeed in developing, manufacturing and marketing products that are more effective or less costly than our products.  The competition for developing a commercial device utilizing computed tomography techniques and laser technology is difficult to ascertain given the proprietary nature of the technology.

Item 7A.  Quantitative and Qualitative Disclosures About Market Risk

As of the date of this report, we believe that we do not have any material quantitative and qualitative market risks.

32

Item 8.  Financial Statements

Index to Financial Statements
		Page
Report of Independent Registered Public Accounting Firm		34
Financial Statements
	Balance Sheets	36
	Statements of Operations	37
	Statements of Stockholders’ Equity	38
	Statements of Cash Flows	48
	Notes to Financial Statements	50

33

REPORTS OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRMS

To the Board of Directors and

Stockholders of Imaging Diagnostic Systems, Inc.

We have audited the accompanying balance sheets of Imaging Diagnostic Systems, Inc. (A Development Stage Enterprise) as of June 30, 2007 and 2006, and the related statements of operations, stockholders’ equity, and cash flows for the years ended June 30, 2007and 2006 and for the period December 10, 1993 (date of inception) to June 30, 2005. These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audits. The financial statements for the period December 10, 1993 (date of inception) to June 30, 2005 reflect total revenues and a net loss of $1,292,248 and $77,128,255 respectively, of the cumulative totals. The other auditors’ report has been furnished to us and our opinion, insofar as it relates to amounts included for such period, is based solely on the report of such other auditors.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of the Company as of June 30, 2007 and 2006, and the results of its operations and cash flows for the years then ended and for the period December 10, 1993 (date of inception) to June 30, 2007 in conformity with generally accepted accounting principles in the United States of America.

The accompanying financial statements have been prepared assuming that Imaging Diagnostic Systems, Inc. will continue as a going concern.  As more fully described in Note 5, the Company has incurred recurring operating losses and will have to obtain additional capital to sustain operations.  These conditions raise substantial doubt about the Company’s ability to continue as a going concern.  Management’s plans in regard to these matters are also described in Note 5.  The accompanying financial statements do not include any adjustments to reflect the possible effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the effectiveness of Imaging Diagnostic Systems, Inc.’s internal control over financial reporting as of June 30, 2007, based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO), and our report dated August 28, 2007 expressed an unqualified opinion on management’s assessment of internal control over financial reporting and an unqualified opinion on the effectiveness of internal control over financial reporting.

  /s/  SHERB & CO, LLP

  Certified Public Accountants

Boca Raton, Florida

August 28, 2007

34

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

The Board of Directors and Stockholders

Imaging Diagnostic Systems, Inc.

We have audited the accompanying statements of operations, stockholders' equity and cash flows of Imaging Diagnostic Systems, Inc. (a Development Stage Company) for the year ended June 30, 2005 and for the period December 10, 1993 (date of inception) to June 30, 2005.  These financial statements are the responsibility of the Company's management.  Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States).  Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.  An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements.  An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation.  We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the results of operations and cash flows of Imaging Diagnostic Systems, Inc. (a Development Stage Company), for the year ended June 30, 2005 and for the period December 10, 1993 (date of inception) to June 30, 2005 in conformity with United States generally accepted accounting principles.

The Company is in the development stage as of June 30, 2005 and to date has had no significant operations.  Recovery of the Company's assets is dependent on future events, the outcome of which is indeterminable.  In addition, successful completion of the Company's development program and its transition, ultimately, to attaining profitable operations is dependent upon obtaining adequate financing to fulfill its development activities and achieving a level of sales adequate to support the Company's cost structure.

The accompanying financial statements have been prepared assuming the Company will continue as a going concern.  The Company has suffered recurring losses and has yet to generate an internal cash flow that raises substantial doubt about its ability to continue as a going concern.  Management's plans in regard to these matters are described in Note 5.  The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 /s/  Margolies, Fink and Wichrowski

Certified Public Accountants

Pompano Beach, Florida

August 22, 2005

35

IMAGING DIAGNOSTIC SYSTEMS, INC.
(a Development Stage Company)
Balance Sheets
June 30, 2007 and 2006
ASSETS
	2007			2006
Current assets:
Cash and cash equivalents	$	477,812		$	1,467,687
Accounts receivable, net of allowances for doubtful accounts
of $29,967 and $40,000, respectively		119,866			432,084
Loans receivable		63,602			73,617
Inventories, net of reserve of $408,000 and $108,000, respectively		1,363,156			1,891,904
Prepaid expenses		36,784			42,846
Total current assets		2,061,220			3,908,138
Property and equipment, net		2,030,795			2,035,183
Intangible assets, net		273,412			307,588
Total assets	$	4,365,427		$	6,250,909
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable and accrued expenses	$	585,991		$	558,993
Customer deposits		88,114			40,000
Short term debt		250,000			-
Total current liabilities		924,105			598,993
Commitments and contingencies		-			-
Stockholders equity:
Common stock, no par value; authorized 450,000,000 shares,
issued 311,538,038 and 247,676,633 shares, respectively		99,120,731			94,560,316
Additional paid-in capital		2,661,650			2,230,337
Deficit accumulated during the development stage		(98,341,059	)		(91,138,737	)
Total stockholders' equity		3,441,322			5,651,916
Total assets & stockholders' equity	$	4,365,427		$	6,250,909
See accompanying notes to the financial statements.

36

IMAGING DIAGNOSTIC SYSTEMS, INC.
(a Development Stage Company)
Statements of Operations
										From Inception
										(December 10,
	Year Ended			Year Ended			Year Ended			1993) to
	June 30, 2007			June 30, 2006			June 30, 2005			June 30, 2007
Net Sales	$	65,136		$	675,844		$	374,952		$	2,033,228
Cost of Sales		17,870			316,189			166,685			864,615
Gross Profit		47,266			359,655			208,267			1,168,613
Operating Expenses:
General and administrative		3,012,575			3,366,426			3,014,800			49,965,745
Research and development		2,089,497			2,046,688			2,553,567			18,387,032
Sales and marketing		1,351,521			1,210,917			1,083,706			7,089,718
Inventory valuation adjustments		493,596			184,219			499,194			4,412,010
Depreciation and amortization		176,158			175,807			187,539			2,773,073
Amortization of deferred compensation		-			-			-			4,064,250
Total Operating Expenses		7,123,347			6,984,057			7,338,806			86,691,828
Operating Loss		(7,076,081	)		(6,624,402	)		(7,130,539	)		(85,523,215	)
Gain (Loss) on sale of fixed assets		-			(2,439	)		-			3,146
Interest income		11,455			8,416			5,680			294,388
Other income		250,001			21,500			409,962			681,463
Interest expense		(387,697	)		(565,797	)		(598,021	)		(6,949,081	)
Net Loss		(7,202,322	)		(7,162,722	)		(7,312,918	)		(91,493,299	)
Dividends on cumulative preferred stock:
From discount at issuance		-			-			-			(5,402,713	)
Earned		-			-			-			(1,445,047	)
Net loss applicable to
common shareholders	$	(7,202,322	)	$	(7,162,722	)	$	(7,312,918	)	$	(98,341,059	)
Net Loss per common share:
Basic and diluted	$	(0.03	)	$	(0.03	)	$	(0.04	)	$	(0.92	)
Weighted average number of
common shares outstanding:
Basic and diluted		271,667,256			218,846,738			185,636,553			106,483,084
See accompanying notes to the financial statements.

37

IMAGING DIAGNOSTIC SYSTEMS, INC.
(a Development Stage Company)
Statements of Stockhoders' Equity
From December 10, 1993 (date of inception) to June 30, 2007
											Deficit
											Accumulated
	Preferred Stock (**)				Common Stock				Additional		During the
	Number of				Number of				Paid-in		Development			Subscriptions			Deferred
	Shares		Amount		Shares		Amount		Capital		Stage			Receivable			Compensation			Total
Balance at December 10, 1993 (date of inception)		0	$	-		0	$	-	$	-	$	-		$	-		$	-		$	-
Issuance of common stock, restated for reverse
stock split		-		-		510,000		50,000		-		-			-			-			50,000
Acquisition of public shell		-		-		178,752		-		-		-						-			-
Net issuance of additional shares of stock		-		-		15,342,520		16,451		-		-						-			16,451
Common stock sold		-		-		36,500		36,500		-		-						-			36,500
Net loss		-				-		-		-		(66,951	)					-			(66,951	)
Balance at June 30, 1994		-		-		16,067,772		102,951		-		(66,951	)		-			-			36,000
Common stock sold		-		-		1,980,791		1,566,595		-		-			(523,118	)		-			1,043,477
Common stock issued in exchange for services		-		-		115,650		102,942		-		-			-			-			102,942
Common stock issued with employment agreements		-		-		75,000		78,750		-		-			-			-			78,750
Common stock issued for compensation		-		-		377,500		151,000		-		-			-			-			151,000
Stock options granted		-		-		-		-		622,500		-			-			(622,500	)		-
Amortization of deferred compentsation		-		-		-		-		-		-			-			114,375			114,375
Forgiveness of officers' compensation		-		-		-		-		50,333		-			-			-			50,333
Net loss		-		-		-		-		-		(1,086,436	)		-			-			(1,086,436	)
Balance at June 30, 1995		-		-		18,616,713		2,002,238		672,833		(1,153,387	)		(523,118	)		(508,125	)		490,441

38

IMAGING DIAGNOSTIC SYSTEMS, INC.
(a Development Stage Company)
Statements of Stockhoders' Equity (Continued)
From December 10, 1993 (date of inception) to June 30, 2007
																Deficit
																Accumulated
	Preferred Stock (**)						Common Stock						Additional			During the
	Number of						Number of						Paid-in			Development			Subscriptions			Deferred
	Shares			Amount			Shares			Amount			Capital			Stage			Receivable			Compensation			Total
Balance at June 30, 1995		-			-			18,616,713			2,002,238			672,833			(1,153,387	)		(523,118	)		(508,125	)		490,441
Preferred stock sold, including dividends		4,000			3,600,000			-			-			1,335,474			(1,335,474	)		-			-			3,600,000
Common stock sold		-			-			700,471			1,561,110			-			-			-			-			1,561,110
Cancellation of stock subscription		-			-			(410,500	)		(405,130	)		-			-			405,130			-			-
Common stock issued in exchange for services		-			-			2,503,789			4,257,320			-			-			-			-			4,257,320
Common stock issued with exercise of stock options		-			-			191,500			104,375			-			-			(4,375	)		-			100,000
Common stock issued with exercise of options
for compensation		-			-			996,400			567,164			-			-			-			-			567,164
Conversion of preferred stock to common stock		(1,600	)		(1,440,000	)		420,662			1,974,190			(534,190	)		-			-			-			-
Common stock issued as payment of preferred
stock dividends		-			-			4,754			14,629			-			(14,629	)		-			-			-
Dividends accrued on preferred stock not
yet converted		-			-			-			-			-			(33,216	)		-			-			(33,216	)
Collection of stock subscriptions		-			-			-			-			-			-			103,679			-			103,679
Amortization of deferred compentsation		-			-			-			-			-			-			-			232,500			232,500
Forgiveness of officers' compensation		-			-			-			-			100,667			-			-			-			100,667
Net loss (restated)		-			-			-			-			-			(6,933,310	)		-			-			(6,933,310	)
Balance at June 30, 1996 (restated)		2,400			2,160,000			23,023,789			10,075,896			1,574,784			(9,470,016	)		(18,684	)		(275,625	)		4,046,355
See accompanying notes to the financial statements.

39

IMAGING DIAGNOSTIC SYSTEMS, INC.
(a Development Stage Company)
Statements of Stockhoders' Equity (Continued)
From December 10, 1993 (date of inception) to June 30, 2007
																Deficit
																Accumulated
	Preferred Stock (**)						Common Stock						Additional			During the
	Number of						Number of						Paid-in			Development			Subscriptions			Deferred
	Shares			Amount			Shares			Amount			Capital			Stage			Receivable			Compensation			Total
Balance at June 30, 1996 (restated)		2,400			2,160,000			23,023,789			10,075,896			1,574,784			(9,470,016	)		(18,684	)		(275,625	)		4,046,355
Preferred stock sold, including dividends		450			4,500,000			-			-			998,120			(998,120	)		-			-			4,500,000
Conversion of preferred stock to common stock		(2,400	)		(2,160,000	)		1,061,202			2,961,284			(801,284	)		-			-			-			-
Common stock issued in exchange for services		-			-			234,200			650,129			-			-			-			-			650,129
Common stock issued for compensation		-			-			353,200			918,364			-			-			-			-			918,364
Common stock issued with exercise of stock options		-			-			361,933			1,136,953			-			-			(33,750	)		-			1,103,203
Common stock issued to employee		-			-			(150,000	)		(52,500	)		-			-			-			-			(52,500	)
Common stock issued as payment of preferred
stock dividends		-			-			20,760			49,603			-			(16,387	)		-			-			33,216
Dividends accrued on preferred stock not
yet converted		-			-			-			-			-			(168,288	)		-			-			(168,288	)
Stock options granted		-			-			-			-			1,891,500			-			-			(1,891,500	)		-
Collection of stock subscriptions		-			-			-			-			-			-			16,875			-			16,875
Amortization of deferred compentsation		-			-			-			-			-			-			-			788,000			788,000
Net loss (restated)		-			-			-			-			-			(7,646,119	)		-			-			(7,646,119	)
Balance at June 30, 1997 (restated)		450			4,500,000			24,905,084			15,739,729			3,663,120			(18,298,930	)		(35,559	)		(1,379,125	)		4,189,235
See accompanying notes to the financial statements.

40

IMAGING DIAGNOSTIC SYSTEMS, INC.
(a Development Stage Company)
Statements of Stockhoders' Equity (Continued)
From December 10, 1993 (date of inception) to June 30, 2007
														Deficit
														Accumulated
	Preferred Stock (**)						Common Stock				Additional			During the
	Number of						Number of				Paid-in			Development			Subscriptions			Deferred
	Shares			Amount			Shares		Amount		Capital			Stage			Receivable			Compensation			Total
Balance at June 30, 1997 (restated)		450			4,500,000			24,905,084		15,739,729		3,663,120			(18,298,930	)		(35,559	)		(1,379,125	)		4,189,235
Preferred stock sold, including dividends
and placement fees		501			5,010,000			-		-		1,290,515			(1,741,015	)		-			-			4,559,500
Conversion of preferred stock to common stock		(340	)		(3,400,000	)		6,502,448		4,644,307		(1,210,414	)		-			-			-			33,893
Common stock sold		-			-			500,000		200,000		-			-			-			-			200,000
Common stock issued in exchange for services		-			-			956,000		1,419,130		-			-			-			-			1,419,130
Common stock issued for compensation		-			-			64,300		54,408		-			-			-			-			54,408
Common stock issued with exercise of stock options		-			-			65,712		22,999		-			-			-			-			22,999
Common stock issued in exchange for
licensing agreement		-			-			3,500,000		1,890,000		(3,199,000	)		-			-			-			(1,309,000	)
Dividends accrued on preferred stock not
yet converted		-			-			-		-		-			(315,000	)		-			-			(315,000	)
Stock options granted		-			-			-		-		1,340,625			-			-			(1,340,625	)		-
Collection of stock subscriptions		-			-			-		12,500		-			-			21,250			-			33,750
Amortization of deferred compentsation		-			-			-		-		-			-			-			1,418,938			1,418,938
Net loss (restated)		-			-			-		-		-			(6,715,732	)		-			-			(6,715,732	)
Balance at June 30, 1998 (restated)		611			6,110,000			36,493,544		23,983,073		1,884,846			(27,070,677	)		(14,309	)		(1,300,812	)		3,592,121
See accompanying notes to the financial statements.

41

IMAGING DIAGNOSTIC SYSTEMS, INC.
(a Development Stage Company)
Statements of Stockhoders' Equity (Continued)
From December 10, 1993 (date of inception) to June 30, 2007
														Deficit
														Accumulated
	Preferred Stock (**)						Common Stock				Additional			During the
	Number of						Number of				Paid-in			Development			Subscriptions			Deferred
	Shares			Amount			Shares		Amount		Capital			Stage			Receivable			Compensation			Total
Balance at June 30, 1998 (restated)		611			6,110,000			36,493,544		23,983,073		1,884,846			(27,070,677	)		(14,309	)		(1,300,812	)		3,592,121		*
Preferred stock issued - satisfaction of debt		138			1,380,000			-		-		(161,348	)		(492,857	)		-			-			725,795
Conversion of preferred stock to common stock		(153	)		(1,530,000	)		4,865,034		1,972,296		(442,296	)		-			-			-			-
Common stock sold		-			-			200,000		60,000		-			-			-			-			60,000
Common stock issued - exchange for services
and compensation		-			-			719,442		301,210		-			-			-			-			301,210
Common stock issued - repayment of debt		-			-			2,974,043		1,196,992		-			-			-			-			1,196,992
Common stock issued in exchange for loan fees		-			-			480,000		292,694		-			-			-			-			292,694
Common stock issued with exercise of stock options		-			-			65,612		124,464		-			-			-			-			124,464
Common stock issued in satisfaction of
licensing agreement payable		-			-			3,500,000		1,890,000		-			-			-			-			1,890,000
Redeemable preferred stock sold, deemed dividend		-			-			-		-		-			(127,117	)		-			-			(127,117	)
Dividends accrued-preferred stock not yet converted		-			-			-		-		-			(329,176	)		-			-			(329,176	)
Stock options granted		-			-			-		-		209,625			-			-			(209,625	)		-
Amortization of deferred compentsation		-			-			-		-		-			-			-			1,510,437			1,510,437
Net loss (restated)		-			-			-		-		-			(6,543,292	)		-			-			(6,543,292	)
Balance at June 30, 1999 (restated)		596			5,960,000			49,297,675		29,820,729		1,490,827			(34,563,119	)		(14,309	)		-			2,694,128
See accompanying notes to the financial statements.

42

IMAGING DIAGNOSTIC SYSTEMS, INC.
(a Development Stage Company)
Statements of Stockhoders' Equity (Continued)
From December 10, 1993 (date of inception) to June 30, 2007
															Deficit
															Accumulated
	Preferred Stock (**)						Common Stock					Additional			During the
	Number of						Number of					Paid-in			Development			Subscriptions			Deferred
	Shares			Amount			Shares		Amount			Capital			Stage			Receivable			Compensation		Total
Balance at June 30, 1999 (restated)		596			5,960,000			49,297,675		29,820,729			1,490,827			(34,563,119	)		(14,309	)		-		2,694,128
Conversion of convertible debentures		-			-			4,060,398		3,958,223			-			-			-			-		3,958,223
Conversion of preferred stock to common, net		(596	)		(5,960,000	)		45,415,734		7,313,334			(648,885	)		-			-			-		704,449
Common stock sold		-			-			100,000		157,000			-			-			-			-		157,000
Common stock issued - exchange for services
and compensation, net of cancelled shares		-			-			137,000		(18,675	)		-			-			-			-		(18,675	)
Common stock issued - repayment of debt
and accrued interest		-			-			5,061,294		1,067,665			-			-			-			-		1,067,665
Common stock issued in exchange for
interest and loan fees		-			-			7,297		2,408			-			-			-			-		2,408
Common stock issued with exercise of stock options		-			-			1,281,628		395,810			157,988			-			(13,599	)		-		540,199
Common stock issued with exercise of warrants		-			-			150,652		121,563			97,850			-			-			-		219,413
Issuance of note payable with warrants at a discount		-			-			-		-			500,000			-			-			-		500,000
Dividends accrued-preferred stock not yet converted		-			-			-		-			-			(145,950	)		-			-		(145,950	)
Net loss (restated)		-			-			-		-			-			(6,531,662	)		-			-		(6,531,662	)
Balance at June 30, 2000 (restated)		-			-			105,511,678		42,818,057			1,597,780			(41,240,731	)		(27,908	)		-		3,147,198
See accompanying notes to the financial statements.

43

IMAGING DIAGNOSTIC SYSTEMS, INC.
(a Development Stage Company)
Statements of Stockhoders' Equity (Continued)
From December 10, 1993 (date of inception) to June 30, 2007
														Deficit
														Accumulated
	Preferred Stock (**)						Common Stock				Additional			During the
	Number of						Number of				Paid-in			Development			Subscriptions			Deferred
	Shares			Amount			Shares		Amount		Capital			Stage			Receivable			Compensation		Total
Balance at June 30, 2000 (restated)		-			-			105,511,678		42,818,057		1,597,780			(41,240,731	)		(27,908	)		-		3,147,198
Preferred stock sold, including dividends		500			5,000,000			-		-		708,130			(708,130	)		-			-		5,000,000
Conversion of preferred stock to common, net		(500	)		(5,000,000	)		5,664,067		5,580,531		(708,130	)		-			-			-		(127,599	)
Common stock issued - line of equity transactions		-			-			3,407,613		3,143,666		-			-			-			-		3,143,666
Common stock issued - exchange for services
and compensation		-			-			153,500		227,855		-			-			-			-		227,855
Common stock issued - repayment of debt
and accrued interest		-			-			810,000		1,393,200		-			-			-			-		1,393,200
Common stock issued with exercise of stock options		-			-			3,781,614		1,868,585		-			-			13,599			-		1,882,184
Common stock issued with exercise of warrants		-			-			99,375		119,887		-			-			-			-		119,887
Dividends accrued-preferred stock		-			-			-		-		-			(422,401	)		-			-		(422,401	)
Net loss (restated)		-			-			-		-		-			(9,532,450	)		-			-		(9,532,450	)
Balance at June 30, 2001 (restated)		-			-			119,427,847		55,151,781		1,597,780			(51,903,712	)		(14,309	)		-		4,831,540
See accompanying notes to the financial statements.

44

IMAGING DIAGNOSTIC SYSTEMS, INC.
(a Development Stage Company)
Statements of Stockhoders' Equity (Continued)
From December 10, 1993 (date of inception) to June 30, 2007
											Deficit
											Accumulated
	Preferred Stock (**)				Common Stock				Additional		During the
	Number of				Number of				Paid-in		Development			Subscriptions			Deferred
	Shares		Amount		Shares		Amount		Capital		Stage			Receivable			Compensation			Total
Balance at June 30, 2001 (restated)		-		-		119,427,847		55,151,781		1,597,780		(51,903,712	)		(14,309	)		-			4,831,540
Common stock issued - line of equity transactions		-		-		11,607,866		6,213,805		-		-			-			-			6,213,805
Common stock issued - exchange for services
and compensation		-		-		560,000		294,350		-		-			-			(117,600	)		176,750
Net loss (restated)		-		-		-		-		-		(7,997,652	)		-			-			(7,997,652	)
Balance at June 30, 2002 (restated)		-		-		131,595,713		61,659,936		1,597,780		(59,901,364	)		(14,309	)		(117,600	)		3,224,443
Common stock issued - line of equity transactions		-		-		29,390,708		8,737,772		-		-			-			-			8,737,772
Common stock issued - exchange for services
and compensation		-		-		2,007,618		970,653		-		-			-			117,600			1,088,253
Payment of subscriptions receivable		-		-		-		-		-		-			14,309			-			14,309
Net loss (restated)		-		-		-		-		-		(8,358,774	)		-			-			(8,358,774	)
Balance at June 30, 2003 (restated)		-		-		162,994,039		71,368,361		1,597,780		(68,260,138	)		-			-			4,706,003
See accompanying notes to the financial statements.

45

IMAGING DIAGNOSTIC SYSTEMS, INC.
(a Development Stage Company)
Statements of Stockhoders' Equity (Continued)
From December 10, 1993 (date of inception) to June 30, 2007
											Deficit
											Accumulated
	Preferred Stock (**)				Common Stock				Additional		During the
	Number of				Number of				Paid-in		Development			Subscriptions		Deferred
	Shares		Amount		Shares		Amount		Capital		Stage			Receivable		Compensation		Total
Balance at June 30, 2003 (restated)		-		-		162,994,039		71,368,361		1,597,780		(68,260,138	)		-		-		4,706,003
Common stock issued - line of equity transactions		-		-		8,630,819		6,541,700		-		-			-		-		6,541,700
Common stock issued - exchange for services
and compensation		-		-		734,785		832,950		-		-			-		-		832,950
Common stock issued - exercise of stock options		-		-		967,769		492,701		-		-			-		-		492,701
Net loss		-		-		-		-		-		(8,402,959	)		-		-		(8,402,959	)
Balance at June 30, 2004 (Restated)		-		-		173,327,412		79,235,712		1,597,780		(76,663,097	)		-		-		4,170,395
Common stock issued - line of equity transactions		-		-		26,274,893		7,797,807		-		-			-		-		7,797,807
Common stock issued - exchange for services
and compensation		-		-		285,000		113,850		-		-			-		-		113,850
Common stock issued - exercise of stock options		-		-		13,264		3,404		-		-			-		-		3,404
Net loss		-		-		-		-		-		(7,312,918	)		-		-		(7,312,918	)
Balance at June 30, 2005		-	$	-		199,900,569	$	87,150,773	$	1,597,780	$	(83,976,015	)	$	-	$	-		4,772,538
See accompanying notes to the financial statements.

46

IMAGING DIAGNOSTIC SYSTEMS, INC.
(a Development Stage Company)
Statements of Stockhoders' Equity (Continued)
From December 10, 1993 (date of inception) to June 30, 2007
											Deficit
											Accumulated
	Preferred Stock (**)				Common Stock				Additional		During the
	Number of				Number of				Paid-in		Development			Subscriptions		Deferred
	Shares		Amount		Shares		Amount		Capital		Stage			Receivable		Compensation		Total
Balance at June 30, 2005		-		-		199,900,569		87,150,773		1,597,780		(83,976,015	)		-		-		4,772,538
Common stock issued - line of equity transactions		-		-		47,776,064		7,409,543		-		-			-		-		7,409,543
Fair Value of Stock Option Expenses		-		-		-		-		632,557		-			-		-		632,557
Net loss		-		-		-		-		-		(7,162,722	)		-		-		(7,162,722	)
Balance at June 30, 2006		-		-		247,676,633		94,560,316		2,230,337		(91,138,737	)		-		-		5,651,916
Common stock issued - line of equity transactions		-		-		63,861,405		4,560,415		-		-			-		-		4,560,415
Fair Value of Stock Option Expenses		-		-		-		-		431,313		-			-		-		431,313
Net loss		-		-		-		-		-		(7,202,322	)		-		-		(7,202,322	)
Balance at June 30, 2007		-		-		311,538,038		99,120,731		2,661,650		(98,341,059)			-		-		3,441,322
** See Note 16 for a detailed breakdown by Series.
See accompanying notes to the financial statements.

47

IMAGING DIAGNOSTIC SYSTEMS, INC.
(A Development Stage Company)
Statement of Cash Flows
										From Inception
										(December 10,
	Year Ended			Year Ended			Year Ended			1993) to
	June 30, 2007			June 30, 2006			June 30, 2005			June 30, 2007
Net loss	$	(7,202,322	)	$	(7,162,722	)	$	(7,312,918	)	$	(91,493,299	)
Adjustments to reconcile net loss to net cash
used for operating activities:
Depreciation and amortization		176,158			183,450			187,539			2,780,716
(Gain) Loss on sale of fixed assets		-			2,439			-			(3,146	)
Extinguishment of debt		-			(21,500	)		(409,962	)		(431,462	)
Inventory valuation adjustment		493,596			184,219			499,194			4,412,010
Amoritization of deferred compensation		-			-			-			4,064,250
Noncash interest, compensation and consulting services		367,698			565,373			711,740			18,939,569
Fair Value of Stock Option Expenses		431,313			632,557			-			1,063,870
(Increase) decrease in accounts and
loans receivable - employees, net		332,267			(266,590	)		(249,616	)		(252,120	)
Increase (decrease) in allowance for
doubful account		(10,033	)		40,000			-			29,967
(Increase) decrease in inventories, net		(85,942	)		(55,625	)		(161,828	)		(2,837,997	)
(Increase) decrease in prepaid expenses		6,062			(8,659	)		30,392			(36,784	)
(Increase) decrease in other assets		-			-			-			(306,618	)
Increase (decrease) in accounts payable and
accrued expenses		26,997			(224,974	)		(257,505	)		751,425
Increase (decrease) in other current liabilities		48,114			10,000			(10,000	)		88,114
Total adjustments		1,786,230			1,040,690			339,954			28,261,794
Net cash used for operating activities		(5,416,092	)		(6,122,032	)		(6,972,964	)		(63,231,505	)
Cash flows from investing activities:
Proceeds from sale of property & equipment		-			104			-			29,961
Prototype equipment		-			-			-			(2,799,031	)
Capital expenditures		(16,500	)		(20,079	)		(23,641	)		(4,466,720	)
Net cash used for investing activities		(16,500	)		(19,975	)		(23,641	)		(7,235,790	)
Cash flows from financing activities:
Repayment of capital lease obligation		-			-			-			(50,289	)
Proceeds from convertible debenture		-			-			-			3,240,000
Proceeds from (repayments) loan payable, net		250,000			-			-			2,845,029
Proceeds from issuance of preferred stock		-			-			-			18,039,500
Proceeds from exercise of stock options		-			-			3,404			903,989
Net proceeds from issuance of common stock		4,192,717			6,844,171			7,204,370			45,966,878
Net cash provided by financing activities		4,442,717			6,844,171			7,207,774			70,945,107
Net increase (decrease) in cash and cash equivalents		(989,875	)		702,164			211,169			477,812
Cash and cash equivalents at beginning of period		1,467,687			765,523			554,354			-
Cash and cash equivalents at end of period	$	477,812		$	1,467,687		$	765,523		$	477,812
See accompanying notes to the financial statements.

48

IMAGING DIAGNOSTIC SYSTEMS, INC.
(A Development Stage Company)
Statement of Cash Flows (Continued)
							From Inception
							(December 10,
	Year Ended		Year Ended		Year Ended		1993) to
	June 30, 2007		June 30, 2006		June 30, 2005		June 30, 2007
Supplemental disclosures of cash
flow information:
Cash paid for interest	$	-	$	-	$	78	$	215,962
Supplemental disclosures of noncash
investing and financing activities:
Issuance of common stock and options
in exchange for services	$	-	$	-	$	-	$	6,306,350
Issuance of common stock as loan fees in
connection with loans to the Company	$	-	$	-	$	-	$	293,694
Issuance of common stock as satisfaction of
loans payable and accrued interest	$	-	$	-	$	-	$	3,398,965
Issuance of common stock as satisfaction of
certain accounts payable	$	-	$	-	$	-	$	257,892
Issuance of common stock in
exchange for property and equipment	$	-	$	-	$	-	$	89,650
Issuance of common stock and other current liability
in exchange for patent liceensing agreement	$	-	$	-	$	-	$	581,000
Issuance of common stock for
compensation	$	-	$	-	$	113,850	$	2,691,788
Issuance of common stock through
exercise of incentive stock options	$	-	$	-	$	-	$	3,117,702
Issuance of common stock as
payment for preferred stock dividends	$	-	$	-	$	-	$	507,645
Acquisition of property and equipment
through the issuance of a capital
lease payable	$	-	$	-	$	-	$	50,289
See accompanying notes to the financial statements.

49

IMAGING DIAGNOSTIC SYSTEMS, INC.

(a Development Stage Company)

Notes to Financial Statements

(1)           BACKGROUND

The Company, ("Imaging Diagnostic Systems, Inc.") was organized in the state of New Jersey on November 8, 1985, under its original name of Alkan Corp.  On April 14, 1994, a reverse merger was effected between Alkan Corp. and the Florida corporation of Imaging Diagnostic Systems, Inc. ("IDSI-Fl.").  IDSI-Fl. was formed on December 10, 1993. (See Note 4)  Effective July 1, 1995 the Company changed its corporate status to a Florida corporation.

The Company is a development stage enterprise and during this stage will utilize the proceeds of $4.4 million from the sale and lease-back of its property in Plantation, FL (See Note 22).  Should additional working capital be required, the Company will obtain such capital through the use of its Fifth Private Equity Credit Agreement.  Since January 2003, the Company has had revenues of $2,033,228 from the sale of its CTLM® Breast Imaging System.  There is no assurance that once the development of the CTLM® device is completed and finally receives Federal Drug Administration marketing clearance, that the Company will achieve a profitable level of operations.

(2)           SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

(a) Use of estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.

(b) Revenue Recognition

We recognize revenue in accordance with the guidance presented in the SEC’s Staff Accounting Bulletin No. 104.  We sell our medical imaging products, parts, and services to independent distributors and in certain unrepresented territories directly to end-users.  Revenue is recognized when persuasive evidence of a sales arrangement exists, delivery has occurred such that title and risk of loss have passed to the buyer or services have been rendered, the selling price is fixed or determinable, and collectibility is reasonable assured.  Unless agreed otherwise, our terms with international distributors provide that title and risk of loss passes F.O.B. origin.

To be reasonably assured of collectibility, our policy is to minimize the risk of doing business with distributors in countries which are having difficult financial times by requesting payment via an irrevocable letter of credit (“L/C”) drawn on a United States bank prior to shipment of the CTLM®.  It is not always possible to obtain an L/C from our distributors so in these cases we must seek alternative payment arrangements which include third-party financing, leasing or extending payment terms to our distributors.

50

IMAGING DIAGNOSTIC SYSTEMS, INC.

(a Development Stage Company)

Notes to Financial Statements (Continued)

(2)           SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

(c) Allowance for Doubtful Accounts

In the event that management determines that a receivable becomes uncollectible, or events or circumstances change, which result in a temporary cessation of payments from the distributor, we will make our best estimate of probable or potential losses in our accounts receivable balance using the allowance method for each quarterly period.  Management will periodically review the receivables at the end of each quarterly reporting period and the appropriate accrual will be made based on current available evidence and historical experience.

Our allowance for doubtful accounts decreased to $29,967 as of June 30, 2007 from $40,000 in the prior fiscal year.

(d) Cash and cash equivalents

Holdings of highly liquid investments with original maturities of three months or less and investment in money market funds are considered to be cash equivalents by the Company.

(e) Inventory

Inventories, consisting principally of raw materials, work-in-process (including completed units under testing), finished goods and units placed on consignment, are carried at the lower of cost or market.  Cost is determined using the first-in, first-out (FIFO) method.  Raw materials consist of purchased parts, components and supplies.  Work-in-process includes completed units undergoing final inspection and testing.

We have used and will continue to use CTLM® systems from finished goods as demonstrators or for clinical collaboration.  At the conclusion of the demonstration or clinical collaboration period, the CTLM® may be sold at reduced prices.  On a quarterly basis, using the guidance of ARB 43, Chapter 4, Statement 5, our ability to realize the value of our inventory is based on a combination of factors including the following: how long a consigned system has been used for demonstration or clinical collaboration purpose; the utility of the goods as compared to their cost; physical obsolescence; historical usage rates; forecasted sales or usage; product end of life dates; estimated current and future market values; and new product introductions.

Due to recent technological advances resulting in overall lower costs for certain inventory components; the Company has reduced these components of its inventory to their net realizable value.  The inventory valuation adjustments are reflected in the statement of operations and amounted to $493,596, $184,219, $499,194, and $4,412,010, for the years ended June 30, 2007, 2006 and 2005, and for the period December 10, 1993 (date of inception) to June 30, 2007, respectively.

51

IMAGING DIAGNOSTIC SYSTEMS, INC.

(a Development Stage Company)

Notes to Financial Statements (Continued)

(2)           SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

(f) Property, equipment and software development costs

Property and equipment are stated at cost, less accumulated depreciation and amortization.  Depreciation and amortization are computed using straight-line methods over the estimated useful lives of the related assets.  Expenditures for renewals and betterments which increase the estimated useful life or capacity of the asset are capitalized; expenditures for repairs and maintenance are expensed when incurred.

Under the criteria set forth in Statement of Financial Accounting Standards No. 86, capitalization of software development costs begins upon the establishment of technological feasibility for the product.  The establishment of technological feasibility and the ongoing assessment of the recoverability of these costs require considerable judgment by management with respect to certain external factors, including, but not limited to, anticipated future gross product revenues, estimated economic life and changes in software and hardware technology.  After considering the above factors, the Company has determined that software development costs, incurred subsequent to the initial acquisition of the basic software technology, should be properly expensed.  Such costs are included in research and development expense in the accompanying statements of operations.

(g) Research and development

Research and development expenses consist principally of expenditures for equipment and outside third-party consultants, raw materials which are used in testing and the development of the Company's CTLM® device or other products, product software and compensation to specific company personnel.  The non-payroll related expenses include testing at outside laboratories, parts associated with the design of initial components and tooling costs, and other costs which do not remain with the developed CTLM® device.  The software development costs are with outside third-party consultants involved with the implementation of final changes to the developed software.  All research and development costs are expensed as incurred.

(h) Net loss per share

In 1998, the Company adopted SFAS No. 128, (“Earnings Per Share”), which requires the reporting of both basic and diluted earnings per share.  Basic net loss per share is determined by dividing loss available to common shareholders by the weighted average number of common shares outstanding for the period.  Diluted loss per share reflects the potential dilution that could occur if options or other contracts to issue common stock were exercised or converted into common stock, as long as the effect of their inclusion is not anti-dilutive.

52

IMAGING DIAGNOSTIC SYSTEMS, INC.

(a Development Stage Company)

Notes to Financial Statements (Continued)

(2)           SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

(i) Patent license agreement

The patent license agreement will be amortized over the seventeen-year life of the patent, the term of the agreement.  See Note 2(m) Intangible Assets for disclosure on impairment policy.

(j) Stock-based compensation

In December 2004, the Financial Accounting Standards Board (“FASB”) issued SFAS No. 123 (revised 2004), Share-Based Payment (“SFAS No. 123(R)”), which is a revision of SFAS No. 123, and supersedes APB Opinion No. 25.  SFAS No. 123(R) requires all share-based payments to employees, including grants of employee stock options, to be recognized in the financial statements based on their fair values, beginning with the next fiscal year that begins after June 15, 2005.  In addition, SFAS No. 123(R) will cause unrecognized expense related to previously issued options vesting after the date of initial adoption to be recognized as a charge to results of operations over the remaining vesting period.  We were required to adopt SFAS 123(R) in our first quarter of fiscal year 2006.

The FASB has concluded that companies may adopt the new standard in one of two ways: the modified prospective transition method and the modified retrospective transition method.  Under the modified retrospective transition method, prior periods may be retroactively adjusted either as of the beginning of the year of adoption or for all periods presented.  The modified prospective transition method requires that compensation expense be recorded for all unvested stock options and share awards at the beginning of the fiscal period of adoption of SFAS 123(R), while the retrospective method would record compensation expense for all unvested stock options and share awards beginning with the fiscal period retroactively adjusted.  The Company adopted SFAS 123(R) on July 1, 2005 and elected to use the modified prospective transition method.

SFAS 123(R) is a new and very complex accounting standard, the application of which requires significant judgment and the use of estimates, particularly surrounding Black-Scholes assumptions such as stock price volatility, expected option lives, and expected option forfeiture rates, to value equity-based compensation.  There is little experience and guidance available with respect to developing these assumptions and models.  There is also uncertainty as to how the standard will be interpreted and applied as more companies adopt the standard and companies and their advisors gain experience with the standard.  SFAS 123(R) requires the recognition of the fair value of stock compensation in net income.

53

IMAGING DIAGNOSTIC SYSTEMS, INC.

(a Development Stage Company)

Notes to Financial Statements (Continued)

(2)           SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

The fair value concepts were not changed significantly in SFAS 123(R); however, in adopting this Standard, companies were given the option to choose among alternative valuation models and amortization assumptions.  We elected to continue to use the Black-Scholes option pricing model and expense the options as compensation over the requisite service period of the grant.  We will reconsider use of the Black-Scholes model if additional information becomes available in the future that indicates another model would be more appropriate, or if grants issued in future periods have characteristics that cannot be reasonably estimated using this model.

				From Inception
				(December 10,
	Year Ended			1993) to
	June 30, 2005			June 30, 2005
				(Restated)
Net loss to common shareholders,
as reported	$	(7,312,918	)	$	(83,976,015	)
Less: stock-based employee compensation
determined under the fair value method,
net of income tax effect		620,907			5,537,149
Net loss to common shareholders,
pro forma	$	(7,933,825	)	$	(89,513,164	)
Basic and diluted loss per share -
As reported	$	(.04	)	$	(1.02	)
Pro forma	$	(.04	)	$	(1.09	)

For purposes of the preceding pro forma disclosures, the weighted average fair value of each option has been estimated on the date of grant using the Black-Scholes options-pricing model with the weighted average assumptions listed below used for grants in 2007, 2006 and 2005, respectively.

	Year Ended	Year Ended	Year Ended
	June 30, 2007	June 30, 2006	June 30, 2005
Volatility	72.34%	71.11%	66.16%
Risk Free Interest Rate	5%	4%	4%
Expected Term	8 yrs	8 yrs	10 yrs

Our expected term assumption of eight years for the year ended June 30, 2007, was based upon the guidance provided by SEC Staff Accounting Bulletin 107 enabling us to use the simplified method for “plain vanilla” options for this calculation.  This provision may be used for grants made on or before December 31, 2007.

See Note 18 – Stock Options

54

IMAGING DIAGNOSTIC SYSTEMS, INC.

(a Development Stage Company)

Notes to Financial Statements (Continued)

(2)           SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

(k) Long-lived assets

Effective July 1, 1996, the Company adopted the provisions of Statement of Financial Accounting Standards No. 121. “Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to be Disposed Of” (“SFAS 121”).  This statement requires companies to write down to estimated fair value long-lived assets that are impaired.  The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable.  In performing the review of recoverability the Company estimates the future cash flows expected to result from the use of the asset and its eventual disposition.  If the sum of the expected future cash flows is less than the carrying amount of the assets, an impairment loss is recognized.

The Company has determined that no impairment losses need to be recognized through the fiscal year ended June 30, 2007.

In August of 2001, the Company adopted the provisions of Statement of Financial Accounting Standards No. 144, Accounting for the Impairment or Disposal of Long-Lived Assets (“SFAS 144”), which addresses accounting and financial reporting for the impairment and disposal of long-lived assets. This statement is effective for the Company beginning July 1, 2002. The Company does not believe that the adoption of SFAS 144 will have a significant impact on its financial position and results of operations.

(l) Income taxes

The Company provides for income taxes using the asset and liability method as required by Statement of Financial Accounting Standards No. 109 “Accounting for Income Taxes” (“SFAS 109”).  This method recognizes the amount of federal and state taxes payable or refundable for the current year as well as deferred tax assets and liabilities for the future tax consequence of events recognized in the financial statements and income tax returns.  Deferred income tax assets and liabilities are adjusted to recognize the change in tax laws or tax rates. These changes are recognized in income in the year that includes the enactment date.

(m) Intangible assets

Intangible assets, consisting of the patent license agreement and certain initial UL and CE costs are reflected in “Intangible Assets” on the balance sheet, net of accumulated amortization (Note 8).  The patent license agreement has a fixed life of seventeen years and will continue to be amortized over its remaining useful life.  During the fiscal year ending June 30, 1999, we incurred costs of $8,225 related to the process of obtaining UL and CE approvals and determined that these costs should be amortized based on their useful life of three years on a straight-line basis.

Long-lived assets, including patents, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may    not be recoverable.  Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset.  If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets.  Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell.

55

IMAGING DIAGNOSTIC SYSTEMS, INC.

(a Development Stage Company)

Notes to Financial Statements (Continued)

(2)           SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

The impairment analysis for patents can be very subjective as we rely upon signed distribution, dealer or license agreements with variable cash flows to substantiate the recoverability of these long-lived assets.  In our analysis we also take into account our position as a world-wide market leader in CT optical tomography; net sales of CTLM® systems of $2,033,228 since January 2003; the growing acceptance of our technology with over 9,000 scans performed world-wide; approvals or product registration in the following countries: CE Mark for the European Union, Canada, Peoples Republic of China, Argentina, Brazil and Colombia.  We believe the fair value of our patent license clearly exceeds the carrying amount of $273,412.

We have recorded accumulated amortization of $307,588 with a balance remaining of $273,412, which will be amortized over the next eight years at $8,544 per quarter.  We will continue to test for impairment on an annual basis or more frequently if events and circumstances change using the guidance provided in FAS-142.  Examples of such events and circumstances are:

· A significant adverse change in legal factors or in the business climate

· An adverse action or assessment by a regulator

· Unanticipated competition

· Loss of key personnel

· An expectation that all or a significant portion of a reporting unit will be sold or otherwise disposed of.

Based on our analysis, we determined that there was no impairment as of June 30, 2007.

   (n ) Warranty Reserve

The Company established a warranty reserve effective for the fiscal year ending June 30, 2005.  The table below reflects the Warranty Reserve established for the last three fiscal years.  Although the Company tests its product in accordance with its quality programs and processes, its warranty obligation is affected by product failure rates and service delivery costs incurred in correcting a product failure. Should actual product failure rates or service costs differ from the Company’s estimates, which are based on limited historical data, where applicable, revisions to the estimated warranty liability would be required.

	Year Ended	Year Ended	Year Ended
	June 30, 2007	June 30, 2006	June 30, 2005
Warranty Reserve	$14,952	$24,799	$14,400

(o) Deemed preferred stock dividend

The accretion resulting from the incremental yield embedded in the conversion terms of the convertible preferred stock is computed based upon the discount from market of the common stock at the date the preferred stock was issued.  The resulting deemed preferred stock dividend subsequently increases the value of the common shares upon conversion.

56

IMAGING DIAGNOSTIC SYSTEMS, INC.

(a Development Stage Company)

Notes to Financial Statements (Continued)

(2)           SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

(p) Discount on convertible debt

The discount which arises as a result of the allocation of proceeds to the beneficial conversion feature upon the issuance of the convertible debt increases the effective interest rate of the convertible debt and will be reflected as a charge to interest expense.  The amortization period will be from the date of the convertible debt to the date the debt first becomes convertible.

(q) Comprehensive income

SFAS 130, “Reporting Comprehensive Income”, requires a full set of general-purpose financial statements to be expanded to include the reporting of “comprehensive income”.  Comprehensive income is comprised of two components, net income and other comprehensive income.  For the period from December 10, 1993 (date of inception) to June 30, 2007, the Company had no items qualifying as other comprehensive income.

(r) Impact of recently issued accounting standards

In June 2006, the FASB issued Interpretation (FIN) No. 48 Accounting for Uncertainty in Income Taxes — an interpretation of FASB Statement No. 109 (FIN 48).  FIN 48 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements in accordance with SFAS No. 109 Accounting for Income Taxes.  This Interpretation prescribes a recognition threshold and measurement attribute for financial statement recognition, measurement and disclosure of tax positions that a company has taken or expects to be taken on a tax return.  Additionally, FIN 48 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods and transition.  FIN 48 is effective for fiscal years beginning after December15, 2006, with early adoption permitted.  The Company currently expects that adoption of FIN 48 will not have a material effect on the Company’s consolidated financial position and results of operations.

In September 2006, the FASB issued SFAS No. 157 “Fair Value Measurements.” SFAS No. 157 defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles, and expands disclosures about fair value measurements. SFAS No. 157 does not require any new fair value measurements, rather it applies under existing accounting pronouncements that require or permit fair value measurements. SFAS No. 157 is effective for fiscal years beginning after November 15, 2007, which will be our fiscal year 2009.  We are currently evaluating the impact of SFAS No. 157 on our financial statements.

In September 2006, the Securities and Exchange Commission (“SEC”) issued Staff Accounting Bulletin No. 108 (SAB 108) “Considering the Effects of Prior Year Misstatements in Current Year Financial Statements.” SAB 108 provides guidance on quantifying financial statement misstatements, including the effects of prior year errors on current year financial statements. SAB 108 is effective for fiscal years beginning after November 15, 2006, which will be our fiscal year 2008.

57

IMAGING DIAGNOSTIC SYSTEMS, INC.

(a Development Stage Company)

Notes to Financial Statements (Continued)

(2)           SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

In February 2007, the FASB issued Statement of Financial Accounting Standards No. 159, The Fair Value Option for Financial Assets and Financial Liabilities—Including an Amendment of FASB Statement No. 115 (“SFAS 159”). This standard permits an entity to choose to measure many financial instruments and certain other items at fair value. Most of the provisions in Statement 159 are elective; however, the amendment to FASB Statement No. 115, Accounting for Certain Investments in Debt and Equity Securities, applies to all entities with available-for-sale and trading securities. SFAS 159 is effective for fiscal years beginning after November 15, 2007. We are currently evaluating the impact this adoption will have on our financial statements.

 (s) Reclassifications

    Certain amounts in the prior period financial statements have been reclassified to conform with the current period presentation.

(3)           OTHER INCOME

During the fiscal year ending June 30, 2007, the Company sold its LILA technology to Bioscan Inc. for the sum of $250,001 which we received and recorded as Other Income.

(4)           MERGER

On April 14, 1994, IDSI-Fl. acquired substantially all of the issued and outstanding shares of Alkan Corp.  The transaction was accounted for as a reverse merger in accordance with Accounting Principles Board Opinion No. 16, wherein the shareholders of IDSI-Fl. retained the majority of the outstanding stock of Alkan Corp. after the merger. (see Note 17)

As reflected in the Statement of Stockholders’ Equity, the Company recorded the merger with the public shell at its cost, which was zero, since at that time the public shell did not have any assets or equity.  There was no basis adjustment necessary for any portion of the merger transaction as the assets of IDSI-Fl. were recorded at their net book value at the date of merger.  The 178,752 shares represent the exchange of shares between the companies at the time of merger.

As part of the transaction, the certificate of incorporation of Alkan was amended to change its name to Imaging Diagnostic Systems, Inc.

58

IMAGING DIAGNOSTIC SYSTEMS, INC.

(a Development Stage Company)

Notes to Financial Statements (Continued)

(5)           GOING CONCERN

The Company is currently a development stage enterprise and our continued existence is dependent upon our ability to resolve our liquidity problems, principally by obtaining additional debt and/or equity financing.  We have yet to generate a positive internal cash flow, and until significant sales of our product occur, we are mostly dependent upon debt and equity funding.  See Item 7 “Management’s Discussion and Analysis of Financial Condition and Results of Operations”.

In the event that we are unable to obtain debt or equity financing or we are unable to obtain such financing on terms and conditions acceptable to us, we may have to cease or severely curtail our operations.  This would materially impact our ability to continue as a going concern.  In the event that we are unable to draw on our private equity line, alternative financing would be required to continue operations.  Management has been able to raise the capital necessary to reach this stage of product development and has been able to obtain funding for capital requirements to date. There is no assurance that, if and when Food and Drug Administration (“FDA”) marketing clearance is obtained, the CTLM® will achieve market acceptance or that we will achieve a profitable level of operations.

We have commenced our planned principal operations of the manufacture and sale of our sole product, the CTLM®, CT Laser Mammography System. We are continuing to appoint distributors and are installing systems under our clinical collaboration program as part of our global commercialization program.  We have sold a total of 13 systems as of June 30, 2007; however, we continue to operate as a development stage enterprise because we have yet to produce significant revenues.  Should additional working capital be required, the Company will obtain such capital through the use of its Fifth Private Equity Credit Agreement (See Note 22).  We have to create product awareness as a foundation to developing our markets through our existing distributor network and through the appointment of additional distributors and the training of their field service engineers.  We would be able to exit SFAS 7 Development Stage Enterprise reporting upon having sufficient revenues for two successive quarters such that we would not have to utilize our Fifth Private Equity Credit Agreement or alternative funding sources for capital to cover our quarterly operating expenses.

(6)           INVENTORIES

Inventories consisted of the following:

	June 30,
	2007			2006
Raw materials consisting of purchased parts, components and supplies	$	848,254		$	845,516
Work-in process including units undergoing final inspection and testing		44,058			139,462
Finished goods		878,844			1,014,926
Sub-Total Inventories	$	1,771,156		$	1,999,904
Less Inventory Reserve		(408,000	)		(108,000	)
Total Inventory - Net	$	1,363,156		$	1,891,904

We review our Inventory for parts that have become obsolete or in excess of our manufacturing requirements and our Finished Goods for valuation pursuant to our Critical Accounting Policy for Inventory.  For the fiscal year ending June 30, 2007 we have identified $408,000 of Inventory that we deem impaired due to the lack of inventory turnover.  For the fiscal year ending June 30, 2006 we had identified $108,000 of Inventory that was in excess of our manufacturing requirements or warranty parts retention policy.  These amounts have been recorded as Inventory Reserve.

59

IMAGING DIAGNOSTIC SYSTEMS, INC.

(a Development Stage Company)

Notes to Financial Statements (Continued)

(7)           PROPERTY AND EQUIPMENT

The following is a summary of property and equipment, less accumulated depreciation:

	June 30,
	2007			2006
Furniture and fixtures	$	262,264		$	262,264
Building and land		2,092,529			2,092,529
Computers, equipment and software		416,849			400,349
CTLM® software costs		352,932			352,932
Trade show equipment		298,400			298,400
Clinical equipment		121,094			-
Laboratory equipment		212,560			212,560
Total Property & Equipment		3,756,628			3,619,034
Less: accumulated depreciation		(1,725,833	)		(1,583,851	)
Total Property & Equipment - Net	$	2,030,795		$	2,035,183

For the fiscal year ending June 30, 2007, we reclassified the net realizable value of $121,094 of CTLM® systems in Inventory to Clinical equipment as these CTLM® systems continue to be used as product demonstrators and for international clinical collaboration.

The estimated useful lives of property and equipment for purposes of computing depreciation and amortization are:

Furniture, fixtures, clinical, computers, laboratory
equipment and trade show equipment	5-7 years
Building	40 years
CTLM® software costs	5 years

Telephone equipment, acquired under a long-term capital lease at a cost of $50,289, is included in furniture and fixtures.  The CTLM® software is fully amortized.

(8)           INTANGIBLE ASSETS

Intangible assets consist of the following:

	June 30,
	2007		2006
Patent license agreement, net of accumulated
amortization of $307,588 and $273,412 respectively	$	273,412	$	307,588
UL & CE approvals, net of accumulated amortization of $8,225
and $8,225 respectively		-		-
Totals	$	273,412	$	307,588

During June 1998, the Company signed an exclusive Patent License Agreement with its former chief executive officer. (See Note 21)  The officer was the originator of patents issued on December 2, 1997 which covers some of the technology of the CTLM®.  Pursuant to the terms of the agreement, the Company was granted the exclusive right to modify, customize, maintain, incorporate, manufacture, sell, and otherwise utilize and practice the Patent, all improvements thereto and all technology related to the process, throughout the world.  The license shall apply to any extension or re-issue of the Patent.  The term of license is for the life of the Patent and any renewal thereof, subject to termination, under certain conditions.  As consideration for the License, the Company issued to the officer 7,000,000 shares of common stock (See Note 17). The License agreement has been recorded at the historical cost basis of the chief executive officer, who owned the patent.  The amortization expense for the year ended June 30,

60

IMAGING DIAGNOSTIC SYSTEMS, INC.

(a Development Stage Company)

Notes to Financial Statements (Continued)

(8)           INTANGIBLE ASSETS (Continued)

2007 for the patent license agreement is $34,176, with a balance to be amortized over the remaining life of the patent which is eight (8) years.  We will review the value of this patent and test it for impairment on an annual basis.  No impairment of this intangible asset was identified for the fiscal year ending June 30, 2007.

The core costs of obtaining the initial UL and CE approvals have an indefinite life, and intangible assets having an indefinite life are not amortized at the point of acquisition or subsequent to point of acquisition in accordance with the guidance of SFAS 142.  We recorded the initial costs of these systems and protocols as an intangible asset with an indefinite life because we believed that the costs of obtaining them applied to our Company’s entire functional process including manufacturing, labeling and compliance.  We followed the guidance provided in a paradigm, Figure 23-1: Summary of Accounting for Intangible Assets by SFAS 142, in which questions are asked relative to indefinite life, asset impairment and whether assumption of indefinite life is still valid.

(9)           ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses consist of the following:

	June 30,
	2007		2006
Accounts payable - trade	$	329,391	$	313,153
Accrued property taxes payable		30,819		30,819
Accrued compensated absences		138,868		155,535
Other accrued expenses		86,913		59,486
Totals	$	585,991	$	558,993

(10)           CUSTOMER DEPOSITS

Customer deposits consisted of the following:

	June 30,
	2007		2006
Customer deposits	$	88,114	$	40,000
Total	$	88,114	$	40,000

Deposits received from customers are identified and accounted for as customer deposits and are presented as both a current asset and an offsetting current liability on our balance sheet.  In the event of a cancellation or termination of a customers’ order, the deposit is refunded less any fees previously agreed to.

(11)           SHORT-TERM DEBT

Short-term debt consisted of the following:

	June 30,
	2007		2006
Loan payable	$	250,000	$	-
Total	$	250,000	$	-

The Company executed a promissory note dated June 27, 2007 for $250,000 from Charlton Avenue. LLC., which was repaid in full on August 2, 2007.  The Company has no other short-term debt.

61

IMAGING DIAGNOSTIC SYSTEMS, INC.

(a Development Stage Company)

Notes to Financial Statements (Continued)

(12)           EQUITY LINE OF CREDIT

On August 17, 2000 the Company finalized a financing agreement with a private institutional equity investor, which contained two component parts, a $25 million Private Equity Agreement and a private placement of 500 shares of Series K convertible preferred stock as bridge financing in the amount of $5,000,000 (See Note 15). The Private Equity Agreement committed the investor to purchase up to $25 million of common stock subject to certain conditions pursuant to Regulation D over the course of 12 months after an effective registration of the shares.  The timing and amounts of the purchase by the investor were at the sole discretion of the Company.  However, they were required to draw down a minimum of $10 million from the credit line over the twelve-month period.  The purchase price of the shares of common stock was set at 91% of the market price.  The market price, as defined in the agreement, was the average of the three lowest closing bid prices of the common stock over the ten day trading period beginning on the put date and ending on the trading day prior to the relevant closing date of the particular tranche.

On May 15, 2002, the Company entered into a second private equity agreement, which replaced the original Private Equity Agreement.  The terms of the second Private Equity Agreement were substantially equivalent to the terms of the original agreement, except that (i) the commitment period was three years from the effective date of a registration statement covering the second Private Equity Agreement shares, (ii) the minimum amount required to be drawn through the end of the commitment period was $2,500,000, (iii) the minimum stock price requirement was reduced to $.20, and (iv) the minimum average trading volume was reduced to $40,000.

On October 29, 2002, the Company entered into a new “Third Private Equity Credit Agreement” which the Company intended to supplement the second Private Equity Agreement.  The terms of the Third Private Equity Credit Agreement were substantially equivalent to the terms of the prior agreement, in that (i) the commitment period was three years from the effective date of a registration statement covering the Third Private Equity Credit Agreement shares, (ii) the maximum commitment was $15,000,000, (iii) the minimum amount required to be drawn through the end of the commitment period was $2,500,000, (iv) the minimum stock price requirement was reduced to $.10, and (v) the minimum average trading volume in dollars was reduced to $20,000.

On January 9, 2004, the Company entered into a new “Fourth Private Equity Credit Agreement” which replaced the prior private equity agreements.  The terms of the Fourth Private Equity Credit Agreement were more favorable to the Company than the terms of the prior Third Private Equity Credit Agreement.  The new, more favorable terms were: (i) The put option price was 93% of the three lowest closing bid prices in the ten day trading period beginning on the put date and ending on the trading day prior to the relevant closing date of the particular tranche, while the prior Third Private Equity Credit Agreement provided for 91%, ii) the commitment period was two years from the effective date of a registration statement covering the Fourth Private Equity Credit Agreement shares, while the prior Third Private Equity Credit Agreement was for three years, (iii) the maximum commitment was $15,000,000, (iv) the minimum amount the Company was required to draw through the end of the commitment period was $1,000,000, while the prior Third Private Equity Credit Agreement minimum amount was  $2,500,000, (v) the minimum stock price requirement was controlled by the Company as it had the option of setting a floor price for each put transaction (the previous minimum stock price in the Third Private Equity Credit Agreement was fixed at $.10), (vi) there were no fees associated with the Fourth Private Equity Credit Agreement; the prior private equity agreements required the payment of a 5% consulting fee, which was subsequently lowered to 4% by mutual agreement in September 2001, and (vii) the elimination of the requirement of a minimum average daily trading volume in dollars.  The previous trading volume requirement in the Third Private Equity Credit Agreement was $20,000.

On March 21, 2006, the Company and Charlton entered into a new “Fifth Private Equity Credit Agreement,” which replaced the Company’s prior Fourth Private Equity Credit Agreement upon the April 25, 2006, effectiveness of our

62

IMAGING DIAGNOSTIC SYSTEMS, INC.

(a Development Stage Company)

Notes to Financial Statements (Continued)

(12)           EQUITY LINE OF CREDIT (Continued)

S-1 Registration Statement filed on March 23, 2006 to register shares underlying the Fifth Private Equity Credit Agreement.  The terms of the Fifth Private Equity Credit Agreement are similar to the terms of the prior Fourth Private Equity Credit Agreement.  The new credit line’s material terms are (i) The put option price is 93% of the three lowest closing bid prices in the ten day trading period beginning on the put date and ending on the trading day prior to the relevant closing date of the particular tranche (the “Valuation Period”), (ii) the commitment period is two years from the effective date of a registration statement covering the Fifth Private Equity Credit Agreement shares, (iii) the maximum commitment is $15,000,000, (iv) the minimum amount the Company must draw through the end of the commitment period is $1,000,000,  (v)  the minimum stock price, also known as the floor price is computed as follows:  In the event that, during a Valuation Period, the Bid Price on any Trading Day falls more than 18% below the closing trade price on the trading day immediately prior to the date of the Company’s Put Notice (a “Low Bid Price”), for each such Trading Day the parties shall have no right and shall be under no obligation to purchase and sell one tenth of the Investment Amount specified in the Put Notice, and the Investment Amount shall accordingly be deemed reduced by such amount.  In the event that during a Valuation Period there exists a Low Bid Price for any three Trading Days—not necessarily consecutive—then the balance of each party’s right and obligation to purchase and sell the Investment Amount under such Put Notice shall terminate on such third Trading Day (“Termination Day”), and the Investment Amount shall be adjusted to include only one-tenth of the initial Investment Amount for each Trading Day during the Valuation Period prior to the Termination Day that the Bid Price equals or exceeds the Low Bid Price and (vi) there are no fees associated with the Fifth Private Equity Credit Agreement.  The conditions to the Company’s ability to draw under this private equity line, as described above, may materially limit the draws available to the Company.

These financing agreements have had no warrants attached to either the bridge financing or the private equity line.  Furthermore, the Company was not required to pay the investor’s legal fees, but the Company previously paid a 5% consulting fee for the money funded in all prior transactions up until the approval of the Fourth Private Equity Credit Agreement.  The Company sold $2,840,000 of common stock under the terms of the initial private equity agreement during the year ended June 30, 2001.  The total shares issued by the Company amounted to 3,407,613.  The Company incurred $139,985 of consulting fees and recorded $303,666 of deemed interest expense as a result of the 9% discount off of the market price. During the year ended June 30, 2002, an additional $5,585,000 of common stock was sold under the terms of the applicable equity credit line agreement, and the Company issued a total of 11,607,866 shares of common stock.  The Company incurred $296,250 of consulting fees and recorded $628,805 of deemed interest expense as a result of the 9% discount off of the market price. During the year ended June 30, 2003, an additional $7,881,000 of common stock was sold under the terms of the applicable equity credit line agreement, and the Company issued a total of 29,390,708 shares of common stock.  The Company incurred $211,800 of consulting fees and recorded $856,772 of deemed interest expense as a result of the 9% discount off of the market price.  During the year ended June 30, 2004, an additional $5,850,000 of common stock was sold under the terms of the equity credit line agreements, and the Company issued a total of 8,630,819 shares of common stock.  The Company incurred $188,000 of consulting fees which was solely from the Third Private Equity Credit Agreement and recorded a total of $691,701 of deemed interest expense of which $555,897 is a result of the 9% discount off the market price under the Third Private Equity Credit Agreement and $135,804 is a result of the 7% discount off the market price under the Fourth Private Equity Credit Agreement.  During the year ended June 30, 2005, an additional $7,204,370 of common stock was sold under the terms of the Fourth Private Equity Credit Agreement and the Company issued a total of 26,274,893 shares of common stock.  The Company recorded a total of $593,437 of deemed interest expense as a result of the 7% discount off the market price under the Fourth Private Equity Credit Agreement.

During the year ended June 30, 2006, an additional $6,844,171 of common stock was sold under the terms of the equity credit line agreements, and the Company issued a total of 47,776,064 shares of common stock.  The Company recorded a total of $565,372 of deemed interest expense as a result of the 7% discount off the market price under the Fourth Private Equity Credit Agreement and Fifth Private Equity Credit Agreement.  During the year ended June 30, 2007, an additional $4,192,717 of common stock was sold under the terms of the Fifth Private Equity Credit Agreement and the Company issued a total of 63,861,405 shares of common stock.  The Company recorded a total of $367,698 of deemed interest expense as a result of the 7% discount off the market price under the Fifth Private Equity Credit Agreement.

63

IMAGING DIAGNOSTIC SYSTEMS, INC.

(a Development Stage Company)

Notes to Financial Statements (Continued)

(13)           LEASES

The Company leases certain office equipment under operating leases expiring in future years.  Minimum future lease payments under the non-cancelable operating lease having a remaining term in excess of one year as of June 30, 2007 are as follows:

Year ending June 30,	Amount
2008	$	3,888
2009		3,888
2010		3,888
Thereafter		6,709
Total minimum future lease payments	$	18,373

Total rent expense for all operating leases amounted to $7,749, $9,090 and $12,229 for the years ended June 30, 2007, 2006 and 2005, respectively, and $366,487 from inception (December 10, 1993) to June 30, 2007.

(14)           INCOME TAXES

No provision for income taxes has been recorded in the accompanying financial statements as a result of the Company's net operating losses.  The Company has unused tax loss carryforwards of approximately $75,590,000 to offset future taxable income.  Such carryforwards expire in years beginning 2014 through 2027.  There would be no limitation as to the utilization of the net operating losses in future years resulting from the issuance of additional common stock during the fiscal year ended June 30, 2007.  The deferred tax asset recorded by the Company as a result of these tax loss carryforwards is approximately $28,724,000 and $26,364,000 at June 30, 2007 and 2006, respectively.  The Company has reduced the deferred tax asset resulting from its tax loss carryforwards by a valuation allowance of an equal amount as the realization of the deferred tax asset is uncertain.  The net change in the deferred tax asset and valuation allowance from July 1, 2006 to June 30, 2007 was an increase of approximately $2,360,000. The reconciliation of income tax computed at the U.S. federal statutory rate of 35% and the state rate net of federal benefit of 3%, has been offset by permanent differences relating to stock option expense and the discount recorded on the equity lines of credit in the amount of 15% per annum and by a full valuation allowance against the related net operating loss for each of the respective years then ended.

(15)           REDEEMABLE CONVERTIBLE PREFERRED STOCK

On March 17, 1999, the Company finalized the private placement to foreign investors of 35 shares of its Series G Redeemable Convertible Preferred Stock at a purchase price of $10,000 per share and two year warrants to purchase 65,625 shares of the Company’s common stock at an exercise price of $.50 per share. The agreement was executed pursuant to Regulation D as promulgated by the Securities Act of 1933, as amended.  A total of 43,125 warrants were exercised during the year ended June 30, 2000, and an additional 9,375 warrants were exercised during the year ended June 30, 2001.

The Series G Preferred Stock had no dividend provisions.  The preferred stock was convertible, at any time, for a period of two years thereafter, in whole or in part, without the payment of any additional consideration, into fully paid and nonassessable shares of the Company’s no par value common stock based upon the “conversion formula”.  The conversion formula stated that the holder of the Series G Preferred Stock would receive shares determined by dividing (i) the sum of $10,000 by the (ii) “Conversion Price” in effect at the time of conversion.  The “Conversion Price” shall be equal to the lesser of $.54 or seventy-five percent (75%) of the Average Closing Price of the Company’s common stock for the ten-day trading period ending on the day prior to the date of conversion.

In connection with the sale, the Company issued three preferred shares to an unaffiliated investment banker for placement and legal fees, providing net proceeds to the Company of $350,000.  The shares underlying the preferred shares and warrant are entitled to demand registration rights under certain conditions.

64

IMAGING DIAGNOSTIC SYSTEMS, INC.

(a Development Stage Company)

Notes to Financial Statements (Continued)

(15)           REDEEMABLE CONVERTIBLE PREFERRED STOCK (Continued)

Pursuant to the Registration Rights Agreement (“RRA”) the Company was required to register 100% of the number of shares that would be required to be issued if the Preferred Stock were converted on the day before the filing of the S-2 Registration Statement.  In the event the Registration Statement was not declared effective within 120 days, the Series G Holders had the right to force the Company to redeem the Series G Preferred Stock at a redemption price of 120% of the face value of the preferred stock.  The Registration Statement was declared effective on July 29, 2000.  During the year ended June 30, 2000, the Series G Preferred Stock was converted into 3,834,492 shares of the Company’s common stock.

(16)           CONVERTIBLE PREFERRED STOCK

On April 27, 1995, the Company amended the Articles of Incorporation to provide for the authorization of 2,000,000 shares of no par value preferred stock.  The shares were divided out of the original 50,000,000 shares of no par value common stock.  All Series of the convertible preferred stock are not redeemable and automatically convert into shares of common stock at the conversion rates three years after issuance.

The Company issued 4,000 shares of “Series A Convertible Preferred Stock” (“Series A Preferred Stock”) on March 21, 1996 under a Regulation S Securities Subscription Agreement.  The agreement called for a purchase price of $1,000 per share, with net proceeds to the Company, after commissions and issuance costs, amounting to $3,600,000.

The holders of the Series A Preferred Stock could have converted up to 50% prior to May 28, 1996, and may convert their remaining shares subsequent to May 28, 1996 without the payment of any additional consideration, into fully paid and nonassessable shares of the Company’s no par value common stock based upon the “conversion formula”.  The conversion formula states that the holder of the Preferred Stock will receive shares determined by dividing (i) the sum of $1,000 plus the amount of all accrued but unpaid dividends on the shares of Convertible Preferred Stock being so converted by the (ii) “Conversion Price”.  The “Conversion Price” shall be equal to seventy-five percent (75%) of the Market Price of the Company’s common stock; provided, however, that in no event will the “Conversion Price” be greater than the closing bid price per share of common stock on the date of conversion.

As of June 30, 1996, 1,600 shares of the Series A Preferred Stock had been converted into a total 425,416 shares (including accumulated dividends) of the Company’s common stock.  The remaining 2,400 shares of Series A Preferred Stock were converted into 1,061,202 shares (including accumulated dividends) of the Company’s common stock during the fiscal year ended June 30, 1997.

The Company issued 450 shares of “Series B Convertible Preferred Stock” (“Series B Preferred Stock”) and warrants to purchase up to an additional 112,500 shares of common stock on December 17, 1996 pursuant to Regulation D and Section 4(2) of the Securities Act of 1933.  The agreement called for a purchase price of $10,000 per share, with proceeds to the Company amounting to $4,500,000.

The holders of the Series B Preferred Stock could have converted up to 34% of the Series B Preferred Stock 80 days from issuance (March 7, 1997), up to 67% of the Series B Preferred Stock 100 days from issuance (March 27, 1997), and may convert their remaining shares 120 days from issuance (April 19, 1997) without the payment of any additional consideration, into fully paid and nonassessable shares of the Company’s no par value common stock based upon the “conversion formula”.  The conversion formula states that the holder of the Series B Preferred Stock will receive shares determined by dividing (i) the sum of $10,000 by the (ii) “Conversion Price” in effect at the time of conversion.  The “Conversion Price” shall be equal to eighty-two percent (82%) of the Market Price of the Company’s common stock; provided, however, that in no event will the “Conversion Price” be greater than $3.85.  The warrants are exercisable at any time for an exercise price of $5.00 and will expire five years from the date of issue.

65

IMAGING DIAGNOSTIC SYSTEMS, INC.

(a Development Stage Company)

Notes to Financial Statements (Continued)

(16)           CONVERTIBLE PREFERRED STOCK (Continued)

On September 4, 1998, the Company received a notice of conversion from the Series B Holders.  The Series B Holders filed a lawsuit against the Company on October 7, 1998.  The Company was served on October 19, 1998.  The lawsuit alleged that the Company has breached its contract of sale to the Series B Holders by failing to convert the Series B Holders and failure to register the common stock underlying the Preferred Stock.  The Series B Holders demanded damages in excess of $75,000, to be determined at trial, together with interest costs and legal fees.  On April 6, 1999, the Series B Holders sold their preferred stock to an unaffiliated third party (“the Purchaser”) with no prior relationship to the Company, or the Series B Holders.  As part of the purchase agreement, the Series B Holders were required to dismiss the lawsuit with prejudice and the Company and the Series B Holders exchanged mutual general releases (see Series I).

As of June 30, 2000, the Series B Preferred Stock has been converted into 30,463,164 shares of the Company’s common stock, and 60 shares were canceled at the request of the holder.

During the years ended June 30, 1999 and 1998 the Company issued a total of six Private Placements of convertible preferred stock (see schedule incorporated into Note 16).  The Private Placements are summarized as follows:

Series C Preferred Stock

On October 6, 1997, the Company finalized the private placement to foreign investors of 210 shares of its Series C Convertible Preferred Stock at a purchase price of $10,000 per share and warrants to purchase up to 160,000 shares of the Company’s common stock at an exercise price of $1.63 per share, and warrants to purchase up to 50,000 shares of the Company’s common stock at an exercise price of $1.562 per share.  The agreement was executed pursuant to Regulation S as promulgated by the Securities Act of 1933, as amended.  As of June 30, 2001, 40,000 warrants at the $1.63 exercise price were exercised, and the remaining 140,000 warrants had expired.  The remaining 50,000 warrants ($1.562 exercise price) are outstanding as of June 30, 2001.

In connection with the sale, the Company paid an unaffiliated investment banker $220,500 for placement and legal fees, providing net proceeds to the Company of $1,879,500.

Series D Preferred Stock

On January 9, 1998, the Company finalized the private placement to foreign investors of 50 shares of its Series D Convertible Preferred Stock at a purchase price of $10,000 per share and warrants to purchase up to 25,000 shares of the Company’s common stock at an exercise price of $1.22 per share. The agreement was executed pursuant to Regulation S as promulgated by the Securities Act of 1933, as amended.  As of June 30, 2001 the warrants had expired.

In connection with the sale, the Company issued four preferred shares to an unaffiliated investment banker for placement fees and paid legal fees of $5,000, providing net proceeds to the Company of $495,000.  The shares underlying the preferred shares and warrant are entitled to demand registration rights under certain conditions.

Series E Preferred Stock

On February 5, 1998, the Company finalized the private placement to foreign investors of 50 shares of its Series E Convertible Preferred Stock at a purchase price of $10,000 per share and warrants to purchase up to 25,000 shares of the Company’s common stock at an exercise price of $1.093 per share. The agreement was executed pursuant to Regulation S as promulgated by the Securities Act of 1933, as amended.  As of June 30, 2001 the warrants had expired.

In connection with the sale, the Company issued four preferred shares to an unaffiliated investment banker for placement fees and paid legal fees of $5,000, providing net proceeds to the Company of $495,000.  The shares underlying the preferred shares and warrant are entitled to demand registration rights under certain conditions.

66

IMAGING DIAGNOSTIC SYSTEMS, INC.

(a Development Stage Company)

Notes to Financial Statements (Continued)

(16)           CONVERTIBLE PREFERRED STOCK (Continued)

Series F Preferred Stock

On February 20, 1998, the Company finalized the private placement to foreign investors of 75 shares of its Series F Convertible Preferred Stock at a purchase price of $10,000 per share. The agreement was executed pursuant to Regulation S as promulgated by the Securities Act of 1933, as amended.

In connection with the sale, the Company paid an unaffiliated investment banker $50,000 for placement and legal fees, providing net proceeds to the Company of $700,000. The shares underlying the preferred shares and warrant are entitled to demand registration rights under certain conditions.

Series H Preferred Stock

On June 2, 1998, the Company finalized the private placement to foreign investors of 100 shares of its Series H Convertible Preferred Stock at a purchase price of $10,000 per share and Series H-“A” warrants to purchase up to 75,000 shares of the Company’s common stock at an exercise price of $1.00 per share, and Series H-“B” warrants to purchase up to 50,000 shares of the Company’s common stock at an exercise price of $1.50 per share. The agreement was executed pursuant to Regulation D as promulgated by the Securities Act of 1933, as amended.  As of June 30, 2001 none of the warrants had been exercised.

In connection with the sale, the Company issued eight preferred shares and paid $10,000 to an unaffiliated investment banker for placement and legal fees, providing net proceeds to the Company of $990,000.  The shares underlying the preferred shares and warrant are entitled to demand registration rights under certain conditions.

The Company was in technical default of the Registration Rights Agreement (“RRA”), which required the S-2 Registration Statement to be declared effective by October 2, 1998.  Pursuant to the RRA, the Company was required to pay the Series H holders, as liquidated damages for failure to have the Registration Statement declared effective, and not as a penalty, 2% of the principal amount of the Securities for the first thirty days, and 3% of the principal amount of the Securities for each thirty day period thereafter until the Company procures registration of the Securities. On March 25, 1999, the Company issued 424,242 shares of common stock as partial payment of the liquidated damages.  The cumulative liquidated damages expense for the years ended June 30, 2001 amounted to $140,000.

Series I Preferred Stock

On April 6, 1999, the Company entered into a Subscription Agreement with the Purchaser of the Series B Preferred Stock whereby the Company agreed to issue 138 shares of its Series I, 7% Convertible Preferred Stock ($1,380,000).  The consideration for the subscription agreement was paid as follows:

1.  Forgiveness of approximately $725,795 of accrued interest (dividends) in connection with the Series B Convertible Preferred stock.  The Company recorded the forgiveness of the accrued interest (dividends) by reducing the accrual along with a reduction in the accumulated deficit.

2.  Settlement of all litigation concerning the Series B Convertible Preferred stock.

3.  Cancellation of 112,500 warrants that were issued with the Series B Convertible Preferred stock.

4.  A limitation on the owner(s) of the Series B Convertible Preferred stock to ownership of not more than 4.99% of the Company’s outstanding common stock at any one time.

The Series I Preferred stock pays a 7% premium, to be paid in cash or freely trading common stock at the Company’s sole discretion, upon conversion.

67

IMAGING DIAGNOSTIC SYSTEMS, INC.

(a Development Stage Company)

Notes to Financial Statements (Continued)

(16)           CONVERTIBLE PREFERRED STOCK (Continued)

Series K Preferred Stock

On July 17, 2000, the Company finalized the private placement to foreign investors of 500 shares of its Series K Convertible Preferred Stock at a purchase price of $10,000 per share. The agreement was executed in accordance with and in reliance upon the exemption from securities registration by Rule 506 under Regulation D as promulgated by the Securities Act of 1933, as amended.

The entire amount of the Series K Convertible Preferred Stock was converted or redeemed by the Company during the year ended June 30, 2001 into 5,664,067 shares of common stock, including 219,225 shares as payment of the 9% accrued dividend.

The following schedule reflects the number of shares of preferred stock that have been issued, converted and are outstanding as of June 30, 2007, including certain additional information with respect to the deemed preferred stock dividends that were calculated as a result of the discount from market for the conversion price per share:

68

IMAGING DIAGNOSTIC SYSTEMS, INC.
(a Development Stage Company)
Notes to Financial Statements (Continued)
(16) COVERTIBLE PREFERRED STOCK (Continued)
	Series A						Series B						Series C						Series D						Series E						Series F						Series H						Series I						Series K						Total
	Shares			Amount			Shares			Amount			Shares			Amount			Shares			Amount			Shares			Amount			Shares			Amount			Shares			Amount			Shares			Amount			Shares			Amount			Shares			Amount
Balance at June 30, 1995		-		$	-			-		$	-			-		$	-			-		$	-			-		$	-			-		$	-			-		$	-			-		$	-			-		$	-			-		$	-
Sale of Series A		4,000			3,600,000																																																			4,000			3,600,000
Series A conversion		(1,600	)		(1,440,000	)																																																		(1,600	)		(1,440,000	)
Balance at June 30, 1996		2,400			2,160,000																																																			2,400			2,160,000
Sale of Series B								450			4,500,000																																													450			4,500,000
Series A conversion		(2,400	)		(2,160,000	)																																																		(2,400	)		(2,160,000	)
Balance at June 30, 1997		-			-			450			4,500,000																																													450			4,500,000
Sale of preferred stock
(Series C - H)														210			2,100,000			54			540,000			54			540,000			75			750,000			108			1,080,000															501			5,010,000
Conversion of preferred stock														(210	)		(2,100,000	)		(25	)		(250,000	)		(30	)		(300,000	)		(75	)		(750,000	)																				(340	)		(3,400,000	)
Balance at June 30, 1998		-			-			450			4,500,000			-			-			29			290,000			24			240,000			-			-			108			1,080,000															611			6,110,000
Sale of Series I																																												138			1,380,000									138			1,380,000
Conversion of preferred stock								(60	)		(600,000	)								(29	)		(290,000	)		(24	)		(240,000	)								(40	)		(400,000	)														(153	)		(1,530,000	)
Balance at June 30, 1999		-			-			390			3,900,000			-			-			-			-			-			-			-			-			68			680,000			138			1,380,000			-			-			596			5,960,000
Conversion of preferred stock, net								(390	)		(3,900,000	)																										(68	)		(680,000	)		(138	)		(1,380,000	)								(596	)		(5,960,000	)
Balance at June 30, 2000		-			-			-			-			-			-			-			-			-			-			-			-			-			-			-			-			-			-			-			-
Sale of Series K																																																		50			5,000,000			50			5,000,000
Conversion of preferred stock																																																		(50	)		(5,000,000	)		(50	)		(5,000,000	)
Balance at June 30, 2001		-		$	-			-		$	-			-		$	-			-		$	-			-		$	-			-		$	-			-		$	-			-		$	-			-		$	-			-		$	-
Additional information:
Discount off market price					25	%					18	%					25	%					25	%					25	%					30	%					25	%					25	%					12.5	%
Fair market value-issue rate				$	8.31					$	3.25					$	1.63					$	0.99					$	1.07					$	1.24					$	0.57					$	0.38					$	1.13
Deemed preferred stock dividend				$	1,335,474					$	998,120					$	705,738					$	182,433					$	182,250					$	318,966					$	351,628					$	492,857					$	708,130

69

IMAGING DIAGNOSTIC SYSTEMS, INC.

(a Development Stage Company)

Notes to Financial Statements (Continued)

(17)           COMMON STOCK

On June 8, 1994, at a special meeting of shareholders of the Company, a one for one hundred reverse stock split was approved reducing the number of issued and outstanding shares of common stock from 68,875,200 shares to 688,752 shares (510,000 shares of original stock, for $50,000, and the 178,752 shares acquired in the merger).  In addition, the board of directors approved the issuance of an additional 27,490,000 shares of common stock that had been provided for in the original merger documents.  However, during April, 1995 the four major shareholders agreed to permanently return 12,147,480 of these additional shares.  Therefore, the net additional shares of common stock issued amounts to 15,342,520 shares, and the net additional shares issued as a result of this transaction have been reflected in the financial statements of the Company (See Statement of Stockholders’ Equity).

The Company has sold 1,290,069 shares of its common stock through Private Placement Memorandums dated April 20, 1994 and December 7, 1994, as subsequently amended.  The net proceeds to the Company under these Private Placement Memorandums were approximately $1,000,000.  In addition, the Company has sold 690,722 shares of "restricted common stock" during the year ended June 30, 1995.  These shares are restricted in terms of a required holding period before they become eligible for free trading status.  As of June 30, 1995, receivables from the sale of common stock during the year amounted to $523,118.  During the year ended June 30, 1996, 410,500 shares of the common stock related to these receivables were canceled and $103,679 was collected on the receivable.  The unpaid balance on these original sales and other subsequent sales of common stock, in the amount of $35,559, as of June 30, 1997, is reflected as a reduction to stockholder’s equity on the Company’s balance sheet.

During the year ended June 30, 1995, 115,650 shares of common stock were issued to satisfy obligations of the Company amounting to $102,942, approximately $.89 per share. The stock was recorded at the fair market value at the date of issuance.

In addition, during the year ended June 30, 1995, wages accrued to the officers of the Company in the amount of $151,000, were satisfied with the issuance of 377,500 shares of restricted common stock.  Compensation expense has been recorded during the fiscal year pursuant to the employment agreements with the officers.  In addition, during the year ended June 30, 1995, 75,000 shares of restricted common stock were issued to a company executive pursuant to an employment agreement. Compensation expense of $78,750 was recorded in conjunction with this transaction.

During the year ended June 30, 1996, the Company sold, under the provisions of Regulation S, a total of 700,471 shares of common stock.  The proceeds from the sale of these shares of common stock amounted to $1,561,110.  The Company issued an additional 2,503,789 shares ($4,257,320) of its common stock as a result of the exercise of stock options issued in exchange for services rendered during the year.  Cash proceeds associated with the exercise of these options and the issuance of these shares amounted to $1,860,062, with the remaining $2,397,258 reflected as noncash compensation.  These 2,503,789 shares were issued at various times throughout the fiscal year.  The stock has been recorded at the fair market value at the various grant dates for the transactions.  Compensation, aggregating $2,298,907, has been recorded at the excess of the fair market value of the transaction over the exercise price for each of the transactions.

As of June 30, 1996, there were a total of 425,416 shares of common stock issued as a result of the conversion of the Series A Convertible Preferred Stock and the related accumulated dividends (See Note 16).

70

IMAGING DIAGNOSTIC SYSTEMS, INC.

(a Development Stage Company)

Notes to Financial Statements (Continued)

(17)           COMMON STOCK (Continued)

Common stock issued to employees as a result of the exercise of their incentive stock options and their non-qualified stock options during the fiscal year ended June 30, 1996 amounted to 1,187,900, of which 996,400 shares were issued pursuant to the provisions of the non-qualified stock option plan and were exercised in a “cash-less” transaction, resulting in compensation to the officers of $567,164.  Compensation cost was measured as the excess of fair market value of the shares received over the value of the stock options tendered in the transaction.  The excess of fair market value at July 15, 1995 approximated $.57 per share on the 996,400 shares issued.

During the year ended June 30, 1997, the Company issued a total of 1,881,295 shares ($5,461,589) of its common stock.  The conversion of Series A Convertible Preferred Stock, including accrued dividends (See Note 16), accounted for the issuance of 1,081,962 shares ($2,808,643).  The remaining 799,333 shares were issued as follows:

1. Services rendered by independent consultants in exchange for 31,200 shares.  Research and development expenses of $90,480 were charged as the fair market value at November 20, 1996 was $2.90 per share.

2. On December 20, 1996, bonus stock was issued to Company employees, 3,200 shares.  Compensation expense of $10,463 was charged as the fair market value at that date was $3.27 per share.

3. On January 3, 1997 bonus stock was issued to the officers of the Company, 350,000 shares.  Compensation expense of $907,900 was charged, as the fair market value at that date was $2.59 per share.

4. On February 13, 1997, 4,000 shares were issued to an outside consultant in exchange for services performed.  Consulting services of $11,500 were recorded, representing the fair market value ($2.88 per share) on that date.

5. Services rendered by an independent consultant during June 1997 in exchange for 199,000 shares.  Consulting expenses of $548,149 were charged, as the fair market value on the date of the transaction was approximately $2.75 per share.

6. Exercise of incentive stock options comprised of 27,000 shares ($33,750) exercised and paid for at $1.25 per share, and 334,933 shares ($1,103,203) acquired in the exchange for options tendered in a cash-less transaction.

7. The Company repurchased 150,000 shares ($52,500), which had been previously acquired by one of its employees.

During the year ended June 30, 1998, the Company issued a total of 11,588,460 shares ($8,583,721) of its common stock.  The conversion of Convertible Preferred Stock (see Note 16) accounted for the issuance of 6,502,448 shares ($4,984,684).  The remaining 5,056,012 shares were issued as follows:

1. Services rendered by independent consultants in exchange for 100,000 shares.  Consulting expenses of $221,900 were charged as the fair market value at July 10, 1997 was $2.22 per share.

71

IMAGING DIAGNOSTIC SYSTEMS, INC.

(a Development Stage Company)

Notes to Financial Statements (Continued)

(17)           COMMON STOCK (Continued)

2. Services rendered by an independent consultant in exchange for 200,000 shares.  Consulting expenses of $400,000 were charged as the fair market value at August 20, 1997 was $2.00 per share.

3. Services rendered by an independent consultant in exchange for 40,000 shares.  Consulting expenses of $67,480 were charged as the fair market value at September 4, 1997 was $1.69 per share.

4. Services rendered by a public relations company in exchange for 166,000 shares.  Public relations expenses of $269,750 were charged as the fair market value at October 24, 1997 was $1.63 per share.

5. On December 15, 1997, bonus stock was issued to Company employees, for 39,300 shares.  Compensation expense of $41,658 was charged as the fair market value at that date was $1.06 per share.

6. Services rendered by an independent consultant in exchange for 250,000 shares.  Consulting expenses of $320,000 were charged as the fair market value at January 7, 1998 was $1.28 per share.

7. Services rendered by an independent consultant during May 1998 in exchange for 200,000 shares.  Consulting expenses of $140,000 were charged, as the fair market value on that date was $.70 per share.

8. The Company sold 500,000 shares on May 15, 1998 in a Regulation D offering at $.40 per share, and received cash proceeds of $200,000.

9. On June 5, 1998, the Company issued to its chief executive officer 3,500,000 shares ($1,890,000) as consideration for an exclusive Patent License Agreement (see Note 8).  The market value of the stock on this date was $.54 per share.  The excess of the fair market value of the common stock over the historical cost basis of the patent license was recorded as a distribution to the shareholder; recorded as a reduction to additional paid-in capital of $3,199,000.

10. On June 11, 1998, the Company issued 25,000 shares to its corporate counsel as additional bonus compensation.  Legal expenses of $12,750 were recorded as the market value of the stock on that date was $.51 per share.

11.  A total of 65,712 non-qualified stock options were exercised and proceeds of $22,999 ($.35 per share) was received by the Company.

72

IMAGING DIAGNOSTIC SYSTEMS, INC.

(a Development Stage Company)

Notes to Financial Statements (Continued)

(17)           COMMON STOCK (Continued)

On July 10, 1998, the majority shareholders of the Company authorized, by written action, the Company’s adoption of an Amendment to the Company’s Articles of Incorporation increasing the Company’s authorized shares of common stock from 48,000,000 shares to 100,000,000 shares.  The Florida Statutes provide that any action to be taken at an annual or special meeting of shareholders may be taken without a meeting, without prior notice and without a vote, if the action is taken by a majority of outstanding stockholders of each voting group entitled to vote.  On August 5, 1998, the Company filed an Information Statement with the Securities and Exchange Commission with regard to the Written Action.  The Majority Shareholders consent with respect to the Amendment was effective on February 18, 1999. The number of authorized shares was further increased to 150,000,000 shares during the shareholders annual meeting held on May 10, 2000, and increased again during the 2002 annual meeting to 200,000,000 shares, effective January 3, 2003.

During the year ended June 30, 1999, the Company issued a total of 12,804,131 shares ($5,837,656) of its common stock.  The conversion of Convertible Preferred Stock (see Note 16) accounted for the issuance of 4,865,034 shares ($1,972,296).  The remaining 7,939,097 shares were issued as follows:

1. The Company sold 200,000 shares on August 5, 1998 in a Regulation D offering at $.30 per share, and received cash proceeds of $60,000.

2. In June 1999, the Company issued to its chief executive officer 3,500,000 shares ($1,890,000), representing the balance of shares to be issued as consideration for the exclusive Patent License Agreement (see Note 8).

3. On November 9, 1998, the Company issued 15,000 shares to its corporate counsel as additional bonus compensation.  Legal expenses of $10,800 were recorded as the market value of the stock on that date was $.72 per share.

4. A total of 65,612 non-qualified stock options were exercised and proceeds of $22,964 ($.35 per share) was received by the Company.  An additional $101,500 was received this year for stock sold in the prior year.

5. A total of 480,000 shares were issued in connection with loans that were received by the Company.  The total loan fee expenses (based on the market value of the stock at the date of issuance) charged to the statement of operations for the year was $292,694, or an average of $.61 per share.

6. A total of 2,974,043 shares were issued as repayment of various accounts payable and loans payable during the year.  A total of $1,196,992 (average of $.40 per share) of debts were satisfied through the issuance of the stock.

7. On December 11, 1998, bonus stock was issued to Company employees, for 130,200 shares.  Compensation expense of $79,422 was charged as the fair market value at that date was $.61 per share.

8. On March 26, 1999, the Company issued 424,242 shares of stock as partial-payment ($140,000) on the liquidated damages in connection with Series H Preferred Stock.  The fair market value at that date was $.33 per share.

73

IMAGING DIAGNOSTIC SYSTEMS, INC.

(a Development Stage Company)

Notes to Financial Statements (Continued)

(17)           COMMON STOCK (Continued)

9. During the year a total of 150,000 shares were issued for to various independent parties for services rendered to the Company.  Expenses of $81,788 were charged, or an average price of $.50 per share.

During the year ended June 30, 2000, the Company issued a total of 56,214,003 shares ($12,997,328) of its common stock.  The conversion of Convertible Debentures accounted for the issuance of 4,060,398 shares ($3,958,223), the conversion of Redeemable Convertible Preferred Stock (see Note 15) accounted for the issuance of 3,834,492 shares ($507,115), and the conversion of Convertible Preferred Stock (see Note 16) accounted for the issuance of 41,581,242 shares ($6,806,219).  The remaining 6,737,871 shares were issued as follows:

1. The Company sold 100,000 shares on April 27, 2000 in a Regulation D offering at $1.57 per share, and received cash proceeds of $157,000.

2. A total of 5,061,294 shares were issued as repayment of various loans payable during the year.  A total of $1,067,665 (average of $.21 per share) of debts were satisfied through the issuance of the stock.

3. On November 12, 1999, bonus stock was issued to Company employees, for 145,000 shares.  Compensation expense of $12,325 was charged as the fair market value at that date was $.09 per share.  The company also canceled 8,000 shares, which had been previously issued to an independent contractor for consulting services.  A reduction of $31,000 was recorded to consulting expenses for the year.

4. A total of 7,297 shares were issued in connection with a loan that was received by the Company.  The total loan fee expense and interest charged to income amounted to $2,408 during the year.

5. During the year at total of 150,652 shares were issued for the exercise of warrants.  On March 21, 2000, the Company received $100,000 for the exercise of 107,527 warrants at an exercise price of $.93 per share.  The Company recorded a charge to consulting expense, as the fair market value at the date the warrants were issued was $1.84.  The Company also received $21,563 from the exercise of 43,125 of Series G Preferred Stock warrants during the last quarter of the fiscal year.

6. Exercise of 1,281,628 incentive stock options, ($395,810) exercised and paid for at prices ranging from $.13 per share to $1.13 per share.

During the year ended June 30, 2001, the Company issued a total of 13,916,169 shares ($12,333,724) of its common stock.  The conversion of Convertible Preferred Stock (see Note 16) accounted for the issuance of 5,664,067 shares ($5,580,531), and the common stock issued through the equity line of credit (See Note 12) accounted for the issuance of 3,407,613 shares ($3,143,666).  The remaining 4,844,489 shares were issued as follows:

1. A total of 810,000 shares were issued as repayment of a loan payable during the year.  A total of $530,000 of debt was satisfied through the issuance of the stock, and an additional $863,200 was charged as interest expense as the fair market value of the stock at the date of issuance was $1.72 per share.

74

IMAGING DIAGNOSTIC SYSTEMS, INC.

(a Development Stage Company)

Notes to Financial Statements (Continued)

(17)           COMMON STOCK (Continued)

2. On December 7, 2000, 143,500 shares of bonus stock were issued to Company employees.  Compensation expense of $219,555 was charged as, the fair market value of the common stock at that date was $1.53 per share.  The Company also issued 10,000 shares on May 17, 2001.  Consulting services of $8,300 was charged, as the fair market value of the stock was $.83 per share.

3. During the year a total of 99,375 shares of common stock were issued for the exercise of warrants.  The Company received $4,687 from the exercise of 99,375 Series G Preferred Stock warrants.  On August 10, 2000, the Company received $65,200 for the exercise of 40,000 Series C Preferred Stock warrants at an exercise price of $1.63 per share.

4. Common stock issued to officers as a result of the exercise of their incentive stock options and their non-qualified stock options amounted to 3,755,414 shares.  The options were exercised in a “cash-less” transaction, resulting in compensation to the officers of $1,848,566.  An additional 26,200 shares were issued to employees upon the exercise of their incentive stock options during the year, at exercise prices ranging from $.35 per share to $.60 per share.

During the year ended June 30, 2002, the Company issued a total of 12,167,866 shares ($6,508,155) of its common stock.  The common stock issued through the equity line of credit (See Note 12) accounted for the issuance of 11,607,866 shares ($6,213,805).  The remaining 560,000 shares were issued as follows:

1. On November 21, 2001, 210,000 shares of bonus stock were issued to Company employees.  Deferred compensation of $117,600 was charged as, the fair market value of the common stock at that date was $.56 per share, and the stock will not be physically delivered to the employees until January 2003.

2. A total of 350,000 shares were issued in conjunction with the settlement on March 22, 2002 of a lawsuit.  Settlement expense of $176,750 has been charged on the statement of operations, as the fair market value of the stock at the date of issuance was $.51 per share.

During the year ended June 30, 2003, the Company issued a total of 31,398,326 shares ($9,708,425) of its common stock.  The common stock issued through the equity line of credit (See Note 12) accounted for the issuance of 29,390,708 shares ($8,737,772).  The remaining 2,007,618 shares were issued as follows:

1. During December 2002, 258,500 shares of bonus stock were issued to Company employees.  Compensation of $62,425 was charged as, the fair market value of the common stock on the dates of issuance averaged $.24 per share.  In addition, the Company recorded an adjustment for deferred compensation, which resulted in a reduction to common stock for $73,500.

2. A total of 1,194,118 shares were issued in conjunction with the settlement on June 5, 2003 of a lawsuit.  Settlement expense of $841,853 has been charged on the statement of operations, as the fair market value of the stock at the date of issuance was $.70 per share.

75

IMAGING DIAGNOSTIC SYSTEMS, INC.

(a Development Stage Company)

Notes to Financial Statements (Continued)

(17)           COMMON STOCK (Continued)

3. During the year a total of 555,000 shares were issued to various parties for services rendered to the Company.  Expenses of $139,875 were charged, or an average price of $.25 per share.

During the year ended June 30, 2004, the Company issued a total of 10,333,373 shares ($7,867,351) of its common stock.  The common stock issued through the equity line of credit (See Note 12) accounted for the issuance of 8,630,819 shares ($6,541,700).  The remaining 1,702,554 shares were issued as follows:

1. During November 2003, 401,785 shares were issued in conjunction with the settlement on September 18, 2003 of a lawsuit.  Settlement expense of $450,000 has been charged on the statement of operations as the fair market value of the stock at the date of the settlement agreement was $1.12 per share.

2. During January 2004, 333,000 shares of bonus stock were issued to Company employees.  Compensation of $382,950 was charged as the fair market value of the common stock on the date of issuance was $1.15 per share.

3. Common stock issued to directors as a result of the exercise of their incentive stock options amounted to 450,000 shares during the year.  The Company received $262,500 from the exercise of 450,000 option shares.  The exercise prices range from $.55 per share to $.65 per share.

4. Common stock issued to employees as a result of the exercise of their incentive stock options amounted to 517,769 shares during the year.  The Company received $230,201 from the exercise of 517,769 option shares. The exercise prices range from $.19 per share to $.65 per share.

During the year ended June 30, 2005, the Company issued a total of 26,573,157 shares ($7,915,061) of its common stock.  The common stock issued through the equity line of credit (See Note 12) accounted for the issuance of 26,274,893 shares ($7,797,807).  The remaining 298,264 shares were issued as follows:

1. During September 2004, 100,000 restricted shares were issued to our CEO in conjunction with his employment agreement.  Compensation of $38,000 was charged as the fair market value of the common stock on the date of issuance was $.38 per share.

2. During January 2005, 185,000 shares of bonus stock were issued to Company employees.  Compensation of $75,850 was charged as the fair market value of the common stock on the date of issuance was $.41 per share.

3. Common stock issued to employees as a result of the exercise of their incentive stock options amounted to 13,264 shares during the year.  The Company received $3,404 from the exercise of 13,264 option shares.  The exercise prices range from $.20 per share to $.27 per share.

During the year ended June 30, 2006, the Company issued a total of 47,776,064 shares ($7,409,543) of its common stock.  The common stock issued through the equity line of credit (See Note 12) accounted for the issuance of 47,776,064 shares ($7,409,543).

During the year ended June 30, 2007, the Company issued a total of 63,861,405 shares ($4,560,415) of its common stock.  The common stock issued through the equity line of credit (See Note 12) accounted for the issuance of 63,861,405 shares ($4,560,415).

76

IMAGING DIAGNOSTIC SYSTEMS, INC.

(a Development Stage Company)

Notes to Financial Statements (Continued)

(18)           STOCK OPTIONS

Prior to the implementation of FAS 123R (effective at the beginning of the entity’s first fiscal year that begins after June 15, 2005) the Company followed the provisions of APB No. 25.   In accordance with the provisions of APB No. 25, the Company records the discount from fair market value on the non-qualified stock options as a charge to deferred compensation at the date of grant and credits additional paid-in capital.  The compensation is amortized to income over the vesting period of the options.

In December 2004, the FASB issued SFAS No. 123 (revised 2004), "Share Based Payment" ("SFAS No. 123R") and in March 2005, the SEC issued SAB 107 regarding its interpretation of SFAS No. 123R. The standard requires companies to expense the grant-date fair value of stock options and other equity-based compensation issued to employees and is effective for annual periods beginning after June 15, 2005.  Effective January 1, 2006, the Company adopted SFAS No. 123R and related interpretive guidance issued by the FASB and SEC using the modified prospective transition method.  Under the modified prospective transition method, SFAS No. 123R applies to new awards modified, repurchased or cancelled after the required effective date.  Additionally, compensation cost for the portion of the awards for which the requisite service period has not been rendered as of the required effective date is recognized as the requisite service is rendered on or after the required effective date.  Accordingly, the Company's Consolidated Financial Statements have not been restated for prior periods to reflect the adoption of SFAS No. 123R.

During July 1994, the Company adopted a non-qualified Stock Option Plan (the "Plan"), whereby officers and employees of the Company could be granted options to purchase shares of the Company’s common stock.  Under the plan and pursuant to their employment contracts, an officer could be granted non-qualified options to purchase shares of common stock over the next five calendar years, at a minimum of 250,000 shares per calendar year.  The exercise price shall be thirty-five percent of the fair market value at the date of grant.  On July 5, 1995 the Board of Directors authorized an amendment to the Plan to provide that upon exercise of the option, the payment for the shares exercised under the option may be made in whole or in part with shares of the same class of stock.  The shares to be delivered for payment would be valued at the fair market value of the stock on the day preceding the date of exercise. The plan was terminated effective July 1, 1996, however the officers will be issued the options originally provided under the terms of their employment contracts.

On March 29, 1995, the incentive stock option plan was approved by the Board of Directors and adopted by the shareholders at the annual meeting.  This original plan was revised and on January 3, 2000 the Board of Directors adopted the Company’s “2000 Non-Statutory Plan”, and the plan was subsequently approved by the shareholders on May 10, 2000 at the annual meeting.  This plan provided for the granting, exercising and issuing of incentive stock options pursuant to Internal Revenue Code Section 422. The Company was entitled to grant incentive stock options to purchase up to 4,850,000 shares of common stock.  This Plan also allowed the Company to provide long-term incentives in the form of stock options to the Company's non-employee directors, consultants and advisors, who were not eligible to receive incentive stock options. In January 2002, the Board replaced the 1995 Plan and 2000 Plan with a new combined stock option plan, the 2002 Incentive and Non-Statutory Stock Option Plan (the "2002 Plan"), which provided for the grant of incentive and non-statutory options to purchase an aggregate of 6,340,123 shares of Common Stock.  Upon approval of the 2002 Plan, all options outstanding under the 1995 and 2000 Plans remained outstanding; however, no new options could be granted under those plans.  The Board of Directors or a company established compensation committee had direct responsibility for the administration of these plans.

The exercise price of the non-statutory stock options was required to be equal to no less than 50% of the fair market value of the common stock on the date such option is granted.

77

IMAGING DIAGNOSTIC SYSTEMS, INC.

(a Development Stage Company)

Notes to Financial Statements (Continued)

(18)           STOCK OPTIONS (Continued)

On February 4, 2004, the Board of Directors adopted the Company’s 2004 Non-Statutory Stock Option Plan (the “2004 Plan”), which was adopted by the shareholders on March 24, 2004 at the annual meeting, to provide a long-term incentive for employees, non-employee directors, consultants, attorneys and advisors of the Company.  The maximum number of options that may be granted under the 2004 Plan shall be options to purchase 8,432,392 shares of Common Stock (5% of our issued and outstanding common stock as of February 4, 2004).  Options may be granted under the 2004 Plan for up to 10 years after the date of the 2004 Plan.  The 2004 Non-Statutory Stock Plan replaced the 2002 Incentive and Non-Statutory Stock Option Plan.

On August 24, 2005, the Board Of Directors resolved that the Company’s 1995, 2000, 2002 and 2004 Stock Option Plans and Stock Options Agreements that were entered into pursuant to these plans, be amended to increase the post-termination exercise period following the termination of the Optionee’s employment/directorship or in the event of change of control of the Company, to be three (3) years from the date of termination or change of control, subject to those options that were vested as of the date of termination or change of control and subject to the original term of the option, which ever time is less.

On July 26, 2007, the Board of Directors adopted the Company’s 2007 Non-Statutory Stock Option Plan (the “2007 Plan”), which must be adopted by the shareholders at the annual meeting which must occur within one year of the Board’s adoption of the 2007 Plan.  The 2007 Plan will provide a long-term incentive for employees, non-employee directors, consultants, attorneys and advisors of the Company.  The maximum number of options that may be granted under the 2007 Plan shall be options to purchase 15,693,358 shares of Common Stock (5% of our issued and outstanding common stock as of July 26, 2007).  Options may be granted under the 2007 Plan for up to 10 years after the date of the 2007 Plan.  The 2007 Non-Statutory Stock Plan replaced the 2004 Non-Statutory Stock Option Plan.

Transactions and other information relating to the plans are summarized as follows:

Employee Plan:

	Incentive Stock Options					Non Statutory Stock Options
	Shares			Wtd. Avg. Price		Shares			Wtd. Avg. Price
Outstanding at June 30, 1994		-0-					-0-
Granted		75,000		$	1.40		1,500,000		$	1.12
Exercised		-					-
Outstanding at June 30, 1995		75,000			1.40		1,500,000			1.12
Granted		770,309			1.66		750,000			1.44
Exercised		(164,956	)		.92		(1,800,000	)		1.50
Outstanding at June 30, 1996		680,353			1.81		450,000			.13
Granted		371,377			3.27		750,000			3.88
Exercised		(395,384	)		1.10		-
Outstanding at June 30, 1997		656,346			3.07		1,200,000			2.47
Granted		220,755			1.95		750,000			2.75
Exercised		-					(65,712	)		.35
Canceled		(175,205	)		4.25		-

78

IMAGING DIAGNOSTIC SYSTEMS, INC.

(a Development Stage Company)

Notes to Financial Statements (Continued)

(18)STOCK OPTIONS (Continued)

Outstanding at June 30, 1998	701,896		2.42	1,884,288		2.66
Granted	786,635		.48	750,000		.43
Exercised	-			(65,612	)	.35
Canceled	(82,500	)	3.37	-
Outstanding at June 30, 1999	1,406,031		.53 **	2,568,676		2.24
Granted	3,139,459		.34	-
Exercised	(770,702	)	.37	(318,676	)	.35
Canceled	(64,334	)	.47	-
Outstanding at June 30, 2000	3,710,454		.42	2,250,000		2.35
Granted	1,915,700		2.59	-
Exercised	(3,030,964	)	.32	(750,000	)	.31
Canceled	(279,982	)	.60	(1,500,000	)	2.75
Outstanding at June 30, 2001	2,315,208		2.38	-
Granted	6,839,864		.68	-
Exercised	-			-
Canceled	(2,695,482	)	1.17	-
Outstanding at June 30, 2002	6,459,590		.85	-
Granted	1,459,705		.38	-
Exercised	-			-
Canceled	(56,788	)	.74	-
Outstanding at June 30, 2003	7,862,507		.76	-
Granted	1,576,620		1.12	31,748		.69
Exercised	(517,769	)	.44	-
Canceled	(97,525	)	.78	-
Outstanding at June 30, 2004	8,823,833		.84	31,748		.69
Granted	-			4,253,159		.34
Exercised	(13,264	)	.26	-
Canceled	(142,891	)	.68	-
Outstanding at June 30, 2005	8,667,678		.98	4,284,907		.34
Granted	-			532,855		.18
Exercised	-			-
Canceled	(254,277	)	.74	(23,100	)	.26
Outstanding at June 30, 2006	8,413,401		.96	4,794,662		.32
Granted	-			3,927,437		.10
Exercised	-			-
Canceled	(4,804	)	.70	(131,684	)	.16
Outstanding at June 30, 2007	8,408,597		.96	8,590,415		.22

** On June 25, 1999, the exercise price of 502,225 outstanding incentive stock options was restated to $.60 per share. The Company has recorded compensation of $330,569 during the fiscal year ended June 30, 1999 as a result of this re-pricing, in accordance with the guidelines discussed in the FASB Interpretation No. 44, of APB Opinion No. 25.

79

IMAGING DIAGNOSTIC SYSTEMS, INC.

(a Development Stage Company)

Notes to Financial Statements (Continued)

(18)STOCK OPTIONS (Continued)

Director Plan:

	Incentive Stock Options					Non Statutory Stock Options
	Shares			Wtd. Avg. Price		Shares		Wtd. Avg. Price
Outstanding at June 30, 2000		-0-
Granted		150,000		$	.65
Exercised		-
Canceled		-
Outstanding at June 30, 2001		150,000			.65
Granted		300,000			.55
Exercised		-
Canceled		-
Outstanding at June 30, 2002		450,000			.58
Granted		400,000			.18
Exercised		-
Canceled		-
Outstanding at June 30, 2003		850,000			.40		-
Granted		100,000			1.07		700,000		.76
Exercised		(450,000	)		.58		-
Canceled		-					-
Outstanding at June 30, 2004		500,000			.39		700,000		.76
Granted		-					800,000		.35
Exercised		-					-
Canceled		-					-
Outstanding at June 30, 2005		500,000			.39		1,500,000		.54
Granted		-					800,000		.14
Exercised		-					-
Canceled		-					-
Outstanding at June 30, 2006		500,000			.39		2,300,000		.40
Granted		-					800,000		.08
Exercised		-					-
Canceled		-					-
Outstanding at June 30, 2007		500,000			.39		3,100,000		.32

A summary of the vested and exercisable stock options of the Company is presented as follows:

	June 30, 2007		June 30, 2006		June 30, 2005
Employee ISO		8,377,119		8,023,860		7,699,103
Director ISO		500,000		500,000		500,000
Employee Non-Statutory		3,748,584		2,261,800		88,486
Director Non-Statutory		2,550,000		1,750,000		950,000
Total		15,175,703		12,535,660		9,237,589

80

IMAGING DIAGNOSTIC SYSTEMS, INC.

(a Development Stage Company)

Notes to Financial Statements (Continued)

(18) STOCK OPTIONS (Continued)

Shares of authorized common stock have been reserved for the exercise of all options outstanding.  The following summarizes the option transactions that have occurred:

On July 5, 1994 the Company issued non-qualified options to its officers and directors to purchase an aggregate of 750,000 shares of common stock at 35% of the fair market value at the date of grant.  Compensation expense of $567,164 was recorded during the year ended June 30, 1996 as a result of the discount from the market value.

On November 7, 1994, the Company granted 300,000 non-qualified options to its general counsel, then a vice-president of the Company, at an exercise price of $0.50 per share.  Deferred compensation of $150,000 was recorded on the transaction and is being amortized over the vesting period.  The options were all exercised as of June 30, 1997.

On March 30, 1995, the Company granted to the director of engineering, a non-qualified option to purchase up to 150,000 shares of common stock per year, or a total of 450,000 shares, during the period March 30, 1995 and ending March 31, 1999.  The exercise price shall be $0.35 per share.  The options did not “vest” until one year from the anniversary date.  Deferred compensation of $472,500 was recorded on the transaction and is being amortized over the vesting period.  The Company also granted the individual, incentive options to purchase 75,000 shares of common stock at an exercise price of $1.40 per share.  The options originally expired on March 30, 1998, but were reissued on March 30, 1998 for two years.

On July 5, 1995 the Company issued non-qualified options to its officers and directors to purchase an aggregate of 750,000 shares of common stock at 35% of the fair market value at the date of grant.  Compensation expense was recorded during the year ended June 30, 1996 as a result of the discount from the market value.

On September 1, 1995, the Company issued to its three officers and directors incentive options to purchase 107,527 shares, individually, at an exercise price of $0.93 per share (110% of the fair market value).  The options expired on September 1, 1999.

On September 1, 1995, the Company issued to an employee incentive options to purchase 119,047 shares of common stock at an exercise price of $0.84 per share.  The options expired on September 1, 1999

At various dates during the fiscal year ended June 30, 1996, the Company issued to various employees incentive options to purchase 328,681 shares of common stock at prices ranging from $0.81 to $8.18.  In all instances, the exercise price was established as the fair market value of the common stock at the date of grant, therefore no compensation was recorded on the issuance of the options.  In most cases, one-third of the options vested one year from the grant date, with one-third vesting each of the next two years.  The options expire in ten years from the grant date.

On July 4, 1996, the Company issued to its three officers and directors incentive options to purchase 22,883 shares, individually, at an exercise price of $4.37 per share (110% of the fair market value).  The options expired on July 4, 2001.

On July 5, 1996 the Company issued non-qualified options to its officers and directors to purchase an aggregate of 750,000 shares of common stock at 35% of the fair market value at the date of grant.  Deferred compensation of $1,891,500 was recorded on the transaction and was being amortized over the remaining term of the employment contracts (three years).

81

IMAGING DIAGNOSTIC SYSTEMS, INC.

(a Development Stage Company)

Notes to Financial Statements (Continued)

(18) STOCK OPTIONS (Continued)

At various dates during the year ended June 30, 1997, the Company issued to various employees incentive options to purchase 264,778 shares of common stock at prices ranging from $2.56 to $3.81.  In all instances, the exercise price was established as the fair market value of the common stock at the date of grant, therefore no compensation was recorded on the issuance of the options.  In most cases, one-third of the options vested one year from the grant date, with one-third vesting each of the next two years.  The options expired in ten years from the grant date.

On July 4, 1997, the Company granted to its three officers and directors incentive options to purchase 34,000 shares, individually, at an exercise price of $2.94 per share (110% of the fair market value).  The options expired on July 4, 2002.

On July 5, 1997, the Company issued non-qualified options to its officers and directors to purchase 750,000 shares of common stock at 35% of the fair market value at the date of grant.  Deferred compensation of $1,340,625 was recorded on the transaction and was amortized over the remaining term of the employment contract (two years).

At various dates during the year ended June 30, 1998, the Company issued to various employees incentive options to purchase 204,905 shares of common stock at prices ranging from $.55 to $2.60.  In all instances, the exercise price was established as the fair market value of the common stock at the date of grant, therefore no compensation was recorded on the issuance of the options.  In most cases, one-third of the options vested one year from the grant date, with one-third vesting each of the next two years.  The options expired in ten years from the grant date.

On July 5, 1998, the Company issued non-qualified options to its officers and directors to purchase 750,000 shares of common stock at 35% of the fair market value at the date of grant.  Deferred compensation of $622,500 was recorded on the transaction and was amortized over the remaining term of the employment contract (one year).

At various dates during the year ended June 30, 1999, the Company issued to various employees incentive options to purchase 786,635 shares of common stock at prices ranging from $.46 to $.60.  In all instances, the exercise price was established as the fair market value of the common stock at the date of grant, therefore no compensation was recorded on the issuance of the options.  In most cases, one-third of the options vested one year from the grant date, with one-third vesting each of the next two years.  The options expired in ten years from the grant date.

At various dates during the year ended June 30, 2000, the Company issued to its officers and various employees incentive options to purchase 3,139,459 shares of common stock at prices ranging from $.23 to $4.38.  The exercise price was established at the fair market value of the common stock at the date of grant for employees and 110% of the fair market value at the date of grant for officers, therefore no compensation was recorded on the issuance of the options.  The officers’ options vested immediately, while the employees’ options vested one-third from the grant date, with one-third vesting each of the next two years.  The options expire in five years from the grant date.

At various dates during the year ended June 30, 2001, the Company issued to its officers and various employees incentive options to purchase 1,915,700 shares of common stock at prices ranging from $.65 to $2.85.  The exercise price was established as the fair market value of the common stock at the date of grant for employees and 110% of the fair market value at the date of grant for officers, therefore no compensation was recorded on

82

IMAGING DIAGNOSTIC SYSTEMS, INC.

(a Development Stage Company)

Notes to Financial Statements (Continued)

(18) STOCK OPTIONS (Continued)

the issuance of the options.  The officers’ options vested immediately, while the employees’ options vested one-third from the grant date, with one-third vesting each of the next two years.  The options expired in five years from the grant date.

In addition, on November 20, 2000 the Company granted to each director a stock option to purchase 50,000 shares (an aggregate of 150,000 shares) of the Company’s common stock at an exercise price of $.65 per share.  The option expires in ten years and became exercisable on a quarterly pro-rata basis (12,500 shares) from the date of grant.  The option is not intended to be an incentive stock option pursuant to Section 422 of the Internal Revenue Code.

At various dates during the year ended June 30, 2002, the Company issued to its officers and various employees incentive options to purchase 6,839,864 shares of common stock at prices ranging from $.50 to $.93.  The exercise price was established as the fair market value of the common stock at the date of grant for employees and 110% of the fair market value at the date of grant for officers, therefore no compensation was recorded on the issuance of the options.

Vesting for certain of the officers’ options was immediately, while the other officers’ options and the employees’ options vested over varying periods up to three years from the date of grant.  The options expire from four to ten years from the grant date.

In addition, on November 20, 2001 the Company granted to each director a stock option to purchase 100,000 shares (an aggregate of 300,000 shares) of the Company’s common stock at an exercise price of $.55 per share.  The option expired in ten years and became exercisable on a quarterly pro-rata basis (25,000 shares) from the date of grant.  The option was not intended to be an incentive stock option pursuant to Section 422 of the Internal Revenue Code.

At various dates during the year ended June 30, 2003, the Company issued to its officers and various employees incentive options to purchase 1,459,705 shares of common stock at prices ranging from $.19 to $.79.  The exercise price was established as the fair market value of the common stock at the date of grant for employees and 110% of the fair market value at the date of grant for officers, therefore no compensation was recorded on the issuance of the options.  Vesting for certain of the officers’ options was immediate, while the other officers’ options and the employees’ options vested over varying periods up to three years from the date of grant.  The options expire from four to ten years from the grant date.

In addition, at various dates during the year ended June 30, 2003 the Company granted to each new director a stock option to purchase 100,000 shares (an aggregate of 400,000 shares) of the Company’s common stock at exercise price ranging from $.20 to $.25 per share.  The option expires in ten years and became exercisable on a quarterly pro-rata basis (25,000 shares) from the date of grant.  The option was not intended to be an incentive stock option pursuant to Section 422 of the Internal Revenue Code.

At various dates during the year ended June 30, 2004, the Company issued to its officers and various employees incentive options to purchase 1,576,620 shares of common stock at prices ranging from $.81 to $1.25.  At various dates during the year ended June 30, 2004, the Company issued to various employees Non-Statutory options to purchase 31,748 shares of common stock at prices ranging from $.39 to $.78.  The exercise price was established as the fair market value of the common stock at the date of grant for employees, and 110% of the fair market value at the date of grant for an officer, therefore no compensation was recorded on the issuance of the

83

IMAGING DIAGNOSTIC SYSTEMS, INC.

(a Development Stage Company)

Notes to Financial Statements (Continued)

(18) STOCK OPTIONS (Continued)

options.  Vesting for certain of the officers’ options is immediate, while the other officers’ options and the employees’ options vested over varying periods up to five years from the date of grant.  The options expire from four to ten years from the grant date.

In addition, at various dates during the year ended June 30, 2004, the Company issued to its Directors stock options to purchase 100,000 shares of the Company’s common stock at prices ranging from $1.03 to $1.11.  At various dates during the year ended June 30, 2004, the Company issued to its Directors Non-Statutory options to purchase 700,000 shares of common stock at prices ranging from $.69 to $.88.  The options expire in ten years and became exercisable on a quarterly pro-rata basis (50,000 shares) from the date of grant.  Options issued to the Directors are not intended to be incentive stock options pursuant to Section 422 of the Internal Revenue Code.

At various dates during the year ended June 30, 2005, the Company issued to various employees and two consultants Non-Statutory options to purchase 4,253,159 shares of common stock at prices ranging from $.20 to $.44.  The exercise price was established as the fair market value of the common stock at the date of grant for employees and 110% of the fair market value at the date of grant for an officer, therefore no compensation was recorded on the issuance of the options.  Vesting for certain of the officers’ options was immediate, while the other officers’ options and the employees’ options vest over varying periods up to five years from the date of grant.  The options expire from four to ten years from the grant date.

At various dates during the year ended June 30, 2005, the Company issued to its Directors Non-Statutory options to purchase 800,000 shares of common stock at prices ranging from $.31 to $.44.  The options expire in ten years and shall become exercisable on a quarterly pro-rata basis (50,000 shares) from the date of grant.  Options issued to the Directors are not intended to be incentive stock options pursuant to Section 422 of the Internal Revenue Code.

At various dates during the year ended June 30, 2006, the Company issued to various employees Non-Statutory options to purchase 532,855 shares of common stock at prices ranging from $.14 to $.30.  The exercise price was established as the fair market value of the common stock on the date of grant for employees.  Options granted during the fiscal year ended June 30, 2006 vest over varying periods from one year up to three years from the date of grant.  The options expire ten years from the grant date.

At various dates during the year ended June 30, 2006, the Company issued to its Directors Non-Statutory options to purchase 800,000 shares of common stock at prices ranging from $.13 to $.14.  The options expire in ten years and shall become exercisable on a quarterly pro-rata basis (50,000 shares) from the date of grant.  Options issued to the Directors are not intended to be incentive stock options pursuant to Section 422 of the Internal Revenue Code.

For the fiscal year ending June 30, 2006, the total compensation for options recorded was $632,558.  We have $479,717 of non-cash unvested stock option compensation remaining to be expensed over the next three years.  These unvested options are being expensed each quarter over the remaining vesting periods.

At various dates during the year ended June 30, 2007, the Company issued to various employees Non-Statutory options to purchase 3,927,437 shares of common stock at prices ranging from $.085 to $.127.  The exercise price was established as the fair market value of the common stock on the date of grant for employees.  Options granted during the fiscal year ended June 30, 2007 vest over varying periods from six-months up to three years from the date of grant.  The options expire ten years from the grant date.

At various dates during the year ended June 30, 2007, the Company issued to its Directors Non-Statutory options to purchase 800,000 shares of common stock at prices ranging from $.069 to $.089.  The options expire in ten years and shall become exercisable on a quarterly pro-rata basis (50,000 shares) from the date of grant.  Options issued to the Directors are not intended to be incentive stock options pursuant to Section 422 of the Internal Revenue Code.

84

IMAGING DIAGNOSTIC SYSTEMS, INC.

(a Development Stage Company)

Notes to Financial Statements (Continued)

(18)           STOCK OPTIONS (Continued)

For the fiscal year ending June 30, 2007, the total compensation for options recorded was $431,313.  We have $299,911 of non-cash unvested stock option compensation remaining to be expensed over the next three years.  These unvested options are being expensed each quarter over the remaining vesting periods.

The following table summarizes information about all of the stock options outstanding at June 30, 2007:

		Outstanding options						Exercisable options
				Weighted
				average
Range of				remaining		Weighted				Weighted
exercise prices		Shares		life (years)		avg. price		Shares		avg. price
$	.069 - 1.25		19,491,462		6.45	$	.42		14,068,153	$	.54
	1.26 - 2.49		107,550		2.63		.56		107,550		.56
	2.50 - 2.85		1,000,000		3.00		2.85		1,000,000		2.85
$	.19 - 2.85		20,599,012		6.27	$	.54		15,175,703	$	.70

At June 30, 2007, the Company has issued options pursuant to four different stock option plans, which have been previously described.  On July 26, 2007 the Board adopted the 2007 Non-Statutory Stock Option Plan which will be submitted to the shareholders for adoption within one year.  Options granted to our CEO and directors after January 1, 2007 were inadvertently granted pursuant to the 2004 Non-Statutory Stock Option Plan which had reached the maximum number of options that may be granted.  Therefore, the Company provided amendments to those stock option agreements changing the Plan from the 2004 Plan to the 2007 Plan.

(19)           CONCENTRATION OF CREDIT RISK

During the year, the Company has maintained cash balances in excess of the Federally insured limits.  The funds are with a major money center bank.  Consequently, the Company does not believe that there is a significant risk in having these balances in one financial institution.  The cash balance with the bank at June 30, 2007 was $477,812.

(20) FAIR VALUE OF FINANCIAL INSTRUMENTS

The carrying values of cash and cash equivalents, receivables, accounts payable, short-term debt and accrued liabilities approximated their fair values due to the short maturity of these instruments.  The Company believes that its accounts receivable are fully collectible as recorded with the exception of one account where an allowance of $29,967 for doubtful account has been provided.  The fair value of the Company’s debt obligations is estimated based on the quoted market prices for the same or similar issues or on current rates offered to the Company for debt of the same remaining maturities.  At June 30, 2007 and 2006, the aggregate fair value of the Company’s debt obligations approximated its carrying value.

85

IMAGING DIAGNOSTIC SYSTEMS, INC.

(a Development Stage Company)

Notes to Financial Statements (Continued)

(21)           COMMITMENTS AND CONTINGENCIES

In June 1998, IDSI signed an exclusive patent license agreement with Mr. Grable, which encompasses the technology for the CTLM®.  Mr. Grable’s interests in the patent license agreement passed to his estate in August 2001.  Mrs. Grable is the principal beneficiary of Mr. Grable’s estate.  The term of the license is for the life of the Patent (17 years) and any renewals, subject to termination under specific conditions.  The license agreement provides for a royalty based upon a percentage, ranging from 6% to 10%, of the dollar amount earned from each sale before taxes minus the cost of the goods sold and commissions or discounts paid.  We are obligated to pay royalties based on the formula upon receiving PMA to market the CTLM® in the U.S.  In addition, following issuance of the PMA, Mrs. Grable would be eligible for minimum royalties of $250,000 per year based on the sales of the products and goods in which the CTLM® patent is used.

On January 18, 2007, the Company entered into a three-year employment agreement with Timothy Hansen, our Chief Executive Officer.  The Agreement replaces the initial three-year employment agreement between the Company and Mr. Hansen dated July 8, 2004.  The Agreement is for a three-year term commencing January 18, 2007, and provides an annual base salary of $260,000.

(22)           SUBSEQUENT EVENTS - UNAUDITED

On August 30, 2007, the Company entered into a one-year employment agreement with Allan L. Schwartz, our Executive Vice-President and Chief Financial Officer at an annual salary of $192,400.

On August 30, 2007, the Company entered into a one-year employment agreement with Deborah O’Brien, our Senior Vice-President an annual salary of $138,000.  Ms. O’Brien’s employment agreement becomes effective on September 17, 2007.

On September 13, 2007, we entered into an agreement to sell for $4.4 million and lease-back our commercial building at 6531 NW 18th Court, Plantation, Florida.  The agreement was made with an unaffiliated third party, Superfun B.V., a Netherlands corporation  (“Purchaser”).  This transaction was a result of a proposal we submitted on July 26, 2007 offering to sell the property for $4.4 million cash in a sale/lease-back transaction, which was accepted on July 31, 2007.  In connection with the proposed transaction, we received an initial deposit of $1.1 million on August 2, 2007.  We further agreed to grant the Purchaser a two-year option to purchase 3,000,000 shares of IDSI’s common stock at an exercise price equal to the market price on the date of the initial deposit.  The closing market price of IDSI’s stock on August 2, 2007, was $.035.  The sale agreement requires additional payments of $1.1 million each on September 24, 2007, November 8, 2007, and December 23, 2007, with the closing to occur upon receipt of the final payment.

Upon the closing of the sale/lease-back transaction, the Purchaser and IDSI will execute the lease.  The term of the triple net lease is five years with the first monthly rent payment due six months from the commencement date of the lease.  The monthly rent for the base year is $24,000 plus applicable sales tax.  During the term and any renewal term of the lease, the minimum annual rent shall be increased each year.  Commencing with the first day of the second lease year and on each lease year anniversary thereafter, the minimum annual rent shall be cumulatively increased by $24,000 per each lease year or $2,000 per month plus applicable sales tax.  Either party may cancel the lease without penalty or fault upon 180 days prior notice given to the other party.

From July 1, 2007 through September 12, 2007, we raised a total of $225,000 after expenses through the sale of 6,667,325 shares of common stock to Charlton pursuant to our Fifth Private Equity Credit Agreement.  

The Company has entered into agreements with various distributors located throughout Europe, Asia and South America to market the CTLM® device. The terms of these agreements range from eighteen months to three years. The Company has the right to renew the agreements, with renewal periods ranging from one to five years.

86

(23)           SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)

Fiscal 2007
	Quarter Ended			Quarter Ended			Quarter Ended			Quarter Ended
	June 30, 2007			March 31, 2007			December 31, 2006			September 30, 2006
Net Sales	$	16,365		$	25,236		$	3,673		$	19,862
Gross Profit	$	12,115		$	18,710		$	1,763		$	14,678
Operating Loss	$	(1,940,854	)	$	(1,612,451	)	$	(1,902,461	)	$	(1,620,315	)
Net loss applicable to
common shareholders	$	(2,047,351	)	$	(1,556,376	)	$	(1,944,629	)	$	(1,653,966	)
Net Loss per common share	$	(0.01	)	$	(0.01	)	$	(0.01	)	$	(0.01	)
Weighted avg. no. of common shares,
Basic & Diluted		271,667,256			279,782,438			258,612,545			248,208,822
Cash and Cash Equivalents	$	477,812		$	598,923		$	476,252		$	542,322
Total Assets	$	4,365,427		$	4,999,963		$	5,008,679		$	5,242,328
Deficit accumulated during
the development stage	$	(98,341,059	)	$	(96,293,708	)	$	(94,737,332	)	$	(92,792,703	)
Stockholders' Equity	$	3,441,322		$	4,269,812		$	4,157,688		$	4,587,701
Fiscal 2006
	Quarter Ended			Quarter Ended			Quarter Ended			Quarter Ended
	June 30, 2006			March 31, 2006			December 31, 2005			September 30, 2005
Net Sales	$	4,094		$	-		$	-		$	671,750
Gross Profit	$	(34,831	)	$	-		$	-		$	394,486
Operating Loss	$	(1,404,524	)	$	(1,875,653	)	$	(2,021,665	)	$	(1,322,560	)
Net loss applicable to
common shareholders	$	(1,548,544	)	$	(2,074,702	)	$	(2,128,811	)	$	(1,410,665	)
Net Loss per common share	$	(0.01	)	$	(0.01	)	$	(0.01	)	$	(0.01	)
Weighted avg. no. of common shares,
Basic & Diluted		218,846,738			223,718,450			210,243,309			201,835,198
Cash and Cash Equivalents	$	1,467,687		$	930,956		$	132,331		$	348,565
Total Assets	$	6,250,909		$	5,885,950		$	5,386,944		$	5,700,738
Deficit accumulated during
the development stage	$	(91,138,737	)	$	(89,590,193	)	$	(87,515,491	)	$	(85,386,680	)
Stockholders' Equity	$	5,651,916		$	5,229,430		$	4,507,579		$	4,859,022

87

Item 9.  Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

None

Item 9A.  Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that the information required to be disclosed in the reports that we file under the Securities Exchange Act of 1934 (the "Exchange Act") is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and our Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures.  In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can only provide reasonable assurance of achieving the desired control objectives, and in reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

As required by SEC Rule 13a-15(b), we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and the Company’s Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of our fourth fiscal quarter covered by this report. Based on the foregoing, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level.

There has been no change in our internal controls over financial reporting during our fourth fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal controls over financial reporting.

88

MANAGEMENT’S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING

The management of Imaging Diagnostic Systems, Inc. (the “Company”) is responsible for establishing and maintaining adequate internal control over financial reporting.  Internal control over financial reporting is defined in Rule 13a-15(f) or 15d-15(f) promulgated under the Securities Exchange Act of 1934 as a process designed by, or under the supervision of, the company’s principal executive and financial officers and effected by the company’s board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:

· Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the Company;

· Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and

· Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

The Company’s management assessed the effectiveness of the Company’s internal control over financial reporting as of June 30, 2007.  In making this assessment, the Company’s management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) in Internal Control-Integrated Framework.  The COSO framework is based upon five integrated components of control: control environment, risk assessment, control activities, information and communications and ongoing monitoring.

Based on the assessment performed, management has concluded that the Company's internal control over financial reporting is effective and provides reasonable assurance regarding the reliability of its financial reporting and the preparation of its financial statements as of June 30, 2007 in accordance with generally accepted accounting principles. Further, management has not identified any material weaknesses in internal control over financial reporting as of June 30, 2007.

The Company’s external auditors, Sherb & Co. LLP, have audited the Company’s financial statements for the year ended June 30, 2007 included in this annual report on Form 10-K and, as part of that audit, have issued a report on management's assessment of internal control over financial reporting, a copy of which is included in this annual report on Form 10-K.

/s/ Timothy B. Hansen

Chief Executive Officer and Director

/s/ Allan L. Schwartz

Executive Vice President, Chief Financial Officer and Director

89

Report of Independent Registered Public Accounting Firm

To the Board of Directors and

Stockholders of Imaging Diagnostic Systems, Inc.

We have audited management’s assessment, included in the accompanying Management Report on Internal Controls over Financial Reporting appearing under Item 9A, that Imaging Diagnostic Systems, Inc. maintained effective internal control over financial reporting as of June 30, 2007, based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Imaging Diagnostic Systems, Inc.’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting. Our responsibility is to express an opinion on management’s assessment and an opinion on the effectiveness of the company’s internal control over financial reporting based on our audit.

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, evaluating management’s assessment, testing and evaluating the design and operating effectiveness of internal control, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

In our opinion, management’s assessment that Imaging Diagnostic Systems, Inc. maintained effective internal control over financial reporting as of June 30, 2007, is fairly stated, in all material respects, based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Also in our opinion, Imaging Diagnostic Systems, Inc. maintained, in all material respects, effective internal control over financial reporting as of June 30, 2007, based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the balance sheet and the related statement of operations, stockholders’ equity, and cash flows of Imaging Diagnostic Systems, Inc., and our report dated August 28, 2007 expressed an unqualified opinion.

  /s/  SHERB & CO, LLP

   0;              Certified Public Accountants

Boca Raton, Florida

August 28, 2007

90

Item 9B.  Other Information - Sale/Lease-Back

On September 13, 2007, we entered into an agreement to sell for $4.4 million and lease-back our commercial building at 6531 NW 18th Court, Plantation, Florida.  The agreement was made with an unaffiliated third party, Superfun B.V., a Netherlands corporation  (“Purchaser”).  This transaction was a result of a proposal we submitted on July 26, 2007 offering to sell the property for $4.4 million cash in a sale/lease-back transaction, which was accepted on July 31, 2007.  In connection with the proposed transaction, we received an initial deposit of $1.1 million on August 2, 2007.  We further agreed to grant the Purchaser a two-year option to purchase 3,000,000 shares of IDSI’s common stock at an exercise price equal to the market price on the date of the initial deposit.  The closing market price of IDSI’s stock on August 2, 2007, was $.035.  The sale agreement requires additional payments of $1.1 million each on September 24, 2007, November 8, 2007, and December 23, 2007, with the closing to occur upon receipt of the final payment.

Upon the closing of the sale/lease-back transaction, the Purchaser and IDSI will execute the lease.  The term of the triple net lease is five years with the first monthly rent payment due six months from the commencement date of the lease.  The monthly rent for the base year is $24,000 plus applicable sales tax.  During the term and any renewal term of the lease, the minimum annual rent shall be increased each year.  Commencing with the first day of the second lease year and on each lease year anniversary thereafter, the minimum annual rent shall be cumulatively increased by $24,000 per each lease year or $2,000 per month plus applicable sales tax.  Either party may cancel the lease without penalty or fault upon 180 days prior notice given to the other party.

The remainder of this page is intentionally blank.

91

Part III

Item 10.  Directors, Executive Officers and Corporate Governance

Compensation Discussion and Analysis

This section describes the material elements of compensation awarded to, earned by or paid to the individuals who served as our chief executive officer, our executive vice president & chief financial officer, and our senior vice president during fiscal 2007.  These individuals are listed in the “Summary Compensation Table” below and are referred to as the “Named Executive Officers”.

Our executive compensation programs are determined and proposed by our Compensation Committee and are approved by our Board of Directors.  None of the Named Executive Officers are members of the Compensation Committee or otherwise had any role in determining the compensation of other Named Executive Officers, although the Compensation Committee does consider the recommendations of our CEO in setting compensation levels for our other executive officers.

Executive Compensation Program Objectives and Overview.

The Compensation Committee conducts an annual review of our executive compensation programs to ensure that:

· the program is designed to achieve our goals of promoting financial and operational success by attracting, motivating and facilitating the retention of key employees with outstanding talent and ability; and

· the program adequately rewards performance which is tied to creating stockholder value.

· Our current executive compensation program is based on two components, which are designed to be consistent with our compensation philosophy: (1) base salary and (2) grants of stock options.

In structuring executive compensation packages, the Compensation Committee considers how each component promotes retention and/or motivates performance by the executive.  Base salaries, perquisites and personal benefits, and severance and other termination benefits are primarily intended to attract and retain highly qualified executives. We believe that in order to attract and retain top executives, we need to provide them with compensation levels that reward their continued productive service.  At the present time the Compensation Committee does not award annual incentive bonuses while we are in the development stage but does believe that such annual awards do motivate executive officers to achieve specific strategies and operating objectives and also help us to attract and retain top executives.  The Compensation Committee has discussed the implementation of long-term equity incentives which are primarily intended to align executive officers’ long-term interests with stockholders’ long-term interests, although we believe they also play a role in helping us to attract and retain top executives.  Currently, stock option grants are the part of our executive compensation program designed to reward performance and thus the creation of stockholder value.

We view our current executive compensation program as one in which the individual components combine together to create a total compensation package for each executive officer that we believe achieves our compensation objectives.  In determining our current executive compensation program and the amounts of compensation for each component of our program, the Compensation Committee evaluates the current executive compensation data for companies in our industry.  The Compensation Committee believes that our current executive compensation program is appropriate based on the evaluation of the compensation paid by companies in our industry.

Current Executive Compensation Program Elements.

Base Salaries

Salaries for our three executive officers are reviewed by the Compensation Committee on an annual basis.  During fiscal 2007, the cash salaries paid to Tim Hansen, Allan Schwartz and Deborah O’Brien were $240,810, $191,048, and $130,769, respectively.  During fiscal 2006, the cash salaries paid to Tim Hansen, Allan Schwartz and Deborah O’Brien were $210,000, $185,000, and $112,169, respectively.

92

Annual Incentive Bonuses

The Compensation Committee may elect to award incentive bonuses as part of total compensation to executive officers who have rendered services during the year that exceed those normally required or anticipated or who have achieved specific targeted objectives with regard to sales performance, financial performance, inventory efficiencies and other criteria which may be established from time to time.  These bonuses are intended to reflect the Compensation Committee’s determination to reward any executive who, through extraordinary effort, has substantially benefited the Company and its stockholders during the year.  During fiscal 2007, no annual incentive bonuses were paid.

Stock Option Grants

Our policy is that the long-term compensation of our Named Executive Officers and other executive officers should be directly linked to the value provided to stockholders. Therefore, we have periodically made grants of stock options to provide further incentives to our executives to increase stockholder value.  During fiscal 2007, the stock option grants made to Tim Hansen, Allan Schwartz and Deborah O’Brien were 3,000,000, 250,000 and 250,000, respectively.  During fiscal 2006, the stock option grants made to Tim Hansen, Allan Schwartz and Deborah O’Brien were 0, 100,000 and 0, respectively.  Stock options are granted with an exercise price that is equal to the closing price of our common stock on the grant date.  Thus, the recipients will realize value on their stock options if our stockholders realize value on their shares.  The Compensation Committee bases its grants of stock options to executives on a number of factors, including:

· the executive’s position with us and total compensation package;

· the executive’s performance of his or her individual responsibilities; and

· the executive’s contribution to the success of our financial performance.

Compensation Committee Report

The following statement made by the Compensation Committee shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, and shall not otherwise be deemed filed under either of these acts.

The Compensation Committee has reviewed and discussed with management the Compensation Discussion and Analysis required by Item 402(b) of Regulation S-K.

Based on the review and discussions referred to in the paragraph immediately above, the Compensation Committee recommended to the Board of Directors that the Compensation Discussion and Analysis be included in this Annual Report on Form 10-K.

COMPENSATION COMMITTEE

Jay Bendis, Chairman

Sherman Lazrus

Edward Rolquin

Compensation Committee Interlocks and Insider Participation

No member of the Compensation Committee was an officer or employee of our Company during the prior year or was formerly an officer of our Company.  During the fiscal year ended June 30, 2007, none of our executive officers served on the compensation committee of any other entity, any of whose directors or executive officers served either on our Board of Directors or on our Compensation Committee.

93

The following table sets forth certain information concerning our directors and executive officers:

Name	Age	Position	Year Elected or Appointed
Tim Hansen	63	Chief Executive Officer and Director	2004
Allan L. Schwartz	65	Executive Vice-President, Chief	1994
		Financial Officer and Director
Deborah O’Brien	43	Senior Vice-President	2003
Sherman Lazrus	74	Director	2002
Patrick J. Gorman	53	Director	2003
Edward Rolquin	78	Director	2003
Jay S. Bendis	60	Director	2003

Allan Schwartz is one of the co-founders and as such may be deemed "promoter" and "parent" as defined in the Rules and Regulations promulgated under the Securities Act, as those terms are defined in the rules and regulations promulgated under the Securities Act.  Directors serve until the next meeting of shareholders.  Officers serve at the pleasure of the Board of Directors.

We have adopted a Code of Ethics pursuant to Section 406 of the Sarbanes-Oxley Act of 2002 that applies to our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions.

Tim Hansen

Tim Hansen was appointed our Chief Executive Officer and a Director of the Company by the Board of Directors in July 2004.  Prior to his appointment as CEO and Director of IDSI, Mr. Hansen served as General Manager of Radiation Management Services, a business of Cardinal Health, Inc. (NYSE:CAH) of Dublin, Ohio from January 2002 to July 2004.  From August 2001 to January 2002 he served as the President of Syncor Radiation Management in Cleveland, Ohio, a division of Syncor International Corporation (NASDAQ:SCOR) of Woodland Hills, CA.  Cardinal Health acquired Syncor in January 2003.  From April 2000 to August 2001 Mr. Hansen was a consultant to Inovision, LLC serving as President of Inovision Radiation Measurements in Cleveland, Ohio.  He also served as President of Cleaner Foods, Inc. of Cleveland, OH and a Director of Kliniki St. Paul of Warsaw, Poland from March 2000 to August 2001.  From 1982 to 2000 Mr. Hansen held several high-level executive positions with Picker International, Inc. of Cleveland, Ohio.  From 1999 to 2000 he served as President of Picker Medical Systems, a leading manufacturer of diagnostic imaging systems including CT and MRI scanners, nuclear medicine imagers and X-Ray systems.  Picker International was a wholly owned subsidiary of G.E.C. plc/Marconi Medical Systems with $1.6 billion in annual sales.  Philips Medical Systems acquired Marconi in October 2001.  Prior to Picker, Mr. Hansen was Vice President of Sales, Service and Marketing for Xonics Medical Systems, Inc. of Des Plaines, IL; National Sales Manager, Manager, Business Planning and Marketing Manager, X-Ray and CT for General Electric Medical Systems of Milwaukee, WI; and Regional Sales Manager for Smith Kline Instruments, a subsidiary of Smith Kline and French.  Mr. Hansen holds a Bachelor of Science degree in Economics from the University of Wisconsin-Milwaukee.

Allan L. Schwartz

Mr. Schwartz is Executive Vice-President and Chief Financial Officer of the Company and is responsible for its financial affairs.  He has a wide range of management, marketing, field engineering, construction, and business development experience.  Prior to joining the Company as a founder in 1993, he developed the Chronometric Trading System for analyzing stock market trends using neural networks and developed pre-engineered homes for export to Belize, Central America for S.E. Enterprises of Miami, Florida.  In 1991 he formed Tron Industries, Inc. for the development of low-voltage neon novelty items and self-contained battery powered portable neon.  He is a graduate of C.W. Post College of Long Island University with a B.S. in Business Administration.  Previous innovations by Mr. Schwartz before relocating to Florida have included the use of motion detection sensors in commercial burglar alarm systems for Tron-Guard Security Systems. Inc. and the use of water reclamation systems with automatic car wash equipment.  Mr. Schwartz has been a Director and Officer of the Company since its inception.

94

Deborah O’Brien

Deborah O’Brien was appointed Senior Vice President on September 15, 2003.  Ms. O’Brien has been employed at IDSI since 1995.  During her tenure, she has held the positions of Director of Investor Relations, Vice President of Corporate Communications and most recently, since September 2001, Vice President of Business Development.  Her responsibilities have included developing and executing a strategic corporate communications campaign, managing internal communications, outside public relations, marketing, and clinical applications.  In addition, Ms. O’Brien was directly responsible for the development and establishment of consumer and industry awareness of our CTLM® System via a media outreach which targeted industry publications, national network television, radio, nationally-circulated publications and high traffic internet sites.  As Vice President of Business Development, she was closely involved with various regulatory and marketing projects and played an integral role in the development and preparation of our PMA Application.  She also supervised and managed the collection of clinical data for the PMA process.  Prior to joining IDSI, she worked for seven years in the financial arena, managing investor accounts, and in the medical device industry, marketing medical equipment.  Ms. O’Brien began her career in the mortgage loan industry as an account executive with Citibank.

Sherman Lazrus

Mr. Lazrus has been a Director since December 2002 and serves as a member of the Compensation Committee.  On April 15, 2004, the Board of Directors appointed him Co-Chairman of the Board.  He has enjoyed a distinguished career with nearly 40 years’ experience in government and private sector health care and health care finance. He is currently a member of Diasys Corporation (DYXC) Board of Directors.  From December 1998 to August 2006, Mr. Lazrus served Emergency Filtration Products, Inc., Las Vegas, NV (OTCBB: EMFP) as a Director, Interim Chief Executive Officer and Chairman of the Board of Directors.  Mr. Lazrus presently also serves as President of American Medical Capital, a division of American Medical Enterprises, LLC located in Bethesda, Maryland, a financial services and investment banking company specializing in the healthcare industry, a position he has held since 1991.  Mr. Lazrus was initially employed with the Federal Government and while at the Department of Health, Education and Welfare in 1964 he was involved with the development of the Medicare and Medicaid Programs and served as the Director of Policy Coordination for the two programs.  Also while employed by the Federal Government, Mr. Lazrus served from 1965 to 1966 in the office of the Director of the National Institute of Health and was involved in planning activities in areas involving biomedical research.  He later administered the Social Security Administration’s Disability Insurance Research Programs as Director of Program Analysis.  Mr. Lazrus’s final Federal Government position encompassed the administration of the military health care system serving as the Deputy Assistant Secretary of Defense from 1974 to 1976.  In this position he was the Federal Government’s senior career health official.  Mr. Lazrus also served in the State of Maryland’s Governor’s office as Director of the Governor’s Study Group on Vocational Rehabilitation from 1966 to 1968 and later developed a comprehensive human services delivery system for the City of Washington, D.C. from 1968 to 1972.  While in the private sector, Mr. Lazrus from 1976 to 1978 was Vice President of American Medical International Inc., a major NYSE hospital corporation, which owned and operated numerous hospitals around the world.  The company is now known as Tenet Healthcare Corporation.  As a developer Mr. Lazrus was responsible for the development of various Washington D.C. area office buildings, shopping centers, industrial warehouses and residential communities.  Mr. Lazrus attended George Washington University where he received A.A., B.A. and M.B.A. degrees.

Patrick J. Gorman

Mr. Gorman is a Certified Public Accountant. He has been a Director since January 2003 and serves as Chairman of the Audit Committee. On February 26, 2005, the Board of Directors appointed him Co-Chairman of the Board.  He is currently the Chief Executive Officer and Chairman of the Board of Directors of Applied Nanoscience Inc., a nanotechnology company based in Hauppauge, New York. From 1991 to 2005 he worked in private practice, serving both publicly traded and privately held companies.  Mr. Gorman served as Corporate Tax Manager for Axsys Technologies, Inc. in Deer Park, New York from 1987 to 1990 and Controller/Tax Manager for Computer Associates in Jericho, New York from 1983 to 1986.  Prior to joining Computer Associates, he served as Tax Manager with Ernst & Young in Melville, New York and Tax Accountant for Arthur Andersen in New York City.  Mr. Gorman holds a MS in Taxation from Long Island University and is a member of the NYSSCPA and the AICPA.

95

Edward Rolquin

Mr. Rolquin of Naples, Florida, a consultant and retired corporate executive, has been a Director since February 2003 and serves as a member of the Compensation Committee.  He has enjoyed a distinguished 48-year career in management, sales and finance with international experience in the medical industry.  From 1989 to 1995, he served as a consultant for the Chinese government on various import, export and technology transfer projects.  From 1984 to 1992 Mr. Rolquin was the Founder and President of JR Micrographics in Huntington, NY that specialized in medical records management.  He has served in a management and consultant capacity while working with major international companies such as Anaconda Copper Mining Company in Chile and El Salvador from 1952 to 1984, Mobil Oil from 1976 to 1984, Cerro Corp., (an international mining company in Peru) from 1962 to 1978, and Esso (Standard Oil) from 1957 to 1968.  Mr. Rolquin was responsible for equipping five hospitals for Anaconda, a 100-bed hospital in Chile for Cerro Corp., a 50-bed dispensary for Mobil Oil, and a hospital for Esso.

Jay S. Bendis

Mr. Bendis of Akron, Ohio, has been a Director since February 2003 and serves as a member of the Audit Committee and is Chairman of the Compensation Committee.  On April 15, 2004, the Board of Directors appointed him Co-Chairman of the Board.  He has over 30 years experience in sales and marketing and is currently President of Transfer Technology Consultants, Akron, OH, where he specializes in transferring new product concepts through to commercialization working with established and start-up companies in both domestic and international markets.  Mr. Bendis is also President and CEO of Clinical Analysis Corp. which has developed a portable, handheld chemistry analyzer for patient point of care testing.  He was the Managing Partner of the Crystal Corridor Group, Hudson, OH, which works with Kent State University’s Liquid Crystal Institute in facilitating liquid crystal technology.  From 1995 to 2000, Mr. Bendis was Vice President of Sales and Marketing and a Director of American Bio Medica Corp. a public company in Kinderhook, NY, which develops and markets on-site drug abuse diagnostic kits.  From 1993 to 1999, he was the President and co-founder of Emerging Technology Systems, Akron, OH, which is a research and development company specializing in developing new concept medical devices.  From 1990 to 1992, he was a co-founder and Vice President of Sales and Marketing and a Director for Scientific Imaging

Instruments of Trumbull, CT.  From 1985 to 1990, he served as National Sales Manager of the XANAR Laser Corp., Colorado Springs, CO, a division of Johnson & Johnson, where he directed its national sales force and developed its marketing strategy for integrating high power lasers into the hospital market.  From 1979 to 1984, he was the Sales and Marketing Manager for the IVAC Corp., San Diego, CA, a division of Eli Lilly Corp. and has had sales and management experiences with XEROX and A.M. International.  He has also served as a member of the Edison BioTechnology Center Advisory Council for the State of Ohio.  Mr. Bendis presently serves as a director of Aduromed Corp. (GDVC) and also serves on the Boards of several private companies.  He earned his B.A. in Marketing/Management from Kent State University.

Audit Committee

The Board of Directors has elected Patrick J. Gorman as Chairman of the Audit Committee.  In addition, the Board has determined that Mr. Gorman is an “audit committee financial expert,” as defined under new SEC regulations, who is independent of management of the Company.  Jay S. Bendis also serves as a member of the Audit Committee.

Compensation Committee

The Board of Directors has elected Jay S. Bendis as Chairman of the Compensation Committee.  Sherman Lazrus and Edward Rolquin also serve as members of the Compensation Committee.

Nominating and Corporate Governance Committee

The Board of Directors has elected Sherman Lazrus as Chairman of the Nominating and Corporate Governance Committee.  Jay S. Bendis, Patrick J. Gorman and Edward Rolquin also serve as members of the Nominating and Corporate Governance Committee.

Compliance with Section 16(a) of the Securities Exchange Act of 1934

Section 16(a) of the Securities Exchange Act of 1934 requires our directors and executive officers, and persons who own more than 10 percent of our common stock, to file with the SEC initial reports of ownership and reports of changes in ownership, furnishing us with copies of all Section 16(a) forms they file.  To the best of our knowledge, based solely on review of the copies of such reports furnished to us, all Section 16(a) filing requirements applicable to our officers and directors were complied with during the year ended June 30, 2007.

96

Item 11.  Executive Compensation

The following table sets forth the compensation awarded to, earned by or paid to our Chief Executive Officer, Executive Vice President & CFO, and Senior Vice President for services rendered to us during fiscal 2007.

SUMMARY COMPENSATION TABLE – FISCAL 2007

							Change in
							Pension Value
							and
							Nonqualified
						Non-Equity	Deferred
				Stock	Option	Incentive Plan	Compensation	All other
Name and		Salary	Bonus	Awards	Awards	Compensation	Earnings	Compensation	Total
Principal Position	Year	($)	($)	($)	($)(5)	($)	($)	($)	($)
Timothy B. Hansen
CEO and Director(1),(2)	2007	240,810	-	-	241,960	-	-	-	482,770
Allan L. Schwartz
Exec V.P.,CFO and Director(1),(3)	2007	191,048	-	-	18,500	-	-	-	209,548
Deborah O'Brien
Senior Vice- President(1),(4)	2007	130,769	-	-	35,609	-	-	-	166,378

(1)	All Named Executive Officers receive reimbursement for auto expense in the amount of $500 per month.
(2)	On July 26, 2006, Mr. Hansen received a 7% cost of living increase based on the prior two years' inflation, raising his salary to $226,000.  On January 17, 2007, Mr. Hansen signed a new employment agreement that increased his salary to $260,000.
(3)	Salary recorded for f/y 2007 includes base salary of $185,000 plus $6,048 vacation pay.
(4)	Salary recorded for f/y 2007 includes base salary of $125,000 plus $5,769 vacation pay.  Ms. O’Brien began receiving auto expense in September 2006.
(5)	Amount listed represents the dollar amount we recognized for financial reporting purposes under FASB No. 123R, “Share Based Payment”.  Assumptions made for the purpose of computing this amount are discussed in Note 2(j) to the Notes to our Financial Statements contained in this report.

97

OUTSTANDING EQUITY AWARDS AT FISCAL 2007 YEAR-END

The following table sets forth information concerning unexercised options outstanding for each of our Named Executive Officers at June 30, 2007.

	Option Awards									Stock Awards
																Equity
																Incentive
					Equity									Equity Incentive		Plan Awards:
					Incentive									Plan Awards:		Market or
					Plan Awards:							Market		Number of		Payout Value
	Number of		Number of		Number of					Number of		Value of		Unearned		of Unearned
	Securities		Securities		Securities					Shares or		Shares or		Shares, Units		Shares, Units
	Underlying		Underlying		Underlying					Units of		Units of		or Other		or Other
	Unexercised		Unexercised		Unexercised		Option			Stock That		Stock That		Rights That		Rights That
	Options		Options		Unearned		Exercise		Option	Have Not		Have Not		Have Not		Have Not
		(#)		(#)	Options		Price		Expiration	Vested		Vested		Vested		Vested
Name	Exercisable		Unexercisable			(#)	($)		Date		(#)	($)			(#)	($)
Timothy B. Hansen		1,250,000		250,000		-	$	0.38	7/8/2014		-		-		-		-
CEO and Director(1)		1,000,000		500,000		-	$	0.32	2/23/2015
		-		3,000,000		-	$	0.09	1/18/2017
Allan L. Schwartz		500,000		-		-	$	2.85	8/30/2010		-		-		-		-
Exec V.P., CFO and		500,000		-		-	$	0.77	8/30/2011
Director(2)		500,000		-		-	$	0.30	8/30/2012
		500,000		-		-	$	1.21	8/30/2013
		500,000		-		-	$	0.30	8/30/2014
		100,000		-		-	$	0.20	9/12/2015
		-		250,000		-	$	0.11	9/12/2016
Deborah O'Brien		200,000		-		-	$	0.56	10/25/2011		-		-		-		-
Senior Vice-		25,000		-		-	$	0.50	2/02/2012
President(3)		300,000		2,000		-	$	1.13	9/15/2013
		-		250,000		-	$	0.11	9/12/2016

(1)	Mr. Hansen had 6,000,000 stock options outstanding as of June 30, 2007 of which 2,250,000 are fully vested.
(2)	Mr. Schwartz had 2,850,000 stock options outstanding as of June 30, 2007 of which 2,600,000 are fully vested.
(3)	Ms. O’Brien had 777,000 stock options outstanding as of June 30, 2007 of which 525,000 are fully vested.

98

OPTION EXERCISES AND STOCK VESTED - FISCAL 2007

The following table sets forth information concerning each exercise of stock options for each of our Named Executive Officers during the year ended June 30, 2007.

	Option Awards		Stock Awards
	Number of		Number of
	Shares Acquired	Value Realized	Shares Acquired	Value Realized
	on Exercise	on Exercise	on Vesting	on Vesting
Name	(#)	($)	(#)	($)
Timothy B. Hansen
CEO and Director	-	-	-	-
Allan L. Schwartz
Exec V.P., CFO
and Director	-	-	-	-
Deborah O'Brien
Senior Vice-President	-	-	-	-

Employment Agreements

Timothy B. Hansen

On July 8, 2004, we entered into a three-year employment agreement with Timothy Hansen, our new Chief Executive Officer, commencing on July 26, 2004 at an annual salary of $210,000 and appointed him a Director of the Company.  Mr. Hansen was granted 1,500,000 non-statutory stock options at an exercise price of $.38, the fair market value at the date of the grant, which which vested over the three-year period in accordance with the table below:

Date of Vesting	No. of Option Shares
July 8, 2005	500,000
January 8, 2006	250,000
July 8, 2006	250,000
January 8, 2007	250,000
July 8, 2007	250,000

Mr. Hansen also received 100,000 restricted shares of our common stock.  He also receives a $500 car allowance per month and upon joining the Company he received pre-approved living expenses for a three-month period and moving expenses.

On February 23, 2005, Mr. Hansen was granted an additional 1,500,000 non-statutory stock options at an exercise price of $.32, the fair market value at the date of the grant, which will vest over the three-year period in accordance with the table below:

Date of Vesting	No. of Option Shares
February 23, 2006	500,000
August 23, 2006	250,000
February 23, 2007	250,000
August 23, 2007	250,000
February 23, 2008	250,000

99

On January 18, 2007, we entered into a three-year employment agreement (the “Agreement”) and an accompanying stock option agreement with Timothy B. Hansen, Chief Executive Officer.  The Agreement replaces the initial three-year employment agreement between us and Mr. Hansen dated July 8, 2004.  The Agreement is for a three-year term commencing January 18, 2007, and provides an annual base salary of $260,000 per annum.  The option agreement provides an option to purchase 3,000,000 shares of the Company’s common stock which shall vest and become exercisable in 500,000-share increments every six months beginning July 18, 2007.  The option exercise price per share is $.09.

Date of Vesting	No. of Option Shares
July 18, 2007	500,000
January 18, 2008	500,000
July 18, 2008	500,000
January 18, 2009	500,000
July 18, 2009	500,000
January 18, 2010	500,000

Allan L. Schwartz

On August 30, 2004 Allan L. Schwartz, our Executive Vice-President and Chief Financial Officer, entered into a one-year Employment Extension Agreement, which provided for an annual salary of $185,000 and options to purchase up to an aggregate of 500,000 shares of our common stock at an exercise price of $.30 per share, in accordance with our 2004 Non-Statutory Stock Option Plan.  These options vested on August 30, 2005.  On September 12, 2005, we entered into a one-year employment agreement effective August 30, 2005 with Mr. Schwartz, at an annual salary of $185,000.  Mr. Schwartz was also granted 100,000 non-statutory stock options at an exercise price of $.20 per share, the fair market value at the date of the grant, which will vest on August 30, 2006.  On September 12, 2006, we entered into a one-year employment agreement effective August 30, 2006 with Mr. Schwartz at an annual salary of $185,000.  Mr. Schwartz was also granted 250,000 non-statutory stock options at an exercise price of $.114 per share, the fair market value at the date of the grant, which will vest on August 30, 2007.  On August 30, 2007, we entered into a one-year employment agreement effective August 30, 2006 with Mr. Schwartz at an annual salary of $185,000.  Mr. Schwartz was also granted 250,000 non-statutory stock options at an exercise price of $.058 per share, in accordance with our 2007 Non-Statutory Stock Option Plan.  The exercise price was the fair market value at the date of the grant, which will vest on August 30, 2008.

Deborah O’Brien

On September 15, 2003, we entered into a three-year employment agreement with Deborah O’Brien, our Senior Vice-President at an annual salary of $95,000.  The Senior Vice-President was also granted 302,000 incentive stock options at an exercise price of $1.13 per share, the fair market value at the date of the grant, which will vest ratably over the three-year period.  On September 12, 2006, we entered into a one-year employment agreement with Ms. O’Brien at an annual salary of $125,000.  The Senior Vice-President was also granted a $25,000 performance bonus opportunity (which later expired) and 250,000 non-statutory stock options at an exercise price of $.114 per share, the fair market value at the date of the grant, which will vest in one year.  On August 30, 2007, we entered into a one-year employment agreement commencing on September 15, 2007 with Ms. O’Brien at an annual salary of $138,000.  The Senior Vice-President was also granted 250,000 non-statutory stock options at an exercise price to be determined on September 15, 2007 based on the fair market value at the date of the grant, which will vest in one year.

Potential Payments Upon Termination or Change in Control

Timothy B. Hansen

Upon termination of Mr. Hansen’s employment agreement for any reason other than voluntary termination; termination “without cause” or termination by the Company for “Cause” as defined below, the following will apply:

(b) Termination without Cause.  The Company may terminate the Executive’s employment without cause.  Such termination will become effective upon the date specified in the termination notice, provided that such date is at least 60 days from the date of such notice.  In the event of such termination without cause:

100

(i)              The Company will continue to pay the Executive his salary pursuant to Section 3(a) for 24 months or through the expiration of the Term, whichever is longer.

(ii)              The Company will continue to maintain through the expiration of the Term, for the benefit of the Executive, the employee benefit programs referred to in Section 3(b) as in effect on the date of termination.

(iii)              On the effective date of termination, all options that were scheduled to vest will vest and will remain exercisable for a period of 10 years from the date of this Agreement.

(iv)              The compensation payments and other consideration to which the Executive is entitled on termination without cause shall not be diminished or otherwise affected by any employment thereafter obtained or income thereafter earned by Executive nor will the Company maintain that it is entitled to mitigation of amounts owed under this section for any reason.

(c) Termination for Cause.  The Company may terminate the Executive’s employment at any time for cause by giving written notice of termination setting forth such cause.  Such termination shall become effective upon the giving of such notice, except that, where the basis for cause is capable of cure within 30 days, termination based upon cause shall not become effective unless Executive shall fail to complete such cure within 30 days of receipt of written notice of the existence of such cause. Upon such termination the Executive shall have no right to compensation, commission, bonus, benefits or reimbursement pursuant to this Agreement, for any period subsequent to the effective date of termination.  Further, upon termination for cause, all of the Executive’s unvested stock options shall terminate. For purposes of this section, “cause” shall mean: (1) the Executive is convicted of a felony; (2) the Executive, in carrying out his duties hereunder, commits gross negligence or willful misconduct resulting, in either case, in material harm to the Company; (3) the Executive misappropriates Company funds or otherwise defrauds the Company; (4) the Executive materially breaches any provision of this Agreement; or (5) the Executive materially fails to perform his duties under section 4 resulting in material harm to the Company.

(d) Death or Disability.  Upon the death or disability of the Executive, the Executive shall be entitled to and the Company will pay the Executive’s salary from the date of death or from the date of disability for six months or through the end of the Term, whichever is longer. (For purposes of this Section, “disability” shall mean that for a period of six months in any 12-month period the Executive is incapable of substantially fulfilling his duties because of physical, mental or emotional incapacity arising from injury, sickness or disease.)  Should the Executive be rendered disabled, the Company will continue to maintain for the benefit of the Executive the employee benefit programs referred to in Section 3(b) that were in effect on the date of the disability.

(e) Special Termination.  In the event that (i) the Executive, with or without a change in title or formal corporate action, shall no longer exercise all of his customary duties and responsibilities and shall no longer possess substantially all the authority customary for a CEO in a publicly-traded company; (ii) the Company materially breaches this Agreement or the performance of its duties and obligations hereunder; or (iii) any entity or person not now an executive officer of the Company becomes either individually or as part of a group the beneficial owner of 20% or more of the Company’s common stock, the Executive, by written notice to the Company, may elect to deem the Executive’s employment hereunder to have been terminated by the Company without cause under Section 2(b) hereof, in which event the Executive shall be entitled to the compensation provided for in Section 2(b).

(f) Voluntary Termination.  The Executive, on 30 days prior written notice to the Company, may terminate his employment voluntarily.  Upon such termination, the Company will pay the Executive’s compensation through the date of such termination.  After such date, the Executive shall no longer be entitled to receive any compensation, reimbursement or benefits, and all unvested stock options shall terminate upon termination of the Executive’s employment.

Upon termination of Mr. Hansen’s employment agreement without “cause” or by change of control as defined in paragraph (e) Special Termination (iii), we will be obligated to pay the balance of compensation due on his three-year contract which commenced on January 18, 2007.  Assuming such termination occurred on June 30, 2007, we estimate that amount to be $692,449.

101

Allan L. Schwartz

Upon termination of Mr. Schwartz’s employment agreement for any reason other than voluntary termination; termination “without cause” or termination by the Company for “Cause” as defined below, the following will apply:

(b)         Termination without Cause.  The Company may terminate the Executive’s employment without cause.  Such termination will become effective upon the date specified in the termination notice, provided that such date is at least 60 days from the date of such notice.  In the event of such termination without cause:

(i)              For the remainder of the Term following the effective date of termination, the Company will continue to pay the Executive his salary pursuant to Section 3(a).

(ii)              The Company will continue to maintain for the remainder of the Term following the effective date of termination, for the benefit of the Executive, the employee benefit programs referred to in Section 3(b) as in effect on the date of termination.

(iii)              On the effective date of termination, all options that were scheduled to vest will vest and will remain exercisable for a period of three years from the date of termination.

(c)         Termination for Cause.  The Company may terminate the Executive’s employment at any time for cause by giving written notice of termination setting forth such cause.  Such termination shall become effective upon the giving of such notice, except that, where the basis for cause is capable of cure within 30 days, termination based upon cause shall not become effective unless Executive shall fail to complete such cure within 30 days of receipt of written notice of the existence of such cause. Upon such termination the Executive shall have no right to compensation, commission, bonus, benefits or reimbursement pursuant to this Agreement, for any period subsequent to the effective date of termination.  Further, upon termination for cause, all of the Executive’s unvested stock options shall terminate. For purposes of this section, “cause” shall mean; (1) the Executive is convicted of a felony; (2) the Executive, in carrying out his duties hereunder, commits gross negligence or willful misconduct resulting, in either case, in material harm to the Company; (3) the Executive misappropriates Company funds or otherwise defrauds the Company; (4) the Executive materially breaches any provision of this Agreement; or (5) the Executive materially fails to perform his duties under section 4.

(d)         Death or Disability.  Upon the death or disability of the Executive, the Executive shall be entitled to and the Company will pay the Executive’s salary from the date of death or from the date of disability through the end of the Term. (For purposes of this Section, “disability” shall mean that for a period of six months in any 12-month period the Executive is incapable of substantially fulfilling his duties because of physical, mental or emotional incapacity arising from injury, sickness or disease.)  Should the Executive be rendered disabled, the Company will continue to maintain for the benefit of the Executive the employee benefit programs referred to in Section 3(b) that were in effect on the date of the disability.

(e)         Special Termination.  In the event that (i) the Company materially breaches this Agreement or the performance of its duties and obligations hereunder; or (ii) any entity or person not now an executive officer of the Company becomes either individually or as part of a group the beneficial owner of 20% or more of the Company’s common stock, the Executive, by written notice to the Company, may elect to deem the Executive’s employment hereunder to have been terminated by the Company without cause under Section 2(b) hereof, in which event the Executive shall be entitled to the compensation provided for in Section 2(b).

(f)         Voluntary Termination. The Executive, on 30 days prior written notice to the Company, may terminate his employment voluntarily.  Upon such termination, the Company will pay the Executive’s compensation through the date of such termination.  After such date, the Executive shall no longer be entitled to receive any compensation, reimbursement or benefits and all unvested stock options shall terminate upon termination of the Executive’s employment.

Upon termination of Mr. Schwartz’s employment agreement without “cause” or by change of control as defined in paragraph (e) Special Termination (ii), we will be obligated to pay the balance of compensation due on his one-year contract which commenced on August 30, 2006.  Assuming such termination occurred on June 30, 2007, we estimate that amount to be $30,833.

102

Deborah O’Brien

Upon termination of Ms. O’Brien’s employment agreement for any reason other than voluntary termination; termination “without cause” or termination by the Company for “Cause” as defined below, the following will apply:

(b)         Termination without Cause.  The Company may terminate the Executive’s employment without cause.  Such termination will become effective upon the date specified in the termination notice, provided that such date is at least 60 days from the date of such notice.  In the event of such termination without cause:

(i)              For the remainder of the Term following the effective date of termination, the Company will continue to pay the Executive her salary pursuant to Section 3(a).

(ii)              The Company will continue to maintain for the remainder of the Term following the effective date of termination, for the benefit of the Executive, the employee benefit programs referred to in Section 3(b) as in effect on the date of termination.

(iii)              On the effective date of termination, all options that were scheduled to vest will vest and will remain exercisable for a period of three years from the date of termination.

(c)         Termination for Cause.  The Company may terminate the Executive’s employment at any time for cause by giving written notice of termination setting forth such cause.  Such termination shall become effective upon the giving of such notice, except that, where the basis for cause is capable of cure within 30 days, termination based upon cause shall not become effective unless Executive shall fail to complete such cure within 30 days of receipt of written notice of the existence of such cause. Upon such termination the Executive shall have no right to compensation, commission, bonus, benefits or reimbursement pursuant to this Agreement, for any period subsequent to the effective date of termination.  Further, upon termination for cause, all of the Executive’s unvested stock options shall terminate. For purposes of this section, “cause” shall mean; (1) the Executive is convicted of a felony; (2) the Executive, in carrying out her duties hereunder, commits gross negligence or willful misconduct resulting, in either case, in material harm to the Company; (3) the Executive misappropriates Company funds or otherwise defrauds the Company; (4) the Executive materially breaches any provision of this Agreement; or (5) the Executive materially fails to perform her duties under section 4.

(d)         Death or Disability.  Upon the death or disability of the Executive, the Executive shall be entitled to and the Company will pay the Executive’s salary from the date of death or from the date of disability through the end of the Term. (For purposes of this Section, “disability” shall mean that for a period of six months in any 12-month period the Executive is incapable of substantially fulfilling her duties because of physical, mental or emotional incapacity arising from injury, sickness or disease.)  Should the Executive be rendered disabled, the Company will continue to maintain for the benefit of the Executive the employee benefit programs referred to in Section 3(b) that were in effect on the date of the disability.

(e)         Special Termination.  In the event that (i) the Company materially breaches this Agreement or the performance of its duties and obligations hereunder; or (ii) any entity or person not now an executive officer of the Company becomes either individually or as part of a group the beneficial owner of 20% or more of the Company’s common stock, the Executive, by written notice to the Company, may elect to deem the Executive’s employment hereunder to have been terminated by the Company without cause under Section 2(b) hereof, in which event the Executive shall be entitled to the compensation provided for in Section 2(b).

(f)         Voluntary Termination. The Executive, on 30 days prior written notice to the Company, may terminate her employment voluntarily.  Upon such termination, the Company will pay the Executive’s compensation through the date of such termination.  After such date, the Executive shall no longer be entitled to receive any compensation, reimbursement or benefits and all unvested stock options shall terminate upon termination of the Executive’s employment.

Upon termination of Ms. O’Brien’s employment agreement without “cause” or by change of control as defined in paragraph (e) Special Termination (iii), we will be obligated to pay the balance of compensation due on her one-year contract which commenced on September 15, 2006.  Assuming such termination occurred on June 30, 2007, we estimate that amount to be $26,042.

103

Director Compensation – Fiscal 2007

As of October 1, 2004 the annual base rate for director compensation was increased from $8,000 to $12,000 for each non-employee director payable quarterly, and annual option grants of 200,000 shares vesting 50,000 shares per quarter.  New directors will receive stock options of 100,000 shares for the first year of service and 200,000 shares per year for the second year and each year thereafter.  Our Board of Directors consists of two Co-Chairmen, one of whom is Chairman of the Audit Committee and the other is Chairman of the Compensation Committee.  The annual base rate for the Co-Chairmen was increased on October 1, 2004 from $8,000 to $20,000.  No additional base compensation is paid for serving on the Audit Committee or Compensation Committee.  Board members are paid $800 per diem fees for days in which a board meeting is attended or a non-employee board member is otherwise required to visit the Company or spend a significant amount of a day working on Company matters (“workshop days”).  We reimburse travel expenses for attending board meetings and expenses associated with workshop days.

The following table sets forth certain information regarding the compensation of our directors (other than directors who are also Named Executive Officers) for the fiscal year ended June 30, 2007.

					Change in
					Pension Value
					and
					Nonqualified
	Fees Earned			Non-Equity	Deferred
	or Paid	Stock	Option	Incentive Plan	Compensation	All other
Name and	in Cash	Awards	Awards	Compensation	Earnings	Compensation	Total
Principal Position	($)	($)	($)	($)	($)	($)	($)
Jay Bendis(1)	27,200	-	13,600	-	-	-	40,800
Patrick Gorman(2)	26,800	-	12,467	-	-	-	39,267
Sherman Lazrus(3)	18,400	-	11,967	-	-	-	30,367
Edward Rolquin(4)	18,400	-	13,600	-	-	-	32,000

(1)	Mr. Bendis had 900,000 stock options outstanding as of June 30, 2007 of which 750,000 are fully vested.
(2)	Mr. Gorman had 900,000 stock options outstanding as of June 30, 2007 of which 750,000 are fully vested.
(3)	Mr. Lazrus had 900,000 stock options outstanding as of June 30, 2007 of which 800,000 are fully vested.
(4)	Mr. Rolquin had 900,000 stock options outstanding as of June 30, 2007 of which 750,000 are fully vested.

104

Stock Option Plans

Our 1995 Stock Option Plan was approved by our Board of Directors and adopted by the shareholders at the March 1995 annual meeting.  The plan provided for the granting, exercising and issuing of incentive options pursuant to Internal Revenue Code, Section 422.

On August 30, 1999, we established an equity incentive plan.  The shareholders had to approve this plan within one year.  The maximum number of shares that could be granted under this plan was 15,000,000 shares of common stock and 5,000,000 shares of preferred stock.  The series, rights and preferences of the preferred stock were to be determined by our Board of Directors.  This plan also included any stock available for future stock rights under our 1995 Stock Option Plan.  On January 3, 2000 the Board of Directors decided to replace this equity incentive plan and adoptedour 2000 Non-Statutory Stock Option Plan so as to provide a critical long-term incentive for employees, non-employee directors, consultants, attorneys and advisors of the Company.  On May 10, 2000 our shareholders approved the 2000 Non-Statutory Stock Option Plan, which was replaced with our 2002 Incentive and Non-Statutory Stock Option Plan approved by our shareholders on March 13, 2002.  Our Board of Directors has direct responsibility for the administration of the plan.

On February 4, 2004, the Board of Directors adopted our 2004 Non-Statutory Stock Option Plan (the “2004 Plan”), which was adopted by the shareholders on March 24, 2004 at our annual meeting to provide a long-term incentive for employees, non-employee directors, consultants, attorneys and advisors of the Company and its subsidiaries.  The maximum number of options that may be granted under the 2004 Plan shall be options to purchase 8,432,392 shares of Common Stock (5% of our issued and outstanding common stock as of February 4, 2004).  Options may be granted under the 2004 Plan for up to 10 years after the date of the 2004 Plan.  The 2004 Non-Statutory Stock Plan replaced the 2002 Incentive and Non-Statutory Stock Option Plan.

On August 24, 2005, the Board Of Directors resolved that the Company’s 1995, 2000, 2002 and 2004 Stock Option Plans and Stock Options Agreements that were entered into pursuant to these plans, be amended to increase the post-termination exercise period following the termination of the Optionee’s employment/directorship or in the event of change of control of the Company, to be three years from the date of termination or change of control, subject to those options that were vested as of the date of termination or change of control and subject to the original term of the option, which ever time is less.

On July 26, 2007, the Board of Directors adopted the Company’s 2007 Non-Statutory Stock Option Plan (the “2007 Plan”), which must be adopted by the shareholders at the annual meeting which must occur within one year of the Board’s adoption of the 2007 Plan.  The 2007 Plan will provide a long-term incentive for employees, non-employee directors, consultants, attorneys and advisors of the Company.  The maximum number of options that may be granted under the 2007 Plan shall be options to purchase 15,693,358 shares of Common Stock (5% of our issued and outstanding common stock as of July 26, 2007).  Options may be granted under the 2007 Plan for up to 10 years after the date of the 2007 Plan.  The 2007 Non-Statutory Stock Plan replaced the 2004 Non-Statutory Stock Option Plan.

105

Item 12.  Security Ownership of Certain Beneficial Owners and Management.

The following table shows the beneficial ownership of our common stock as of September 12, 2007 regarding:

· each person that we know of who beneficially owns more than 5% of the outstanding shares of our common stock,

· each current director and executive officer, and

· all executive officers and directors as a group.

Name and Address	Number of Shares Owned	% of Outstanding
of Beneficial Owner	Beneficially (1)(2)	Shares of Common Stock
Linda B. Grable	19,660,274(3)	6.2%
Timothy B. Hansen	3,350,000(4)	1.1%
6531 NW 18th Court
Plantation, FL 33313
Allan L. Schwartz	6,905,520(5)	2.2%
6531 NW 18th Court
Plantation, FL 33313
Deborah O’Brien	1,286,000(6)	0.4%
6531 NW 18th Court
Plantation, FL 33313
Sherman Lazrus	950,000(7)	0.3%
Patrick J. Gorman	1,626,160(8)	0.5%
Edward Rolquin	820,000(7)	0.3%
Jay S. Bendis	865,000(7)	0.3%
All officers and directors	15,802,680(9)	5.1%
as a group (7 persons)
All beneficial owners	35,462,954(10)	11.3%
Listed above (8 persons)

(1)	Except as indicated in the footnotes to this table, based on information provided by such persons, the persons named in the table above have sole voting power and investment power with respect to all shares of common stock shown beneficially owned by them.
(2)	Percentage of ownership is based on 318,205,363 shares of common stock outstanding as of September 12, 2007 plus each person’s options that are exercisable within 60 days.  Shares of common stock subject to stock options that are exercisable within 60 days as of September 12, 2007 are deemed outstanding for computing the percentage of that person and the group.
(3)	Based on the last filing of record includes 3,250,000 shares subject to options and 16,410,274 shares owned by Linda B. Grable.  Ms. Grable retired on April 15, 2004.
(4)	Mr. Hansen was issued 100,000 restricted shares pursuant to his employment agreement dated July 8, 2004.  Includes 3,250,000 shares subject to options.
(5)	Includes 2,850,000 shares subject to options and 9,000 shares owned by the wife of Allan L. Schwartz, Carolyn Schwartz, of which he disclaims beneficial ownership.
(6)	Includes 776,000 shares subject to options.
(7)	Includes 850,000 shares of options owned by Sherman Lazrus, 800,000 shares of options owned by Edward Rolquin and 800,000 shares of options owned by Jay S. Bendis.
(8)	Includes 850,000 shares subject to options and 183,356 shares owned by the wife of Patrick J. Gorman, Diana Gorman, of which he disclaims beneficial ownership.

106

(9)

Includes 10,176,000 shares subject to options held by, Timothy Hansen, Allan Schwartz, Deborah O’Brien, Sherman Lazrus, Patrick J. Gorman, Edward Rolquin and Jay S. Bendis.  Also includes 9,000 shares owned by the wife of Allan L. Schwartz, Carolyn Schwartz, of which he disclaims beneficial ownership and 183,356 shares owned by the wife of Patrick J. Gorman, Diana Gorman, of which he disclaims beneficial ownership.

(10)

Includes all of the shares in footnote 9 plus 3,250,000 shares subject to options held by Linda B. Grable.

Dividend Policy

To date, we have not declared or paid any dividends with respect to our common stock, and the current policy of the Board of Directors is to retain any earnings to provide for our growth.  We do not anticipate paying cash dividends on our common stock in the foreseeable future.

Item 13.  Certain Relationships and Related Transactions

The late Richard and Linda Grable were husband and wife.  Mrs. Grable continues to control a substantial portion of our outstanding stock.

In June 1998, IDSI signed an exclusive patent license agreement with Richard Grable.  The term of the license is for the life of the patent (17 years) and any renewals, subject to termination under specific conditions.  As consideration for this license, we issued Mr. Grable 7,000,000 shares of common stock and granted a royalty ranging from 6% to 10% of the dollar amount earned from each CTLM® sale before taxes minus the cost of the goods sold and commissions or discounts paid.  The royalty provisions do not apply to any sales prior to receipt of the PMA for the CTLM®.  In addition, following issuance of the PMA, IDSI Mr. Grable would be paid a minimum royalty of at least $250,000 per year.  Mr. Grable’s interest in the patent license agreement passed to his estate, of which Linda Grable is the principal beneficiary.

Item 14.  Principal Accounting Fees and Services

For the Fiscal Years ended June 30, 2007 and 2006, we paid audit fees totaling $48,152 and $59,292 respectively, and paid fees for tax services totaling $2,000 and $2,000 respectively.

107

Item 15.  Exhibits, Financial Statement Schedules, and Reports on Form 8-K

(a)  Exhibits

EXHIBIT DESCRIPTION

3.1	Articles of Incorporation (Florida)- Incorporated by reference to Exhibit 3(a) of our Form 10-KSB for the fiscal year ending June 30, 1995.
3.2	Amendment to Articles of Incorporation (Designation of Series A Convertible Preferred Shares) - Incorporated by reference to Exhibit 3.  (i). 6 of our Form 10-KSB for the fiscal year ending June 30, 1996.  File number 033-04008.
3.3	Amendment to Articles of Incorporation (Designation of Series B Convertible Preferred Shares).  Incorporated by reference to our Registration Statement on Form S-1 dated July 1, 1997.
3.4	Amendment to Articles of Incorporation (Designation of Series C Convertible Preferred Shares).  Incorporated by reference to our Form 8-K dated October 15, 1997.
3.5	Amendment to Articles of Incorporation (Designation of Series D Convertible Preferred Shares).  Incorporated by reference to our Form 8-K dated January 12, 1998.
3.6	Amendment to Articles of Incorporation (Designation of Series E Convertible Preferred Shares).  Incorporated by reference to our Form 8-K dated February 19,1998.
3.7	Amendment to Articles of Incorporation (Designation of Series F Convertible Preferred Shares).  Incorporated by reference to our Form 8-K dated March 6, 1998.
3.8	Amendment to Articles of Incorporation (Designation of Series H Convertible Preferred Shares).  Incorporated by reference to our Registration Statement on Form S-2 File Number 333-59539.
3.9	Certificate of Dissolution - is incorporated by reference to Exhibit (3)(a) of our Form 10-KSB for the fiscal year ending June 30, 1995.
3.10	Articles of Incorporation and By- Laws (New Jersey) -are incorporated by reference to Exhibit 3 (i) of our Form 10-SB, as amended, file number 0-26028, filed on May 6, 1995 ("Form 10-SB").
3.11	Certificate and Plan of Merger - is incorporated by reference to Exhibit 3(i) of the Form 10-SB.
3.12	Certificate of Amendment - is incorporated by reference to Exhibit 3(i) of the Form 10-SB.
3.13	Amended Certificate of Amendment-Series G Designation.
3.14	Certificate of Amendment-Series I Designation
3.15	Amended Certificate of Amendment-Series B Designation
3.16	Certificate of Amendment-Series K Designation.  Incorporated by reference to our Form 10-KSB for the fiscal year ending June 30, 2000 filed on September 14, 2000.
10.2	Patent Licensing Agreement.  Incorporated by reference to our Registration Statement on Form S-2, File Number 333-59539.
10.3	Incentive Stock Option Plan - is incorporated by reference to Exhibit 10(b) of the Form 10-SB.
10.60	Employment Agreement with Deborah O’Brien, Senior Vice President dated September 15, 2003.
10.61	Fourth Private Equity Credit Agreement between IDSI and Charlton Avenue LLC dated as of January 9, 2004, with exhibits.  Incorporated by reference to our Form S-2, File Number 333-112377 filed on January 30, 2004.
10.62	Registration Rights Agreement between IDSI and Charlton Avenue, LLC dated as of January 9, 2004.  Incorporated by reference to our Form S-2, File Number 333-112377 filed on January 30, 2004.
10.63	Retirement Agreement between IDSI and Linda B. Grable dated April 15, 2004.  Incorporated by reference to our Form S-2, File Number 333-116694 filed on June 21, 2004.
10.64	Employment Agreement with Timothy B. Hansen, Chief Executive Officer dated July 8, 2004.  Incorporated by reference to our Form 10-K filed on September 17, 2004.
10.65	Employment Agreement with Edward Horton, Chief Operating Officer dated August 15, 2004.  Incorporated by reference to our Form 10-K filed on September 17, 2004.
10.66	One-Year Employment Extension Agreement with Allan L. Schwartz, Executive Vice President and Chief Financial Officer dated August 30, 2004.  Incorporated by reference to our Form 10-K filed on September 17, 2004.
10.67	Stock Option Agreement with Timothy B. Hansen, Chief Executive Officer, dated February 23, 2005.  Incorporated by reference to our Registration Statement on Form S-2, File Number 333-123197 filed on March 8, 2005.
10.68	One-Year Employment Agreement with Allan L. Schwartz, Executive Vice President and Chief Financial Officer dated September 12, 2005.  Incorporated by reference to our Form 10-K filed on September 13, 2005.
10.69	Fifth Private Equity Credit Agreement between IDSI and Charlton Avenue LLC dated March 21, 2006 with all exhibits.  Incorporated by reference to our Form S-1, File Number 333-132664 filed on March 23, 2006.

108

10.70	License Agreement dated as of June 16, 2006, as amended as of August 30, 2006, between Bioscan, Inc. and Imaging Diagnostic Systems, Inc.  Incorporated by reference to our Form 8-K, filed on September 5, 2006.
10.71	One-Year Employment Agreement with Allan L. Schwartz, Executive Vice President and Chief Financial Officer dated September 12, 2006.  Incorporated by reference to our Form 10-K filed on September 13, 2006.
10.72	One-Year Employment Agreement with Deborah O’Brien, Senior Vice President dated September 12, 2006.  Incorporated by reference to our Form 10-K filed on September 13, 2006.
10.73	Employment Agreement dated as of January 18, 2007, between Imaging Diagnostic Systems, Inc. and Timothy B. Hansen.  Incorporated by reference to our Form 8-K filed on January 23, 2007.
10.74	Stock Option Agreement dated as of January 18, 2007, between Imaging Diagnostic Systems, Inc. and Timothy B. Hansen.  Incorporated by reference to our Form 8-K filed on January 23, 2007.
10.75	One-Year Employment and Stock Option Agreement dated as of August 30, 2007 between Imaging Diagnostic Systems, Inc. and Allan L. Schwartz, Executive Vice President and Chief Financial Officer.  Incorporated by reference to our Form 8-K filed on September 6, 2007.
10.76	One-Year Employment and Stock Option Agreement dated as of August 30, 2007 between Imaging Diagnostic Systems, Inc. and Deborah O’Brien, Senior Vice President.  Incorporated by reference to our Form 8-K filed on September 6, 2007.
10.77	2007 Non-Statutory Stock Option Plan
10.78	Agreement of Sale by and between Imaging Diagnostic Systems, Inc. and Superfun B.V. dated September 13, 2007 including Form of Lease Agreement (Exhibit D).  Incorporated by reference to our Form 8-K filed on September 13, 2007.
14.1	Code of Ethics.
31.1	Certification by Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Certification by Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1	Certification by Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2	Certification by Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

109

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, Imaging Diagnostic Systems, Inc. has duly caused this report to be signed on our behalf by the undersigned, thereunto duly authorized,

IMAGING DIAGNOSTIC SYSTEMS, INC.

By:	/s/ Timothy B. Hansen
	Timothy B. Hansen, Chief Executive Officer and Director

Pursuant to the requirements of the Securities Act of 1933, as amended, this Annual Report on Form 10-K has been signed by the following persons in the capacities and on the dates indicated.

Signatures	Title	Date
/s/Timothy B. Hansen	Chief Executive Officer	September 13, 2007
Timothy B. Hansen	and Director
/s/Allan L. Schwartz	Director, Executive Vice-President,	September 13, 2007
Allan L. Schwartz	and Chief Financial Officer
	(Principal Accounting and Financial
	Officer)
/s/ Jay S. Bendis	Co-Chairman of the Board	September 13, 2007
Jay S. Bendis	and Director
/s/ Patrick J. Gorman	Co-Chairman of the Board	September 13, 2007
Patrick J. Gorman	and Director
/s/ Sherman Lazrus	Director	September 13, 2007
Sherman Lazrus
/s/ Edward Rolquin	Director	September 13, 2007
Edward Rolquin

110